# EDGAR Filing Document

**Accession Number:** 0001756655
**File Stem:** 0001628280-26-024244
**Filing Date:** 2026-4
**Character Count:** 287195
**Document Hash:** 72dfe4f29a1a6cfe2755122256572ab5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-26-024244.hdr.sgml**: 20260408

**ACCESSION NUMBER**: 0001628280-26-024244

**CONFORMED SUBMISSION TYPE**: DEF 14A

**PUBLIC DOCUMENT COUNT**: 21

**CONFORMED PERIOD OF REPORT**: 20260520

**FILED AS OF DATE**: 20260408

**DATE AS OF CHANGE**: 20260408

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Ardent Health, Inc.
- **CENTRAL INDEX KEY:** 0001756655
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC [8062]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 611764793
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DEF 14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42180
- **FILM NUMBER:** 26848330

**BUSINESS ADDRESS:**
- **STREET 1:** 340 SEVEN SPRINGS WAY
- **STREET 2:** SUITE 100
- **CITY:** BRENTWOOD
- **STATE:** TN
- **ZIP:** 37027
- **BUSINESS PHONE:** 6152963000

**MAIL ADDRESS:**
- **STREET 1:** 340 SEVEN SPRINGS WAY
- **STREET 2:** SUITE 100
- **CITY:** BRENTWOOD
- **STATE:** TN
- **ZIP:** 37027

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Ardent Health Partners, Inc.
- **DATE OF NAME CHANGE:** 20240717

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Ardent Health Partners, LLC
- **DATE OF NAME CHANGE:** 20181022

?xml version='1.0' encoding='ASCII'? ardt-20260408

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**SCHEDULE 14A**

**(Rule 14a-101)**

**SCHEDULE 14A INFORMATION**

**Proxy Statement Pursuant to Section 14(a) of the Securities**

**Exchange Act of 1934**

---

| | |
|:---|:---|
| Filed by the Registrant | ☒ |
| Filed by a Party other than the Registrant | ☐ |

---

Check the appropriate box:

☐ Preliminary Proxy Statement

☐ Confidential, for use of the Commission Only (as permitted by Rule 14a-6(e)(2))

☒ Definitive Proxy Statement

☐ Definitive Additional Materials

☐ Soliciting Material Pursuant to §240.14a-12

**Ardent Health, Inc**.

(Name of Registrant as Specified in its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

☒ No fee required.

☐ Fee paid previously with preliminary materials.

☐ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11

i

![ARDT Logo.jpg](ardt-20260408_g1.jpg)

**340 SEVEN SPRINGS WAY, SUITE 100**

**BRENTWOOD, TENNESSEE 37027**

April 8, 2026

To Our Stockholders:

You are cordially invited to attend the 2026 Annual Meeting of Stockholders (the "Annual Meeting") of Ardent Health, Inc.,

to be held solely by remote communication via live webcast on Wednesday, May 20, 2026, at 9:00 a.m. (Central Time) by

visiting *www.virtualshareholdermeeting.com/ARDT2026*. The matters to be acted upon at the Annual Meeting are more

fully described in the accompanying Proxy Statement and related materials.

In accordance with rules adopted by the Securities and Exchange Commission, we are mailing to many of our stockholders a

Notice of Internet Availability of Proxy Materials instead of a paper copy of the Proxy Statement and our 2025 Annual

Report to Stockholders. The Notice of Internet Availability of Proxy Materials contains instructions on how stockholders can

access our proxy materials over the internet as well as how stockholders can receive a paper copy of our proxy materials,

including the Proxy Statement, the 2025 Annual Report to Stockholders and a form of proxy card.

It is important that your shares be represented at the Annual Meeting. Whether or not you plan to attend the Annual

Meeting, please vote by proxy as soon as possible by following the instructions located in the Notice of Internet Availability

of Proxy Materials or in the Proxy Statement. Prior to the Annual Meeting, you will be able to vote at *www.proxyvote.com*.

If you attend the Annual Meeting, you may withdraw your proxy and vote your shares personally.

We look forward to your attendance at the Annual Meeting.

Sincerely,

![eSignature - Mark Sotir.jpg](ardt-20260408_g2.jpg)

Mark Sotir

*Chairman of the Board*

**YOUR VOTE IS IMPORTANT.**

**WHETHER OR NOT YOU PLAN TO ATTEND THE ANNUAL MEETING, AFTER REVIEWING THE PROXY MATERIALS, PLEASE** 

**VOTE BY PHONE OR ONLINE FOLLOWING THE INSTRUCTIONS SET FORTH IN THE FOLLOWING PROXY MATERIALS OR, IF** 

**YOU REQUESTED A PRINTED COPY, PLEASE COMPLETE, DATE, SIGN AND RETURN THE PROXY CARD.**

ii

![ARDT Logo.jpg](ardt-20260408_g1.jpg)

**340 SEVEN SPRINGS WAY, SUITE 100**

**BRENTWOOD, TENNESSEE 37027**

**Notice of Annual Meeting of Stockholders**<br>**To Be Held May 20, 2026**<br>

To Our Stockholders:

The 2026 Annual Meeting of Stockholders (the "Annual Meeting") of Ardent Health, Inc. will be held solely by remote

communication via live webcast on Wednesday, May 20, 2026, at 9:00 a.m. (Central Time). You will be able to attend the

Annual Meeting by visiting *www.virtualshareholdermeeting.com/ARDT2026* and entering the 16-digit control number

included in our Notice of Internet Availability of the proxy materials, on your proxy card or in the instructions that

accompanied your proxy materials. Prior to the Annual Meeting, you will be able to vote at *www.proxyvote.com*.

The Annual Meeting is being convened for the following purposes:

(1)To elect 11 nominees as directors;

(2)To approve, on a non-binding advisory basis, the compensation of our named executive officers;

(3)To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal

year ending December 31, 2026; and

(4)To transact any other business that properly comes before the Annual Meeting or any adjournments or

postponements thereof.

The matters to be acted upon at the Annual Meeting are more fully described in the Proxy Statement and related materials.

Please read the materials carefully.

The Board of Directors has fixed the close of business on March 26, 2026 as the record date for determining stockholders

entitled to notice of and to vote at the Annual Meeting or any adjournments or postponements thereof.

Dated: April 8, 2026By order of the Board of Directors,

![eSignature - Mark Sotir.jpg](ardt-20260408_g2.jpg)

Mark Sotir

*Chairman of the Board*

**IMPORTANT**

**WHETHER OR NOT YOU PLAN TO ATTEND THE ANNUAL MEETING, AFTER REVIEWING THE PROXY MATERIALS, PLEASE** 

**VOTE BY PHONE OR ONLINE FOLLOWING THE INSTRUCTIONS SET FORTH IN THE FOLLOWING PROXY MATERIALS OR, IF** 

**YOU REQUESTED A PRINTED COPY, PLEASE COMPLETE, DATE, SIGN AND RETURN THE PROXY CARD.**

iii

**Table of Contents**

---

| | |
|:---|:---|
| <u>[Proxy Statement](#i86b9ce36f36244588cbb1deefbc6ec50_16)</u> | <u>[1](#i86b9ce36f36244588cbb1deefbc6ec50_16)</u> |
| <u>[Information Concerning Solicitation and Voting](#i86b9ce36f36244588cbb1deefbc6ec50_19)</u> | <u>[1](#i86b9ce36f36244588cbb1deefbc6ec50_19)</u> |
| <u>[Proposal 1: Election of Directors](#i86b9ce36f36244588cbb1deefbc6ec50_22)</u> | <u>[3](#i86b9ce36f36244588cbb1deefbc6ec50_22)</u> |
| <u>[Corporate Governance](#i86b9ce36f36244588cbb1deefbc6ec50_25)</u> | <u>[10](#i86b9ce36f36244588cbb1deefbc6ec50_25)</u> |
| <u>[Proposal 2: Non-Binding Advisory Vote on Executive Compensation](#i86b9ce36f36244588cbb1deefbc6ec50_28)</u> | <u>[16](#i86b9ce36f36244588cbb1deefbc6ec50_28)</u> |
| <u>[Management](#i86b9ce36f36244588cbb1deefbc6ec50_34)</u> | <u>[17](#i86b9ce36f36244588cbb1deefbc6ec50_34)</u> |
| <u>[Security Ownership of Certain Beneficial Owners and Management](#i86b9ce36f36244588cbb1deefbc6ec50_37)</u> | <u>[18](#i86b9ce36f36244588cbb1deefbc6ec50_37)</u> |
| <u>[Compensation Discussion and Analysis](#i86b9ce36f36244588cbb1deefbc6ec50_40)</u> | <u>[20](#i86b9ce36f36244588cbb1deefbc6ec50_40)</u> |
| <u>[Compensation Committee Report](#i86b9ce36f36244588cbb1deefbc6ec50_43)</u> | <u>[31](#i86b9ce36f36244588cbb1deefbc6ec50_43)</u> |
| <u>[Executive Compensation](#i86b9ce36f36244588cbb1deefbc6ec50_46)</u> | <u>[32](#i86b9ce36f36244588cbb1deefbc6ec50_46)</u> |
| <u>[CEO Pay Ratio](#i86b9ce36f36244588cbb1deefbc6ec50_606)</u> | <u>[42](#i86b9ce36f36244588cbb1deefbc6ec50_606)</u> |
| <u>[Pay Versus Performance](#i86b9ce36f36244588cbb1deefbc6ec50_49)</u> | <u>[43](#i86b9ce36f36244588cbb1deefbc6ec50_49)</u> |
| <u>[Director Compensation](#i86b9ce36f36244588cbb1deefbc6ec50_52)</u> | <u>[46](#i86b9ce36f36244588cbb1deefbc6ec50_52)</u> |
| <u>[Equity Compensation Plans](#i86b9ce36f36244588cbb1deefbc6ec50_55)</u> | <u>[48](#i86b9ce36f36244588cbb1deefbc6ec50_55)</u> |
| <u>[Proposal 3: Ratification of Appointment of Independent Registered Public Accounting Firm](#i86b9ce36f36244588cbb1deefbc6ec50_58)</u> | <u>[49](#i86b9ce36f36244588cbb1deefbc6ec50_58)</u> |
| <u>[Audit and Compliance Committee Report](#i86b9ce36f36244588cbb1deefbc6ec50_61)</u> | <u>[50](#i86b9ce36f36244588cbb1deefbc6ec50_61)</u> |
| <u>[Certain Relationships and Related Party Transactions](#i86b9ce36f36244588cbb1deefbc6ec50_64)</u> | <u>[51](#i86b9ce36f36244588cbb1deefbc6ec50_64)</u> |
| <u>[General Information](#i86b9ce36f36244588cbb1deefbc6ec50_67)</u> | <u>[56](#i86b9ce36f36244588cbb1deefbc6ec50_67)</u> |
| <u>[Reconciliation of Non-GAAP Measures](#i86b9ce36f36244588cbb1deefbc6ec50_70)</u> | <u>[58](#i86b9ce36f36244588cbb1deefbc6ec50_70)</u> |

---

**NOTE TO READERS**

Unless the context otherwise requires, all references in this Proxy Statement to "Ardent," "the Company," "we," "us" or

"our" mean Ardent Health, Inc. and its affiliates. Ardent Health, Inc. is a holding company that has affiliates that operate

acute care hospitals and other healthcare facilities and employ physicians. The term "affiliates" includes direct and indirect

subsidiaries of Ardent and partnerships and joint ventures in which such subsidiaries are equity owners.

**FORWARD-LOOKING STATEMENTS**

This Proxy Statement contains certain "forward-looking statements," as that term is defined in the U.S. federal securities

laws. These forward-looking statements include, but are not limited to, statements other than statements of historical facts,

including, among others, statements relating to our future financial performance, our business prospects and strategy, the

industry in which we operate and other similar matters. Words such as "anticipates," "expects," "intends," "plans,"

"predicts," "believes," "seeks," "estimates," "could," "would," "will," "may," "can," "continue," "potential," "should" and the

negative of these terms or other comparable terminology often identify forward-looking statements. These forward-looking

statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual

results to differ materially from the results contemplated by the forward-looking statements, including the risk factors and

other cautionary statements discussed in our Annual Report on Form 10-K for the year ended December 31, 2025. The

forward-looking statements pertain only to the date they are made, and we do not undertake any obligation to update

them to reflect new information or events unless required by law. Stockholders are advised not to place undue reliance on

these statements and to consult any additional disclosures we may provide through our other filings with the SEC, such as

Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.

**Proxy Statement**

This Proxy Statement is furnished in connection with the solicitation by the Board of Directors (the "Board") of the Company

of proxies to be voted at the 2026 Annual Meeting of Stockholders (the "Annual Meeting"), to be held solely by remote

communication in a virtual meeting format on Wednesday, May 20, 2026, at 9:00 a.m. (Central Time), for the purposes set

forth in the accompanying notice, and at any adjournments or postponements thereof. This Proxy Statement and the

accompanying proxy are first being mailed or made available to stockholders on or about April 8, 2026.

**Information Concerning Solicitation and Voting**

**Record Date**

The close of business on March 26, 2026 has been fixed as the record date for the determination of stockholders entitled to

vote at the Annual Meeting. As of such date, we had 750,000,000 authorized shares of common stock, $0.01 par value per

share ("Common Stock"), of which 143,095,662 shares were outstanding and entitled to vote, and 50,000,000 authorized

shares of preferred stock, $0.01 par value per share, of which no shares were outstanding. Common Stock is our only

outstanding class of voting stock. Each share of Common Stock will have one vote on each matter to be voted upon at the

Annual Meeting.

**Quorum Requirements**

A majority of the shares of Common Stock entitled to vote, represented in person or by proxy, is required to constitute a

quorum. Abstentions and broker non-votes will be counted for purposes of determining the presence of a quorum at the

Annual Meeting. If a quorum is not present at the time of the Annual Meeting, the stockholders entitled to vote, present in

person or represented by proxy, shall have the power to adjourn the Annual Meeting until a quorum shall be present or

represented by proxy. The Annual Meeting may be adjourned from time to time, whether or not a quorum is present, by

the affirmative vote of a majority of the votes present and entitled to be cast at the Annual Meeting.

**Voting Procedures**

Whether you hold shares directly as the stockholder of record or through a broker, trustee or other nominee, as the

beneficial owner, you may direct how your shares are voted without attending the Annual Meeting. If you hold shares in

street name, you must vote by giving instructions to your broker or nominee. You should follow the voting instructions on

any form that you receive from your broker or nominee. The availability of telephone and Internet voting for shares held in

street name will depend on your broker's or nominee's voting process. Please refer to the instructions in the materials

provided in the Notice of Internet Availability of Proxy Materials or proxy card provided to you for information on the

available voting methods.

If a proxy is properly given prior to or at the Annual Meeting and not properly revoked, it will be voted in accordance with

the instructions, if any, given by the stockholder. Subject to the requirements described below, if no instructions are given,

each proxy will be voted:

• **FOR** the election as directors of the nominees described in this Proxy Statement (Proposal 1);

• **FOR** the approval, on a non-binding advisory basis, of the compensation of our named executive officers (the

"NEOs") set forth in the section below entitled "Compensation Discussion and Analysis" (Proposal 2);

• **FOR** ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm

for the fiscal year ending December 31, 2026 (Proposal 3); and

• In accordance with the recommendation of the Board on any other proposal that may properly come before

the Annual Meeting or any adjournment thereof.

The persons named as proxies were selected by our Board.

Without your instructions, your broker or nominee is permitted to use its own discretion and vote your shares on certain

routine matters (such as Proposal 3), but is not permitted to use its discretion and vote your shares on non-routine matters

(such as Proposals 1 and 2). We urge you to give voting instructions to your broker or nominee on all proposals. Shares that

are not permitted to be voted by your broker or nominee are called "broker non-votes." Broker non-votes are not

considered shares entitled to vote for or against a proposal and, therefore, will have no direct impact on any proposal. If

you abstain from voting on Proposal 1, your abstention will have no effect on the outcome of the election. If you abstain

from voting on Proposals 2 or 3, your abstention will have the same legal effect as a vote against these proposals.

Stockholders who give proxies have the right to revoke them at any time before they are voted by delivering a written

request to our Corporate Secretary at 340 Seven Springs Way, Suite 100, Brentwood, Tennessee 37027, prior to the Annual

Meeting or by submitting another proxy at a later date. The giving of the proxy will not affect the right of a stockholder to

attend the virtual Annual Meeting and vote in person.

**Instructions for the Virtual Annual Meeting**

This year our Annual Meeting will be a completely virtual meeting. There will be no physical meeting location. To participate

in the virtual Annual Meeting, please visit *www.virtualshareholdermeeting.com/ARDT2026* and enter your 16-digit control

number included on your Notice of Internet Availability of Proxy Materials or proxy card provided to you with this Proxy

Statement. If your shares are held in street name and your Notice of Internet Availability of Proxy Materials or voting

instruction form indicates that you may vote those shares through the *www.proxyvote.com* website, then you may access,

participate in, and vote at the Annual Meeting with the 16-digit control number indicated on that Notice of Internet

Availability of Proxy Materials or Voting Instruction Form. Otherwise, if you cannot locate your control number,

stockholders who hold their shares in street name should contact their bank, broker, or other nominee (preferably at least

five days before the Annual Meeting) and obtain their 16-digit control number in order to be able to attend, participate in,

or vote at the Annual Meeting.

We encourage stockholders to log in to the website and access the webcast approximately 15 minutes before the Annual

Meeting. The meeting will begin promptly at 9:00 a.m. (Central Time) on Wednesday, May 20, 2026. Participants should

ensure that they have a strong Wi-Fi connection wherever they intend to participate in the meeting.

If you have any questions on how to attend the Annual Meeting, please contact Ardent Health, Inc., 340 Seven Springs Way,

Suite 100, Brentwood, Tennessee 37027, Attention: Investor Relations, 615-296-3000.

**Voting Prior to the Virtual Annual Meeting**

Whether or not you participate in the virtual meeting, after reviewing the proxy materials, please vote online at

*www.proxyvote.com* or by phone by following the instructions in the Notice of Internet Availability of Proxy Materials or

proxy card. Also, if you requested a printed copy, you may complete, date, sign and return the proxy card by mail, or by

signing the voter instruction form provided by your bank or broker and returning it by mail, if you are the beneficial owner

but not the stockholder of record. This way your shares will be represented whether or not you are able to attend the

Annual Meeting. If you decide to attend the Annual Meeting and wish to change your proxy, you may do so by voting during

the Annual Meeting.

**Miscellaneous**

We will bear the cost of printing, mailing and other expenses in connection with this solicitation of proxies and will also

reimburse brokers and other persons holding shares of Common Stock in their names or in the names of nominees for their

expenses in forwarding the proxy materials to the beneficial owners of such shares. Certain of our directors, officers and

employees may, without any additional compensation, solicit proxies in person or by telephone.

Our management is not aware of any matters other than those described in this Proxy Statement that may be presented for

action at the Annual Meeting. If any other matters properly come before the Annual Meeting, it is intended that the proxies

will be voted with respect thereto in accordance with the judgment of the person or persons voting such proxies subject to

the direction of our Board.

**Proposal 1: Election of Directors**

**Introduction**

Our Board currently consists of 11 members. Each director is to hold office until his or her successor is duly elected and

qualified or until his or her earlier death, resignation or removal. The authorized number of directors may be increased or

decreased by our Board in accordance with our certificate of incorporation. EGI-AM Investments, L.L.C. ("EGI-AM"), an

affiliated entity of Equity Group Investments ("EGI") and our controlling stockholder, has the right, but not the obligation, to

nominate a majority of our directors and to designate the Chairman of the Board, for so long as EGI-AM beneficially owns

50% or more of the total voting power of our outstanding stock, and ALH Holdings, LLC (a subsidiary of Ventas, Inc.

("Ventas")) also has the right, but not the obligation, to nominate one director to the Board, for so long as ALH Holdings, LLC

and any of its affiliates (including Ventas) together beneficially own 4% or more of the total voting power of our outstanding

Common Stock. Pursuant to the terms of the nomination agreement between us, EGI-AM and ALH Holdings, LLC (the

"Nomination Agreement"), Messrs. Sen and Sotir and Mses. Campion and Havdala were designated by EGI-AM and Mr.

Bulgarelli was designated by Ventas. For additional information, see "Certain Relationships and Related Party Transactions –

Nomination Agreement."

**Qualification of Nominees to be Directors**

As described below, our Board is composed of individuals from differing backgrounds and experiences. As reflected in the

table set forth below, we believe that each of our continuing directors possesses unique qualifications, skills and attributes

that complement the performance of the full Board. The experience that each has obtained from his or her professional

background, as set forth below, has qualified him or her to serve on our Board.

**Nominees**

The following table shows the names and ages (as of April 1, 2026) of each of the nominees designated by our Board to

become directors:

---

| | | |
|:---|:---|:---|
| **Name** | **Age** | **Title** |
| Mark Sotir | 62 | Chairman of the Board |
| Martin J. Bonick  | 52 | President and Chief Executive Officer, Director |
| Peter Bulgarelli | 66 | Director |
| Peter Bynoe | 75 | Director |
| Suzanne Campion | 64 | Director |
| Robert A. DeMichiei | 61 | Director |
| William Goodyear | 77 | Director |
| Ellen Havdala | 60 | Director |
| Edmondo Robinson | 50 | Director |
| Rahul Sen | 35 | Director |
| Rob Webb | 56 | Director |

---

Information concerning our nominees is set forth below. The biographical description of each director includes the specific

experience, qualifications, attributes and skills that the Board would expect to consider if it were making a conclusion

currently as to whether such person should serve as a director.

---

| |
|:---|
| **Mark Sotir** |
| Mr. Sotir has served as member of our Board since December 2017 and currently serves as Chair of the Board. Mr. Sotir <br>has been president of Equity Group Investments ("EGI"), a private investment firm founded in 1968 by Sam Zell, since <br>October 2015. In this role, he oversees all aspects of the business and applies his more than 20 years of board and chief <br>executive officer experience by actively engaging with the investment team and portfolio companies to improve business <br>strategies and operating capabilities. In addition, Mr. Sotir is chair of the EGI investment committee and is a member of <br>the board of directors and executive vice president for Chai Trust Company, LLC, which serves as the corporate trustee <br>for the Zell family trusts. Mr. Sotir has served as chair of the board of East Coast Warehouse & Distribution, a provider of <br>temperature-controlled logistics services to the food and beverage industry, since January 2022; Paper Transport, a for-<br>hire trucking company focused on dedicated truckload, intermodal, and brokerage services, since July 2021; and an <br>agricultural equipment dealer since January 2021. Additionally, Mr. Sotir has served on the board of directors of <br>CraneWorks, a dealer of new and used truck-mounted and related mobile crane equipment, since October 2023 and in <br>December 2025, he joined the board of directors for CIT Trucks, a leading truck dealership with full-service locations <br>across the Midwest. Mr. Sotir joined EGI in 2006 as a managing director and has held temporary in-house assignments at <br>EGI portfolio companies to accelerate and increase the effectiveness of turnarounds. Prior to joining EGI, Mr. Sotir was <br>the chief executive officer of Sunburst Technology Corporation and on the company's board of directors. He also served <br>as the president of Budget Group, Inc. (Budget Rent A Car and Ryder Truck Rental) and was on the company's board. . <br>Earlier in his career, Mr. Sotir worked at The Coca-Cola Company in senior brand management and sales roles. Mr. Sotir <br>earned an undergraduate degree in economics from Amherst College and a master's degree in business administration <br>from Harvard Business School. Our Board believes that Mr. Sotir's extensive private equity experience overseeing <br>portfolio companies makes him well-suited to serve on our Board.<br>|

---

---

| |
|:---|
| **Martin ("Marty") J. Bonick** |
| Mr. Bonick has served as president and chief executive officer of Ardent Health since August 2020. As CEO, Mr. Bonick is <br>responsible for the Company's strategic direction, operational performance, and financial results, overseeing a <br>diversified healthcare organization with acute-care hospitals, outpatient facilities and joint venture partnerships across <br>multiple states. Mr. Bonick brings more than 30 years of healthcare leadership experience, with a career spanning <br>hospital operations, system leadership, and provider services organizations. Prior to joining Ardent Health, he served as <br>chief executive officer of PhyMed Healthcare Group, a national provider of anesthesia and pain management services <br>Earlier in his career, Mr. Bonick held senior leadership roles at Community Health Systems where he served as Division <br>President and Vice President of Operations as well as executive positions at Jewish Hospital & St. Mary's Healthcare and <br>OSU Medical Center at Hillcrest HealthCare System. Across these roles, he has led organizations through periods of <br>reimbursement pressure, regulatory change, and operational transformation, with a focus on improving performance <br>and aligning strategy with disciplined capital allocation. Mr. Bonick is a fellow in the American College of Healthcare <br>Executives and serves on the boards of the Federation of American Hospitals, Ensemble Health Partners and Community <br>Hospital Corporation as well as the Via College of Medicine – Auburn Advisory Board. He holds dual master's degrees <br>from Washington University in St. Louis in healthcare administration and information management and a bachelor's <br>degree in psychology from the University of Illinois. The Board believes Mr. Bonick's extensive leadership experience, <br>healthcare expertise and service as president and chief executive officer qualify him to serve as a director of the <br>Company.<br>|

---

---

| |
|:---|
| **Peter Bulgarelli** |
| Mr. Bulgarelli has served as a member of our Board since September 2018. Mr. Bulgarelli serves as a member of the <br>Compensation Committee and the Patient Safety and Quality of Care Committee. Since April 2018, Mr. Bulgarelli has <br>been the executive vice president of outpatient medical and research of Ventas. He also has served as president and <br>chief executive officer of Lillibridge Healthcare Services, Inc., a fully integrated medical office building operating <br>company, and wholly owned subsidiary of Ventas, since April 2018. Mr. Bulgarelli has announced his retirement from <br>Ventas to be effective May 1, 2026. Mr. Bulgarelli joined Ventas in 2018 following a successful 28-year career at Jones <br>Lang LaSalle, Inc., a global professional services firm specializing in real estate, and most recently leading their industry <br>focused businesses including healthcare, life sciences, higher education and the public sector businesses. Since August <br>2018. Mr. Bulgarelli has served on the board of directors of PMB Real Estate Services. He has been a member of the <br>executive board and finance committee of the Ann & Robert H. Lurie Children's Hospital of Chicago, a top-ranked <br>children's hospital and non-profit pediatric medical research center, since August 2022. Mr. Bulgarelli has also served as <br>the past chairman of the Illinois Board for the American Diabetes Association. Mr. Bulgarelli earned an undergraduate <br>degree in civil engineering from the University of Illinois and a master's degree in business administration from <br>Northwestern University's Kellogg Graduate School of Business. Our Board believes that Mr. Bulgarelli is well-qualified to <br>serve as a member of our Board due to his extensive experience in overseeing and managing healthcare related <br>companies.<br>|

---

---

| |
|:---|
| **Peter Bynoe** |
| Mr. Bynoe has served as a member of our Board since August 2015. Mr. Bynoe chairs the Nominating and Corporate <br>Governance Committee and is a member of the Compensation Committee. Mr. Bynoe is a senior advisor at DLA Piper LLP <br>(US) and has represented the international law firm as a partner, executive committee member and practice group <br>leader since 1995. Mr. Bynoe served as managing director at EGI from September 2014 to December 2019, where he <br>sourced and evaluated new investment opportunities, oversaw portfolio companies and led EGI's strategic diversification <br>into the health care sector. Previously, Mr. Bynoe served as chief executive officer of Rewards Network, an EGI portfolio <br>company that provided financing and marketing services to U.S. based restaurants, from September 2013 to August 2014 <br>and as chief operating officer of Loop Capital Markets, a full-service international investment bank/broker dealer, from <br>January 2008 to August 2013. Mr. Bynoe has served on the board of directors of TKO Group Holdings, Inc. since <br>September 2023 and as chairman of the board of Flagship Communities REIT since August 2020. Previously, he served as <br>chairman of Veridiam, Inc. from January 2016 to December 2018 and on the boards of Covanta Holding Company from <br>October 2006 to November 2021; Frontier Communications from September 2007 to April 2020; Real Industry from June <br>2015 to May 2018; JACOR Communications from 1995 to 1999; JG Industries and Huffman-Koos Furnishings from 1992 to <br>1996; Uniroyal Technology Corporation from 1991 to 1995; and River Valley Savings Bank from 1991 to 1994. Mr. <br>Bynoe's civil commitment portfolio includes chairing the Illinois Sports Facility Authority from January 2005 to December <br>2005; Chicago Commission on Landmarks from February 1984 to September 1997; and Chicago Plan Commission from <br>October 1997 to December 2004. His non-profit commitments have included: trustee of RUSH University System for <br>Health since January 1994; life trustee of The Goodman Theatre since January 1984; and trustee of the CORE Center for <br>the Research, Prevention and Care of Infectious Diseases from September 2001 to December 2022. He was elected a <br>member of the Harvard University Board of Overseers from October 1992 to June 2001. Mr. Bynoe was the owner and <br>managing general partner of the NBA's Denver Nuggets from 1989 to 1992. Mr. Bynoe received his bachelor's degree, <br>cum laude, from Harvard College. He earned a Juris Doctorate degree from Harvard Law School and a master's degree in <br>business administration from the Harvard School of Graduate Management Education. He is a member of the Illinois Bar <br>and a registered real estate broker in the state of Illinois. Our Board believes that Mr. Bynoe is well-qualified to serve on <br>our Board because of his strong legal and leadership experience in a variety of industries.<br>|

---

---

| |
|:---|
| **Suzanne Campion** |
| Ms. Campion has served as a member of our Board since December 2021.Ms. Campion serves as a member of the <br>Compensation Committee and the Nominating and Corporate Governance Committee. In 2018, Ms. Campion helped <br>structure and build Doran Leadership Partners, a boutique executive search firm focused on middle market and founder-<br>owned companies and large philanthropic organizations. She served as the managing director and chief operating officer <br>until April 2022 subsequently becoming an advisor to the firm until January 2024. Ms. Campion co-founded <br>NextLevelNPO in 2013, which provides operational, financial and strategic advisory services to non-profit clients. In 2019, <br>she became an advisor to the firm and resigned in early 2024. Previously, Ms. Campion spent her career in finance and <br>over the course of 25 years, she focused on operations, client advisory, investments, financial analysis, strategy, and <br>human resources for a variety of investment firms from August 1988 to September 2012 including Citigroup, Front <br>Barnett Associates, J.P. Morgan & Co., and Bankers Trust Company. Since April 2019, Ms. Campion has served on the <br>board of Chai Trust Company, LLC, the corporate trustee for the Zell family trusts, and serves as the chair of its <br>Governance Committee and its Distribution and Beneficiary Relations Committee. Before moving from Chicago in 2023, <br>Ms. Campion was a board member of the KIPP Chicago Public Charter School Board from January 2014 and served on the <br>Founder's Board of Lurie Children's Hospital of Chicago from January 2005. Upon moving to Santa Fe, New Mexico, Ms. <br>Campion joined the board of one of the largest public dog parks in the country, the Frank S. Ortiz Dog Park. Ms. Campion <br>earned an undergraduate degree in economics from St. Olaf College and a master's degree in business administration <br>from the Kellogg School of Management at Northwestern University. Our Board believes that Ms. Campion's extensive <br>executive and board member experience and demonstrated history of working in finance, operations, strategy and <br>governance makes her well-qualified to serve on our Board.<br>|

---

---

| |
|:---|
| **Robert A. DeMichiei** |
| Mr. DeMichiei has served as a member of our Board since April 2, 2025.Mr. DeMichiei serves as a member of the Audit <br>and Compliance Committee and the Nominating and Corporate Governance Committee. Mr. DeMichiei served as <br>executive vice president and chief financial officer at the University of Pittsburgh Medical Center ("UPMC"), a large <br>nonprofit health system and leading healthcare provider and insurer, from 2004 to 2020. During his tenure, he played a <br>pivotal role in driving UPMC's financial growth and led numerous strategic initiatives, including mergers and acquisitions, <br>supply chain management, and revenue cycle improvements. Prior to joining UPMC, Mr. DeMichiei held various <br>leadership roles with the General Electric Company (NYSE: GE), an equipment, solutions, and services provider, from <br>1997 to 2004, and with PricewaterhouseCoopers, a network of professional services firms, from 1987 to 1997. Mr. <br>DeMichiei has served as a board member of Waystar Holding Corp. (Nasdaq: WAY), a provider of leading healthcare <br>payments software, since January 2020, Ampco-Pittsburgh Corporation (NYSE: AP), a manufacturer of forged and cast <br>engineered products and air and liquid processing products, since May 2022, and Auto Club Enterprises/AAA, a national <br>insurer and member services organization and a part of the AAA federation of motor clubs, since October 2021. Mr. <br>DeMichiei also currently serves as a strategic advisor for Health Catalyst, Inc. (Nasdaq: HCAT), a leading provider of data <br>and analytics technology and services to healthcare organizations, and Omega Healthcare Management Services, a <br>leading provider of revenue cycle management and clinical services to healthcare organizations. He was a founder and <br>former board member of Prodigo Solutions, Inc., a supply chain and data enablement technology company. He is the <br>former chairman and a current board member of the United Way of Southwestern Pennsylvania, the finance committee <br>chair of the Seton Hill University Board of Trustees, audit committee chair of Eradicate Hate Global Summit, and the <br>treasurer and finance committee chair of the Advanced Leadership Institute, which are all charitable organizations. Mr. <br>DeMichiei graduated magna cum laude with a B.A. in Business Economics from the University of Pittsburgh. The Board <br>believes that Mr. DeMichiei is well-qualified to serve on the Board given his extensive experience in healthcare finance <br>and operations including with a multi-faceted health system larger than the Company, as well as his extensive board <br>experience. In addition, the Board determined that Mr. DeMichiei's service for two other public company boards <br>provides valuable perspective and does not impair his ability to effectively serve on our audit and compliance committee. <br>|

---

---

| |
|:---|
| **William Goodyear** |
| Mr. Goodyear has served as a member of our Board and Chairman of our Audit and Compliance Committee since March <br>2019. Mr. Goodyear also serves as a member of the Nominating and Corporate Governance Committee. Mr. Goodyear <br>served as chairman and chief executive officer at Navigant Consulting from 2000 to 2014. From 1994 to 1999, Mr. <br>Goodyear served as chairman of Bank of America Illinois and as president of Bank of America's Global Private Bank. Prior <br>to that he held domestic and international executive positions with Continental Bank Corporation from 1972 until it <br>merged with Bank of America in 1994. From 2015 to 2022, Mr. Goodyear was on the board of Exterran Corporation <br>where he was the lead independent director, chair of the audit committee and a member of the compensation <br>committee. Since October 2014, he has also been a director of Enova, Inc. and a member of its audit committee. Mr. <br>Goodyear has been on the board of Rush University Medical Center for over 30 years serving in various capacities <br>including chairman of the board, chairman of the executive committee and now as an advisor trustee. He is the past <br>chairman of the Museum of Science and Industry and was a member of the Executive Committee. He is currently an <br>emeritus trustee of the University of Notre Dame after previously serving on the Advisory Council for the Mendoza <br>College of Business, the University Board of Trustees and as a Fellow of the University. Mr. Goodyear earned an <br>undergraduate degree in business from Notre Dame and a master's degree in business administration from the Tuck <br>School of Business Administration at Dartmouth College. Mr. Goodyear received an honorary Doctor of Laws degree from <br>Notre Dame in May 2018. Our Board believes that Mr. Goodyear's extensive management and director experience <br>makes him well-qualified to serve on our Board.<br>|

---

---

| |
|:---|
| **Ellen Havdala** |
| Ms. Havdala has served as a member of our Board since January 2019. Ms. Havdala serves as Chairman of the <br>Compensation Committee and a member of the Patient Safety and Quality of Care Committee. In Ms. Havdala's current <br>role as a managing director of EGI, she represents EGI in finding and evaluating potential investments and works with <br>existing portfolio companies. Since joining EGI in September 1990, Ms. Havdala has worked in a variety of capacities for <br>Sam Zell's affiliates. She has served on the board for CraneWorks, Inc., a dealer of new and used truck-mounted and <br>related mobile crane equipment, since April 2024. In addition, she is responsible for establishing and overseeing the Zell <br>Global Entrepreneurship Network, an organization that provides continuing education and mentorship for student and <br>alumni of three entrepreneurship programs sponsored by the Zell Family Foundation. As part of her involvement, she <br>also serves on the board of the Zell Lurie Institute at the University of Michigan Ross School of Business. Previously, she <br>served on the boards of Lanter Delivery Systems, an asset-light overnight dedicated delivery service provider; Equity <br>Distribution Acquisition Corp., a special purpose acquisition company targeting opportunities to apply technological <br>advancement within the industrial sector; SIRVA, Inc., a provider of moving and relocation services; Rewards Network, a <br>dining rewards company; WRS Holding Company, which specializes in environmental construction and remediation; East <br>Mediterranean Gas Company SAE, an Egyptian natural gas transmission business; National Patent Development <br>Corporation, a holding company focused on pharmaceutical and home improvement products; and Home Products <br>International, a global consumer products company. She also held the roles of executive vice president at Equity <br>International and vice president of Scott Sports Group, Inc. Ms. Havdala began her career as a financial analyst with The <br>First Boston Corporation in New York City in 1988. Ms. Havdala graduated magna cum laude with an undergraduate <br>degree in economics from Harvard College and earned her Master of Divinity degree from the University of Chicago in <br>2016. Our Board believes that Ms. Havdala is well-qualified to serve on our Board due to her extensive management and <br>investment experience.<br>|

---

---

| |
|:---|
| **Edmondo Robinson, M.D.** |
| Dr. Robinson has served as a member of our Board since January 2022. Dr. Robinson is the Chairman of the Patient <br>Safety and Quality of Care Committee and serves as a member of the Audit and Compliance Committee. Dr. Robinson <br>has served as a director of TruLite Health, a developer of the only health equity solution to remediate clinical bias, since <br>February 2025 and Carriage Services, Inc. (NYSE: CSV), a leading provider of funeral and cemetery services and <br>merchandise in the United States, since October 2024. He currently serves as a member of the Compensation, Chairman <br>of the Audit and Corporate Governance Committees for Carriage Services, Inc. Dr. Robinson has been the Founder and <br>CEO of Downeast Digital, a company that leverages digital innovation to address critical challenges of medicine, since <br>February 2024 and has served on the Technical Expert Panel, Impact Assessment of CMS Quality and Efficiency Measures <br>for CMS since 2019. Dr. Robinson has also served on the AT&T Healthcare Advisory Council since January 2019 and <br>Digital Medicine Society Founding Members Council since April 2019. Dr. Robinson has been a practicing academic <br>hospitalist at the Moffitt Cancer Center since December 2019 and a professor of Internal Medicine and Oncologic Science <br>at University of South Florida's Morsani College of Medicine since December 2019. Previously, Dr. Robinson held the <br>following positions: Senior Vice President and Chief Digital Officer at Moffitt Cancer Center from December 2019 to <br>January 2024; various roles at ChristianaCare from July 2008 to December 2019; clinical assistant professor of medicine <br>and associate professor of medicine at Sidney Kimmel Medical College from June 2009 to June 2017 and June 2017 to <br>November 2019, respectively; clinical scholar at Robert Wood Johnson Foundation from July 2006 to June 2008; <br>physician at Kaiser Permanente Medical Group from May 2006 to June 2008; and resident physician at Harbor-UCLA <br>Medical Center from July 2003 to June 2006. Dr. Robinson also served on the board of Aster Insights from January 2020 <br>to December 2023. Dr. Robinson is a fellow of the American College of Physicians, a senior fellow of the Society of <br>Hospital Medicine, and an Aspen Institute Health Innovators Fellow. Dr. Robinson earned a medical degree from the <br>University of California, Los Angeles, a master's degree in business administration from the Wharton School and a <br>master's degree in health policy research from the University of Pennsylvania. Our Board believes that Dr. Robinson is <br>well-qualified to serve on our Board due to his extensive medical and information management experience.<br>|

---

---

| |
|:---|
| **Rahul Sen** |
| Mr. Sen has served as a member of our Board since November 2020. Mr. Sen serves as a member of the Compensation <br>Committee. Mr. Sen has been a managing director at EGI since January 2022. As managing director, he sources and <br>evaluates new investment opportunities, negotiates and structures transactions, and works to maximize the value of <br>existing investments. In addition to our Board, Mr. Sen has served on the boards of Baja Aqua-Farms, a Bluefin tuna <br>ranching operation, since November 2023; CraneWorks, a dealer of new and used truck-mounted and related mobile <br>crane equipment, since October 2023; Ventana Exploration and Production II, LLC, an oil and gas acquisition and <br>development company, since February 2019; and EGI's agricultural equipment dealer since January 2021. Mr. Sen also <br>supports EGI's investment in a government contractor business providing information technology hardware and <br>solutions to the federal intelligence agencies since February 2023. He previously served on the boards of RailUSA, LLC, a <br>short-line and regional railroad platform owner and operator, from October 2018 to April 2022; Cross Border Xpress, a <br>binational airport terminal that connects San Diego directly to the Tijuana airport, from February 2019 to May 2020; <br>Entertainment Earth, a pioneer and established leader in the collectibles and toy industry, from July 2022 to June 2024; <br>and Veridiam, Inc., a specialty alloy manufacturer serving the nuclear power, medical, aerospace, and industrial markets, <br>from June 2015 to May 2019. Prior to joining EGI in 2015, Mr. Sen worked as a private equity associate at Big Tree Capital <br>Partners, LLC, a search fund focused on the lower-middle market, from September 2014 to March 2015 and a senior <br>consultant in the strategy and analytics practice at IBM from May 2013 to March 2015. Mr. Sen also provided strategic <br>consulting to technology startups based out of Google's Communitech Hub from November 2012 to April 2013. <br>Previously, he worked at Home Trust Company from May 2012 to August 2012, where he helped with the strategy for <br>the launch of a new direct-to-consumer retail banking deposits business known as Oaken Financial, and at OneClass, a <br>venture-backed startup, from September 2011 to April 2012. Mr. Sen earned an undergraduate degree in business <br>administration from Wilfrid Laurier University. Our Board believes that Mr. Sen's consulting and investment experience <br>makes him well-qualified to serve on our Board.<br>|

---

---

| |
|:---|
| **Rob Webb** |
| Mr. Webb has served as a member of our Board since January 2022. Mr. Webb serves as a member of the Audit and <br>Compliance Committee and the Patient Safety and Quality of Care Committee. Mr. Webb currently serves as the <br>president of Onward Enterprises, an investment and advisory firm focused on driving innovation in healthcare and other <br>industries, and has held this role since August 2021. Since March 2023, he has also served as operating partner of Granite <br>Creek Capital Partners, L.L.C. Mr. Webb previously spent 19 years with UnitedHealth Group in several executive roles, <br>including the president of UnitedHealth Group Ventures from 2012 to July 2021 and chief executive officer of Optum's <br>consumer and specialty network businesses from 2002 to 2012. In addition to Ardent's board, Mr. Webb has served as <br>chairman of Collage Rehabilitation Partners since August 2023 and in a board role for American Well Corporation since <br>November 2022, Delmec Ireland since March 2022 and The Kellogg School Health Care Advisory Board since September <br>2020. Mr. Webb previously served as partner at One Equity Partners from 2000 to 2002 and vice president of EGI from <br>1998 to 2000. From July 2012 to July 2021, he also held board roles at various privately held healthcare companies during <br>his tenure as president of UnitedHealth Group Ventures, including Symphonix Health, Sanvello, Naviguard, Bind <br>Insurance (now Surest), and Level2. Mr. Webb earned an undergraduate degree in Mechanical Engineering from the <br>University of Minnesota and a master's degree in business administration from the Kellogg School of Management at <br>Northwestern University. Our Board believes that Mr. Webb is well-qualified to serve on our Board due to his extensive <br>experience as a healthcare executive and board member, and advocate for innovation in long-established industries.<br>|

---

**Required Vote**

Our Amended and Restated Bylaws (the "Bylaws") provide that a nominee is elected if a plurality of the votes cast by the

holders of the shares of Common Stock entitled to vote in the election at a meeting at which a quorum is present are cast in

favor of such nominee's election. Our Certificate of Incorporation, as amended, ("Certificate of Incorporation") does not

provide for cumulative voting, and, accordingly, the stockholders do not have cumulative voting rights with respect to the

election of directors. Consequently, each stockholder may cast one vote per share of Common Stock held of record for each

nominee. Abstentions and broker non-votes will have no effect on the outcome of the election. If a nominee becomes

unavailable for election, shares covered by a proxy will be voted for a substitute nominee selected by our Board.

**The Board recommends that the stockholders vote FOR each of** <br>**the Board of Director nominees.**<br>

**Corporate Governance**

**Director Independence**

The rules of the New York Stock Exchange (the "NYSE") and the Securities and Exchange Commission (the "SEC") impose

several requirements with respect to the independence of our directors. We are considered a "controlled company" for the

purposes of NYSE's rules and corporate governance standards because EGI-AM controls more than 50% of the voting power

of our outstanding Common Stock. As a result, although the members of our audit and compliance committee are required

to be independent, we are not required to have a majority of our Board be independent, nor are we required to have a

compensation committee or an independent nominating function under the rules of the NYSE. Accordingly, you may not

have the same protections afforded to stockholders of companies that are subject to all of these corporate governance

requirements. If we cease to be a "controlled company" and our shares continue to be listed on the NYSE, we will be

required to comply with these provisions within the applicable transition periods.

Our Board has evaluated the independence of its members based upon the rules of the NYSE and the SEC. For a director to

be considered independent under those rules, our Board must affirmatively determine that the director does not have any

material relationship with us. Applying these standards, our Board has determined that, we had nine independent directors

in 2025. Each of our directors other than Messrs. Bonick and Bulgarelli is an independent director as defined under the rules

of the NYSE applicable to members of our Board. In making this determination, our Board considered the relationships that

each non-employee director has with us and all other facts and circumstances our Board deemed relevant in determining

their independence, including the beneficial ownership of our Common Stock by EGI-AM and Ventas, the roles of Messrs.

Sen and Sotir and Mses. Campion and Havdala with EGI-AM and affiliates of EGI-AM, the role of Mr. Bulgarelli with Ventas

and affiliates of Ventas, the Services Agreement entered into between us and EGI-AM as described under "Certain

Relationships and Related Party Transactions – Services Agreement," and payments made by us to EGI-AM, Ventas and their

respective affiliates, including, in the case of Ventas, the lease agreements associated with the sale of 18 medical office

buildings to Ventas in exchange for $204.0 million on February 9, 2022, and the concurrent entry into agreements to lease

the real estate back from Ventas over a 12-year initial term with eight options to renewal for additional five-year terms,

rent payments under the master lease agreement with Ventas (the "Ventas Master Lease") and payments made with

respect to the repurchase of certain shares held by Ventas for $26.0 million concurrent with the purchase of a minority

interest in the Company by Pure Health Capital Americas 1 SPV RSC LTD ("Pure Health"). The Board has determined that

following Mr. Bulgarelli's retirement from Ventas on May 1, 2026, he will be an independent director as defined under the

rules of the NYSE.

Our Board determined that none of the aforementioned relationships interfere with the independent and objective

oversight by Messrs. Sen and Sotir and Mses. Campion and Havdala of our management or promotion of management's

accountability to our stockholders or with their exercise of independent judgment as a director. Therefore, our Board

concluded that Messrs. Sen and Sotir and Mses. Campion and Havdala each qualify as an independent director under the

applicable NYSE listing rules, and Mr. Bulgarelli will qualify as an independent director following his retirement from Ventas.

**Code of Business Conduct and Ethics and Corporate Governance Guidelines**

Our Board has adopted a code of business conduct and ethics (the "Code of Ethics") that applies to all of our directors,

officers and employees, including our principal executive officer, principal financial officer, principal accounting officer and

persons performing similar functions. We also maintain Corporate Governance Guidelines, which reflect the Board's

commitment to monitor the effectiveness of policy and decision making at the Board and management levels, with a view

to enhancing stockholder value over the long-term. The Code of Ethics and our Corporate Governance Guidelines are

available upon written request to Corporate Secretary, Ardent Health, Inc., at 340 Seven Springs Way, Suite 100,

Brentwood, Tennessee 37027 or on our website at www.ardenthealth.com under the webpage "Investor Relations –

Governance – Governance Documents." If we amend or grant any waiver from a provision of our Code of Ethics that applies

to any of our executive officers, we will publicly disclose such amendment or waiver on our website and as required by

applicable law, including by filing a Current Report on Form 8-K with the SEC.

**Committees of the Board of Directors**

Our Board of Directors has established four standing committees – an Audit and Compliance Committee, a Nominating and

Corporate Governance Committee (the "Nominating Committee"), a Compensation Committee and a Patient Safety and

Quality of Care Committee (the "Quality Committee"), each of which is described below.

***Audit and Compliance Committee***

Our Board of Directors has appointed an Audit and Compliance Committee to assist it in fulfilling its oversight

responsibilities for our financial reports, systems of internal control over financial reporting and accounting policies,

procedures and practices. The primary responsibilities and duties of the Audit and Compliance Committee are:

• Selecting, evaluating, compensating and overseeing the independent registered public accounting firm;

• Reviewing the audit plan, changes in the audit plan, and the nature, timing, scope and results of the audit to

be conducted by the independent registered public accounting firm;

• Overseeing the financial reporting activities, including the Annual Report, and the accounting standards and

principles followed;

• Reviewing and discussing with management and the independent auditor, as appropriate, the effectiveness of

the internal control over financial reporting and our disclosure controls and procedures;

• Reviewing major financial risk exposures (and the steps management has taken to monitor and control these

risks) and the risk assessment and risk management policies and the guidelines, policies and processes for risk

assessment and risk management;

• Approving audit and non-audit services provided by the independent registered public accounting firm;

• Reviewing and, if appropriate, approving or ratifying transactions with related persons required to be

disclosed under SEC rules;

• Meeting with management and the independent registered public accounting firm to review and discuss our

financial statements and other matters;

• Overseeing the internal audit function, including reviewing its organization, performance and audit findings,

and reviewing our disclosure and internal controls;

• Overseeing compliance with applicable legal, ethical and regulatory requirements (other than those assigned

to other committees of the Board);

• Monitoring the integrity of the financial statements and compliance with legal and regulatory requirements as

they relate to our financial statements and accounting matters;

• Establishing procedures for the receipt, retention and treatment of complaints received regarding accounting,

internal controls, auditing or compliance matters;

• Discussing on a periodic basis, or as appropriate, with management, the policies and procedures with respect

to risk assessment;

• Investigating any matters received, and reporting to the Board periodically, with respect to ethics issues,

complaints and associated investigations; and

• Reviewing the audit and compliance committee chart and the committee's performance at least annually.

During 2025, the Audit and Compliance Committee was composed of Dr. Robinson and Messrs. DeMichiei, Goodyear, and

Webb, with Mr. Goodyear serving as the chairperson. During 2025, the Audit and Compliance Committee held eight

meetings. Our Board has determined that each of Dr. Robinson and Messrs. DeMichiei, Goodyear, and Webb qualifies as an

independent director according to the rules and regulations of the SEC and the listing rules of the NYSE with respect to

audit and compliance committee membership.

Our Board has determined that each of Mr. Goodyear and Mr. DeMichiei qualifies as an "audit committee financial expert,"

as such term is defined in the rules and regulations of the SEC. A copy of the charter of our Audit and Compliance

Committee is available on our principal corporate website at *www.ardenthealth.com* under the webpage "Investor

Relations – Governance – Governance Documents."

***Nominating and Corporate Governance Committee***

Our Board of Directors has appointed the Nominating Committee to assist it with director nominations matters. The

primary responsibilities and duties of the Nominating Committee are:

• Identify, evaluate and recommend individuals qualified to become members of the Board, consistent with

criteria approved by the Board;

• Select, or recommend that the Board select, the director nominees to stand for election at each annual

general meeting of the stockholders or any subsidiary or to fill vacancies on the Board;

• Develop and recommend to the Board a set of corporate governance guidelines applicable to the Company

and monitor compliance with such guidelines;

• Review proposed waivers of the code of conduct for directors and executive officers;

• Oversee the annual performance evaluation of the Board (and any committees thereof) and management; and

• Oversee actions in furtherance of the corporate social responsibility and the manner in which the Company

conducts public policy and government relations activities.

The Nominating Committee also recommends directors eligible to serve on all committees of our Board. The Nominating

Committee also reviews and evaluates all stockholder director nominees.

Pursuant to the Nomination Agreement, for so long as EGI-AM beneficially owns more than 50% of the total voting power

of our outstanding Common Stock, EGI-AM's designees will comprise a majority of the Nominating Committee and, for as

long as EGI-AM beneficially owns 4% or more of the total voting power of our outstanding Common Stock, EGI-AM will be

entitled to include at least one of its designees on the Nominating Committee. For additional information, see "Certain

Relationships and Related Party Transactions – Nomination Agreement."

During 2025, the Nominating Committee was composed of Ms. Campion and Messrs. DeMichiei, Bynoe and Goodyear, with

Mr. Bynoe serving as the chairperson. During 2025, the Nominating Committee held four meetings. The Nominating

Committee has a written charter available on our website at *www.ardenthealth.com* under the webpage "Investor Relations

- Governance - Governance Documents."

***Compensation Committee***

Our Board has appointed the Compensation Committee to assist it with executive compensation matters. The primary

responsibilities and duties of the Compensation Committee are to administer the compensation program and other benefit

plans and practices for our key officers (consisting of our executive officers as defined in Rule 3b-7 of the Securities

Exchange Act of 1934, as amended (the "Exchange Act"), other corporate executive officers, and regional presidents) and

members of the Board. Our compensation committee reviews and either approves, on behalf of the Board, or recommends

to the Board for approval, (i) annual salaries, bonuses and other compensation for our executive officers, and (ii) individual

equity awards for our key officers. Our compensation committee also oversees our compensation policies and practices

more generally. The compensation committee periodically reports to the Board.

Our Compensation Committee performs the following functions related to executive compensation:

• Review and approve the goals and objectives relating to the compensation of our key officers, including any

long-term incentive components of the compensation programs;

• Evaluate the performance of the key officers, including, in light of the goals and objectives of our

compensation programs and determine each key officer's compensation based on such evaluation;

• Review, approve and, when appropriate, recommend to the Board new or amended executive compensation

programs, subject, if applicable, to stockholder approval;

• Review the operation and efficiency of the executive compensation programs in light of their goals and

objectives;

• Review and assess risks arising from the compensation programs;

• Periodically review that the executive compensation programs comport with the compensation committee's

stated compensation philosophy;

• Review management succession planning;

• Annually produce reports for filings with government agencies in compliance with applicable law or regulation;

• Review and recommend to the Board the appropriate structure and amount of compensation for the

directors;

• Establish and periodically review policies for the administration of the equity compensation plans; and

• Review the adequacy of the compensation committee and its charter and recommend any proposed changes

to the Board not less than annually.

In deciding upon the appropriate level of compensation for our key officers, the Compensation Committee regularly reviews

our compensation programs relative to our strategic objectives and emerging market practice and other changing business

and market conditions. In addition, the Compensation Committee also takes into consideration the recommendations of

our Chief Executive Officer and independent compensation consultant concerning compensation actions for our other key

officers.

Pursuant to the Nomination Agreement, for so long as EGI-AM beneficially owns more than 50% of the total voting power

of our outstanding Common Stock, EGI-AM's designees will comprise a majority of the Compensation Committee and, for as

long as EGI-AM beneficially owns 4% or more of the total voting power of our outstanding Common Stock, EGI-AM will be

entitled to include at least one of its designees on the Compensation Committee. For additional information, see "Certain

Relationships and Related Party Transactions – Nomination Agreement."

During 2025, the Compensation Committee was composed of Messrs. Bynoe, Bulgarelli and Sen and Mses. Campion and

Havdala, with Ms. Havdala serving as the chairperson. As long as we are a controlled company, we are not required by NYSE

rules to maintain a compensation committee comprised solely of independent directors. During 2025, the Compensation

Committee held five meetings. The Compensation Committee has a written charter that is available on our website at

*www.ardenthealth.com* under the webpage "Investor Relations – Governance – Governance Documents."

***Patient Safety and Quality of Care Committee***

The Quality Committee assists our Board in fulfilling its oversight responsibilities relating to the review of our policies and

procedures concerning the delivery of quality medical care to patients. The Quality Committee maintains communication

between the Board and members of our senior management, with our management having responsibility for the operations

and integrity of our clinical operations and service lines. The Quality Committee reviews matters concerning or relating to

the quality of medical care delivered to patients, efforts to advance the quality of health care provided and patient safety.

The Quality Committee also performs the following functions:

• Review the quality, safety, clinical risk and clinical services improvement strategies and operations;

• Review the policies and procedures developed by the Company to promote quality patient care and patient

safety;

• Retain or approve the recommendation for the retention of consultants or other advisors, from time to time,

concerning quality of patient care and patient safety matters;

• Review the development of internal systems and controls to carry out the standards, policies and procedures

relating to quality of patient care and patient safety, including, without limitation, controls designed to

facilitate communication across the organization regarding patient care and safety improvement opportunities

and activities and the evaluation thereof;

• Review relationships with academic medical centers; and

• Review and oversee policies and practices for promoting the Company's commitment to equity of patient

care.

During 2025, the Quality Committee was composed of Dr. Robinson, Messrs. Bulgarelli and Webb, and Ms. Havdala, with

Dr. Robinson serving as chairperson. During 2025, the Quality Committee held four meetings. The Quality Committee has a

written charter available on our website at *www.ardenthealth.com* under the webpage "Investor Relations – Governance –

Governance Documents."

**Meetings of our Board of Directors and Committees**

During 2025, our Board held a total of ten meetings. Each director attended 75% or more of the meetings of our Board and

the committees of our Board on which such director served, except for Mr. Sen who attended over 73%.

**Nomination of Directors**

***Nominations by the Nominating Committee***

Directors may be nominated by our Nominating Committee, Board, executive officers or by our stockholders in accordance

with our Bylaws, Certificate of Incorporation, applicable laws and any guidelines developed by the Nominating Committee

or the Board. The Nominating Committee is responsible for identifying individuals qualified to become members of the

Board and its committees, and recommending candidates for the Board's selection as director nominees for election at the

annual meeting, to fill vacancies on the Board or at other properly convened meetings of the stockholders in accordance

with our Bylaws, the listing standards of the NYSE and applicable laws and regulations. The Nominating Committee meets to

discuss and evaluate the qualities and skills of each candidate, both on an individual basis and considering the overall

composition and needs of the Board. The Nominating Committee considers each identified candidate's qualifications, which

include the nominee's experience, business acumen, education, integrity, character, commitment, diligence, conflicts of

interest and ability to exercise sound business judgment. We generally seek nominees with a broad diversity of experience,

professions, skills and backgrounds. We do not currently pay a fee to any third party to identify or assist in identifying or

evaluating potential nominees.

***Nominations Pursuant to the Nomination Agreement***

Subject to the terms of the Nomination Agreement and based on its ownership of Common Stock, EGI-AM has the right, but

not the obligation, to nominate a majority of our directors and to designate the Chairman of the Board and ALH Holdings,

LLC (a subsidiary of Ventas) also has the right, but not the obligation, to nominate one director to the Board. For additional

information, see "Certain Relationships and Related Party Transactions – Nomination Agreement."

***Nominations by Our Stockholders***

Our Bylaws govern stockholder nominations of directors. To make a director nomination at the 2027 annual meeting, a

stockholder of record entitled to vote at the annual meeting must deliver a written notice (containing certain information

specified in our Bylaws as discussed below) to the Corporate Secretary at Ardent Health, Inc., 340 Seven Springs Way, Suite

100, Brentwood, Tennessee 37027. If the date of the 2027 annual meeting is within 30 days from the first anniversary of the

preceding year's annual meeting of stockholders, the stockholder's notice must be received at the principal executive

offices of the Company not less than 90 days nor more than 120 days prior to the first anniversary date on which the

Company first mailed its proxy materials or a notice of availability of proxy materials (whichever is earlier) for the

immediately preceding year's annual meeting.

For a stockholder nomination to be deemed proper, the notice must contain certain information specified in our Bylaws,

including information as to the director nominee(s) proposed by the stockholder, a written questionnaire with respect to

the background qualifications of the director nominee(s), a written representation completed by the director nominee(s) in

the form required by the Company, a description of all arrangements or understandings between the stockholder and any

other persons (including each proposed nominee(s) if applicable) in connection with the proposed nominations, a

description of any business or personal interests that would potentially create a conflict of interest between the director

nominee(s) and the Company, the date(s) of first contact between the stockholder and the director nominee(s) with respect

to any proposed nomination, and all other information relating to such director nominee(s) that would be required to be

disclosed in a proxy statement by such stockholder in connection with the solicitation of proxies for the election of directors

in a contested election or otherwise required pursuant to Section 14 of the Exchange Act and the rules and regulations

promulgated thereunder.

In addition to satisfying the foregoing requirements under our Bylaws, to comply with the universal proxy rules,

stockholders who intend to solicit proxies in support of director nominees other than the Board's director nominees must

provide notice that sets forth the information required by Rule 14a-19 under the Exchange Act.

**Communicating with the Board**

Stockholders and other interested parties wishing to communicate with the Board or any of its committees or directors may

do so by writings directed to the Chairman of the Board, c/o Executive Vice President and General Counsel, to the following

address: Ardent Health, Inc., 340 Seven Springs Way, Suite 100, Brentwood, Tennessee 37027.

**Attendance by Members of the Board of Directors at the Annual Meeting of Stockholders**

We encourage each member of our Board of Directors to attend the annual meeting of stockholders. All members of the

Board of Directors who served on the Board at the time of the 2025 Annual Meeting attended the meeting.

**Board Leadership Structure**

The Board determines its leadership structure in a manner that it determines to be in the best interest of the Company and

the stockholders. The Board conducts an annual assessment of its leadership structure to determine that the leadership

structure is the most appropriate for the Company at the time. The Board anticipates that the Company's Chief Executive

Officer will be nominated annually to serve on the Board. Currently, Mark Sotir serves as the Chairman of the Board and

Marty Bonick is our President and Chief Executive Officer. Mr. Bonick is also a member of the Board. The Board of Directors

has carefully considered its leadership structure and believes at this time that the Company and its stockholders are best

served by having the positions of Chairman of the Board and Chief Executive Officer filled by different individuals. In

addition, our independent directors bring experience, oversight and expertise from outside our Company and industry,

while the Chief Executive Officer brings Company-specific experience and expertise. The Board recognizes that depending

on future circumstances, other leadership models may become more appropriate.

**Executive Sessions**

Each regular meeting of the Board shall include an executive session at which no employee directors or other employees

are present. If the non-employee directors include one or more directors who is not independent under the NYSE listing

standards, the independent directors will themselves meet in executive session at least once per year. These executive

sessions may include such topics as the non-employee or independent directors determine. During these executive

sessions, the non-employee or independent directors shall have access to members of management and other guests as

they may determine.

**Risk Oversight**

Our Board is responsible for overseeing our risk management process. The Board fulfills its responsibility by delegating

many of these functions to its committees. Under its charter, the Audit and Compliance Committee is responsible for

meeting periodically with management to review our major financial risks and the steps management has taken to monitor

and control such risks. The Audit and Compliance Committee also oversees our financial reporting and internal controls and

compliance programs.

The Board receives reports on risk management from our senior officers and the Audit and Compliance Committee. Also,

our Executive Vice President and General Counsel provides a summary of our outstanding material litigation and

governmental investigations to our Board at each Board meeting. Additionally, our Board regularly engages in discussions of

the most significant risks that we are facing and how these risks are being managed. Our Board of Directors believes that

the work undertaken by the Audit and Compliance Committee, together with the oversight provided by the full Board,

enables the Board to oversee our risk management function effectively.

**Compensation Committee Interlocks and Insider Participation**

None of the members of our Compensation Committee is or has been an officer or employee of the Company or any of our

subsidiaries. In addition, none of our executive officers serves or has served as a member of the Board, Compensation

Committee or other Board committee performing equivalent functions of any entity that has one or more executive officers

serving as one of our directors or on our Compensation Committee.

**Proposal 2: Non-Binding Advisory Vote on Executive Compensation**

The Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 (the "Dodd-Frank Act") enables our stockholders

to vote to approve, on a non-binding advisory basis, the compensation of our NEOs as described below in the sections

entitled "Compensation Discussion and Analysis" and "Executive Compensation." Because your vote is advisory, it will not

be binding on the Board of Directors or the Compensation Committee, override any decision made by the Board or the

Compensation Committee or create or imply any additional fiduciary duty of the Board or the Compensation Committee.

The Compensation Committee will, however, review the voting results and take them into consideration when making

future decisions regarding executive compensation.

Our executive compensation program is vital to our ability to attract, motivate and retain a highly experienced team of

executives. We believe that the program is structured in a manner that supports our Company and our business objectives.

We are asking our stockholders to indicate their support for the compensation of our NEOs disclosed in this Proxy

Statement. This proposal, commonly known as a "say-on-pay" proposal, gives our stockholders the opportunity to express

their views on the compensation of our NEOs. This vote is not intended to address any specific item of compensation, but

rather the overall compensation of our NEOs and the philosophy, policies and practices described in this Proxy Statement.

Accordingly, we ask our stockholders to vote FOR the following resolution at the Annual Meeting:

RESOLVED, that the Company's stockholders approve, on a non-binding advisory basis, the compensation of the

NEOs as disclosed in the Company's Proxy Statement for the 2026 Annual Meeting of Stockholders pursuant to

Item 402 of Regulation S-K, including the sections entitled "Compensation Discussion and Analysis" and "Executive

Compensation."

Although the results of this advisory vote are not binding on the Board or the Compensation Committee, the Compensation

Committee will review the voting results and take them into consideration when making future decisions regarding

executive compensation.

**The Board recommends that stockholders vote FOR the resolution to approve, on a**<br>**non-binding advisory basis, the compensation of our NEOs.**<br>

**Management**

Below are the names and ages (as of April 1, 2026) of our executive officers, and a brief account of the business experience

of the executive officers who are not members of our Board.

---

| | | |
|:---|:---|:---|
| **Name** | **Age** | **Title** |
| Marty Bonick | 52 | President and Chief Executive Officer |
| Alfred Lumsdaine | 60 | Chief Financial Officer |
| David Caspers | 55 | Chief Operating Officer |
| Stephen C. Petrovich | 59 | Executive Vice President and General Counsel |

---

The term of each executive officer runs until his successor is appointed and qualified, or until his earlier death, resignation

or removal.

**Marty Bonick**

Mr. Bonick's biographical information can be found above under "Proposal 1: Election of Directors – Nominees."

**Alfred Lumsdaine**

Mr. Lumsdaine has served as our chief financial officer since September 2021. As chief financial officer, he provides financial

oversight across all of our organization's activities and assets, as well as development and execution of Ardent's long-range

financial plans. Prior to joining Ardent, Mr. Lumsdaine served as executive vice president of finance of Quorum Health

Corporation ("Quorum") from February 2018 through March 2018 and then served as executive vice president and chief

financial officer of Quorum from April 2018 to July 2021, where he oversaw financial operations for the company's acute

care hospitals and led a major financial restructuring and other strategic initiatives. From 2016 to 2018, he was president of

Population Health for Sharecare, Inc. Mr. Lumsdaine spent almost 15 years at Healthways, Inc. from 2002 to August 2016 in

various roles including controller, chief accounting officer and chief financial officer. Mr. Lumsdaine also served as treasurer

and controller at Logisco from 2000 to 2002; vice president of corporate finance at Aegis Therapies from 1998 to 2000;

corporate controller at Theraphysics in 1997; and assistant vice president of internal audit at Willis North America Inc. from

1996 to 1997. Mr. Lumsdaine began his career at Ernst & Young from 1988 to 1996 where he was in the external audit

practice with a focus on healthcare. Mr. Lumsdaine earned both an undergraduate and a master's degree in accounting

from the University of Tennessee.

**David Caspers**

Mr. Caspers has served as our chief operating officer since March 31, 2025. As chief operating officer, he has oversight of all

of our operations while leading enterprise strategy development and execution. Prior to joining us, Mr. Caspers served as

chief stores officer at Leslie's, Inc. (NASDAQ: LESL) ("Leslie's"), a leading direct-to-consumer pool and spa care brand, from

October 2023 to March 2025. Prior to that, Mr. Caspers served as the senior vice president of retail operations at Leslie's

from May 2023 to October 2023. Prior to joining Leslie's, Mr. Caspers served as the vice president, omni channel retail

healthcare operations for Walmart Inc., a multinational retailer, from August 2022 to May 2023, where he was responsible

for the execution and results for Walmart Health, including healthcare, teams, design, operations, and patient experience.

From August 2015 through August 2022, Mr. Caspers held various roles for Banner Health, a large non-profit health system,

including vice president healthcare operations, vice president special project BUMD, and vice president patient experience.

Prior to that, Mr. Caspers held various positions for Target Corporation. Mr. Caspers is a graduate from St. Cloud State

University and North Dakota State College of Science.

**Stephen C. Petrovich**

Since 2000, Mr. Petrovich has served as General Counsel to Ardent through all of its transactions, transformations and

recapitalizations. Prior to Ardent, from 1993 to 2000, he was Chief Litigation Counsel at Charter Behavioral Health Systems

and an associate at Nelson Mullins Riley and Scarborough and the Kelly Law Firm. Prior to that, Mr. Petrovich clerked for the

Honorable Harold L. Murphy, federal district judge for the Northern District of Georgia from 1991 to 1993. Mr. Petrovich

received a Juris Doctorate degree from the University of Georgia where he was Associate Notes Editor of the Georgia Law

Review and received his undergraduate degree in political science and American history from DePauw University.

**Security Ownership of Certain Beneficial Owners and Management**

The table below sets forth information with respect to ownership of our Common Stock as of March 26, 2026, by:

• Each person who we know to be the beneficial owner of more than 5% of the outstanding shares of Common

Stock;

• Each of our directors and nominees;

• Each of our NEOs; and

• All of our directors and executive officers as a group.

To our knowledge, unless otherwise indicated in the notes to the table, each stockholder listed below has sole voting and

investment power with respect to the shares beneficially owned. All computations are based on 143,095,662 shares of

Common Stock outstanding on March 26, 2026, unless otherwise indicated. Unless otherwise indicated in the table or

footnotes below, the address for each officer and director listed in the table is 340 Seven Springs Way, Suite 100,

Brentwood, Tennessee 37027.

---

| | | |
|:---|:---|:---|
| **Name of Beneficial Owner** | **Amount and Nature of** <br>**Beneficial Ownership**<sup>(1)</sup><br>| **Percent of Class** |
| **>5% Stockholders** | | |
| EGI-AM <sup>(2)</sup> | 77246499 | 54.0% |
| Pure Health <sup>(3)</sup> | 30262664 | 21.1% |
| ALH Holdings, LLC <sup>(4)</sup> | 9342501 | 6.5% |
| **Directors and NEOs** |  |  |
| Martin J. Bonick <sup>(5)</sup> | 1004072 | \* |
| Alfred Lumsdaine <sup>(6)</sup> | 137031 | \* |
| David Caspers <sup>(7)</sup> | 16250 | \* |
| Stephen C. Petrovich <sup>(8)</sup> | 1063583 | \* |
| David Schultz <sup>(9)</sup> | 48968 | \* |
| Ethan Chernin <sup>(10)</sup> | 16578 | \* |
| Mark Sotir  | 24478 | \* |
| Peter Bulgarelli |  |  |
| Peter Bynoe  | 93941 | \* |
| Suzanne Campion  | 36789 | \* |
| Robert A. DeMichiei  | 10073 | \* |
| William Goodyear  | 93941 | \* |
| Ellen Havdala  | 93941 | \* |
| Edmondo Robinson  | 36789 | \* |
| Rahul Sen  | 24478 | \* |
| Rob Webb  | 56789 | \* |
| All directors and executive officers as a group (14 persons) | 2692155 | 1.9% |

---

\*Less than 1%

(1)Under SEC rules, the number of shares shown as beneficially owned includes shares of Common Stock subject to time-vesting restricted stock units

("RSUs") that will vest within 60 days of March 26, 2026. Such shares are deemed to be outstanding for the purpose of computing the "percent of

class" for that individual, but are not deemed outstanding for the purpose of computing the percentage of any other person.

(2)Information is based solely on the Schedule 13G filed by Chai Trust Company, LLC ("Chai Trust"), EGI-AM and EGI-AM Investor, L.L.C. ("EGI-AM

Investor" and together with Chai Trust and EGI-AM Investments, "EGI Investments") with the SEC on November 14, 2024. EGI Investments

reported that it possessed (i) shared voting power with respect to 77,246,499 shares and (ii) shared dispositive power with respect to 77,246,499

shares. The address for EGI Investments is Two North Riverside Plaza, Suite 600, Chicago, Illinois 60606.

(3)Information is based solely on the Schedule 13G filed by Pure Health, Pure Health Holding PJSC, Pure Health Medical Supplies LLC and Pure Health

Capital LLC (collectively, the "Pure Health Entities"), as a group, with the SEC on November 14, 2024. The Pure Health Entities reported that they

possessed (i) shared voting power with respect to 30,262,664 shares and (ii) shared dispositive power with respect to 30,262,664 shares. The

address for Pure Health is 2462 RsCo-work01, 24<sup>th</sup> Floor, Al Sila Tower, Abu Dhabi Global Market Square, Al Maryah Island, Abu Dhabi, UAE. The

address for Pure Health Holding PJSC is Al Dar Real Estate Investment L.L.C. Building, RBW11,0, Al Raha Beach, 2 Al Raha Street, Abu Dhabi, UAE.

The address for Pure Health Medical Supplies LLC is Officer Number 3401 Vision Tower, Al Khaleej Al Tejar Street 1, Business Bay, Dubai, UAE, PO.

Box: 283572. The address for Pure Health Capital LLC is 2, Al Raha Street, Al Raha, Abu Dhabi, 23035, UAE.

(4)Information is based solely on the Schedule 13G filed by Ventas with the SEC on November 14, 2024. Ventas is the sole stockholder of VTR AMS,

Inc., the sole and managing member of ALH Holdings, LLC, and has voting and dispositive power over the 9,342,501 shares held by ALH Holdings,

LLC. Ventas reported that it possessed (i) sole voting power with respect to 9,342,501 shares and (ii) sole dispositive power with respect to

9,342,501 shares. The address for Ventas is 353 N. Clark Street, Suite 3300, Chicago, Illinois 60654.

(5)Includes 32,960 and 44,976 shares issuable upon vesting of RSUs on March 31, 2026 and April 1, 2026, respectively.

(6)Includes 10,307 and 17,991 shares issuable upon vesting of RSUs on March 31, 2026 and April 1, 2026, respectively.

(7)Includes 11,019 shares issuable upon vesting of RSUs on April 1, 2026.

(8)Includes 5,861 and 7,421 shares issuable upon vesting of RSUs on March 31, 2026 and April 1, 2026, respectively. Also includes (i) 186,225 shares

of Common Stock held by the Emilie K. Petrovich GST-2016 Exempt Family Trust, of which Mr. Petrovich is the trustee and Mr. Petrovich's children

are beneficiaries, and (ii) 186,225 shares of Common Stock held by the Stephen C. Petrovich GST-2016 Exempt Family Trust, of which Mr.

Petrovich's spouse is the trustee and Mr. Petrovich's children are beneficiaries. Mr. Petrovich disclaims beneficial ownership of these securities,

except to the extent of Mr. Petrovich's pecuniary interests therein, if any.

(9)Mr. Schultz departed from the Company effective June 16, 2025, and thus he is not considered an executive officer as of March 26, 2026 and his

shares are not included in the shares held by all directors and executive officers as a group.

(10)Mr. Chernin departed from the Company effective March 24, 2026, and thus he is not considered an executive officer as of March 26, 2026 and his

shares are not included in the shares held by all directors and executive officers as a group.

**Delinquent Section 16(a) Reports**

Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), requires our directors, certain

officers, and persons who own more than 10% of a registered class of our equity securities to file initial reports of

ownership and reports of changes in ownership with the SEC. Based solely on our review of the copies of such forms or

written representations from certain reporting persons received by us with respect to fiscal year 2025, we believe that all

reports required to be filed with the SEC pursuant to Rule 16(a) of the Exchange Act during the most recent fiscal year were

timely filed, except for the shares withheld on September 25, 2025 to satisfy the tax obligations in connection with a vesting

event for Messrs. Lumsdaine and Petrovich and David Byers, our Chief Accounting Officer, that were inadvertently reported

late on Form 4 reports filed on September 30, 2025.

**Compensation Discussion and Analysis**

This Compensation Discussion and Analysis ("CD&A") explains our executive compensation program for our named

executive officers ("NEOs") listed below. This CD&A also describes the Compensation Committee's process for making pay

decisions, as well as its rationale for specific decisions related to the fiscal year ended December 31, 2025. For purposes of

the CD&A, the Compensation Committee is referred to as the "Committee." The Company's NEOs for 2025 were as follows:

---

| | |
|:---|:---|
| **Name** | **Title** |
| Marty Bonick | President and Chief Executive Officer |
| Alfred Lumsdaine | Chief Financial Officer |
| David Caspers<sup>(1)</sup> | Chief Operating Officer |
| Stephen C. Petrovich | Executive Vice President and General Counsel |
| David Schultz<sup>(2)</sup> | Former President, Hospital Operations |
| Ethan Chernin<sup>(3)</sup> | Former President, Health Services |
| (1)Mr. Caspers was appointed as the Company's Chief Operating Officer, effective March 31, 2025.<br>(2)Mr. Schultz departed from the Company effective June 16, 2025.<br>(3)Mr. Chernin departed from the Company effective March 24, 2026. | (1)Mr. Caspers was appointed as the Company's Chief Operating Officer, effective March 31, 2025.<br>(2)Mr. Schultz departed from the Company effective June 16, 2025.<br>(3)Mr. Chernin departed from the Company effective March 24, 2026. |

---

**Executive Summary**

***Business Performance***

Management took targeted actions during 2025 to address industry headwinds and strengthen the Company's operating

model. Some notable developments during the year included:

• Revenue growth of 6% to $6.3 billion;

• Adjusted EBITDA growth of 9% with modest margin expansion;

• Admissions growth of 5.3% and adjusted admissions growth of 2.3%;

• Operating cash flow of $471 million, an increase of approximately 49% compared to 2024;

• Launch of the IMPACT operational improvement program, focused on cost optimization and operating efficiency;

and

• Strengthening the balance sheet, including increasing cash to over $700 million and reducing lease-adjusted net

leverage to 2.5x.

Information about non-GAAP financial measures including a reconciliation of such measures is included on page [58](#i86b9ce36f36244588cbb1deefbc6ec50_70) of this

Proxy Statement.

***2025 Compensation Highlights***

Our executive compensation program has three primary elements: base salary, short-term cash incentives (as part of our

Short-Term Incentive Plan, or "STIP"), and long-term equity incentives. Each of these compensation elements serves a

specific purpose in our compensation strategy. Base salary is an essential component to any market-competitive

compensation program. Annual incentives reward the achievement of short-term goals, while long-term incentives drive

our NEOs to focus on long-term sustainable stockholder value creation.

The table below summarizes the key highlights of the executive compensation decisions made by the Committee made for

fiscal year 2025.

---

| | |
|:---|:---|
| **Element** | **Objective** |
| **Base Salaries** | In April 2025, during the historical time for annual merit increases, the NEOs received <br>base salary increases ranging from no increase to a 5.1% increase to, among other <br>things, ensure their base salaries align with competitive market data for their respective <br>roles.<br>|
| **Short-Term Cash Incentives** | Short-term cash incentives were based on both corporate performance measures and <br>individual performance achievements. The Corporate Performance component (90% <br>weighting) of short-term incentives required achievement of a minimum Adjusted <br>EBITDAR (as defined below) threshold. Because the established threshold for 2025 <br>performance was not met, no short-term incentives were earned for the Corporate <br>Performance component. The remaining 10% of the opportunity was based on <br>individual performance objectives. No short-term incentives were earned under the <br>Individual Performance component on a formulaic basis. However, the Committee <br>evaluated individual performance and exercised discretion to approve limited cash <br>bonus awards to certain NEOs in recognition of their maintaining operational <br>performance in a challenging environment, advancing strategic initiatives, and <br>managing cost pressures.<br>|
| **Long-Term Equity Incentives** | Long-term equity incentive grants for 2025 were delivered 35% in time-based restricted <br>stock units ("RSUs") and 65% in performance-based restricted stock units ("PRSUs"), <br>consistent with the approach in 2024. The time-based RSUs vest over a period of three <br>years. The PRSU performance period for the 2025 grant was January 1, 2025 through <br>December 31, 2025 to recognize regulatory uncertainty, while maintaining three-year <br>vesting and adding a three-year relative Total Stockholder Return ("TSR") modifier to <br>strengthen stockholder alignment. PRSUs were based on Adjusted EBITDAR (60%) and <br>net revenue (40%), with payout opportunities ranging from 0% to 200% of target. <br>Performance for the 2025 PRSU grant resulted in an achievement of 90.1% of target <br>(subject to TSR adjustment and continued employment for the three-year term of the <br>award). <br>|

---

***Onboarding David Caspers***

David Caspers joined the Company as Chief Operating Officer effective March 31, 2025. In connection with his employment,

Mr. Caspers' 2025 annual base salary was set at $700,000 and he was eligible for a target short-term incentive award

opportunity for 2025 equal to 90% of base salary. He also received a 2025 long-term equity grant with a target value equal

to 1.75 times his base salary, delivered 35% in RSUs and 65% in PRSUs, consistent with the Company's approach to annual

long-term equity incentives for other executives. In addition, Mr. Caspers received a one-time $75,000 sign-on cash

payment and received shares of the Company's Common Stock with a value equal to $100,000, as well as relocation and

interim travel assistance. He participates in the Company's Executive Severance Plan available to other executive officers.

***2025 Say-on-Pay Results and Stockholder Engagement***

At our 2025 Annual Meeting of Stockholders, approximately 99% of the votes cast supported the Company's executive

compensation program in our first advisory "say-on-pay" vote as a public company. The Committee views this strong level

of support as affirmation of the Company's pay-for-performance philosophy and the alignment of executive compensation

with stockholder interests. The Committee will continue to evaluate stockholder feedback and compensation practices to

ensure the program remains aligned with Company performance and evolving governance best practices.

***Compensation Best Practices and Policies***

We believe the following practices and policies promote sound compensation governance and are in the best interests of

our stockholders and executives.

---

| | | | |
|:---|:---|:---|:---|
| **What We Do** | **What We Do** | **What We Don't Do** | **What We Don't Do** |
| **✔** | Independent Compensation Committee oversight of <br>executive pay decisions<br>| **✕** | No single-trigger change-in-control vesting |
| **✔** | Align a significant portion of pay with financial, <br>operational and quality performance<br>| **✕** | No excise tax gross-ups in connection with change-in-<br>control payments<br>|
| **✔** | Deliver long-term incentives primarily in <br>performance-based equity with multi-year vesting<br>| **✕** | No hedging or pledging of Company securities by <br>executives or directors<br>|
| **✔** | Maintain robust stock ownership guidelines for <br>executives and directors<br>| **✕** | No excessive perquisites or executive-only benefit <br>programs<br>|
| **✔** | Maintain a clawback policy consistent with SEC and <br>NYSE requirements<br>| **✕** | No defined benefit pension or nonqualified deferred <br>compensation plans<br>|

---

**Executive Compensation Philosophy**

Our executive compensation program is designed to support our efforts to recruit, retain and motivate highly capable

executive personnel and to incentivize our executives to achieve our strategic objectives. The key elements of our

compensation philosophy are:

---

| | | |
|:---|:---|:---|
| **Philosophy** | **Objective** | **How We Achieve It** |
| **Linked to Performance** | Incentive programs link payouts directly to <br>meeting challenging annual performance <br>objectives and long-term value creation<br>| A significant portion of our executives' <br>compensation opportunity is linked to our <br>Critical Indicators (defined below), as we <br>believe our executives' pay should be tied <br>to our operational success as well as <br>individual contributions to the Company's <br>business objectives.<br>|
| **Market Based** | Competitive pay opportunity for markets <br>we operate in<br>| We assess pay opportunities and program <br>designs against our peers and competitors <br>in the market for talent<br>|
| **Simple** | Simple programs that are easy for our <br>executives to understand to ensure they <br>are able to focus on critical goals and <br>milestones that are correlated to the <br>Company's success<br>| We use four elements of pay — salary, <br>annual bonus, long-term equity awards <br>and participation in broad-based benefit <br>plans and limited executive benefits — <br>and generally incorporate objective <br>performance metrics in our incentive <br>programs<br>|
| **Sustainable and Responsible** <br>**Value Creation**<br>| Programs that drive long-term, <br>responsible performance and decisions<br>| In addition to earnings growth, short-<br>term incentives include measures focused <br>on delivering quality care and creating <br>patient satisfaction<br>Long-term incentives promote employee <br>retention and are aligned to long-term <br>value creation<br>|

---

**Process for Determining Executive Compensation**

***Role of the Compensation Committee***

The Committee oversees Ardent Health's executive compensation program, including compensation for the Company's

executive officers, corporate executive officers, regional presidents (collectively, "Key Officers"), and non-employee

directors. The Committee is comprised of independent directors and operates pursuant to a written charter available on

our investor relations website. The Committee establishes and approves performance goals relevant to executive

compensation, evaluates performance against those goals, and determines resulting compensation outcomes. The

Committee approves compensation for all Key Officers other than the CEO and recommends the CEO's compensation to the

independent members of the full Board for approval. The Committee also oversees the Company's equity and incentive

compensation plans and may retain independent advisors to assist in carrying out its responsibilities.

***Role of Management***

In carrying out its responsibilities, the Committee receives input from the CEO. The CEO provides performance assessments

and compensation recommendations for the Company's Key Officers, other than himself. The CEO does not participate in

deliberations or decisions regarding his own compensation. The Committee retains full discretion and authority over all

compensation decisions for Key Officers and recommends the CEO's compensation to the independent members of the full

Board for approval.

***Role of the Compensation Consultant***

Pursuant to its charter, the Committee has the authority to retain, at the expense of the Company, independent

compensation consultants and other advisors to assist in carrying out its responsibilities. The Committee is directly

responsible for the appointment, compensation, and oversight of its advisors.

Willis Towers Watson ("WTW") served as the Committee's independent compensation consultant through August 2025 and

assisted the Committee with executive and director compensation matters, including competitive benchmarking analyses,

incentive plan design considerations and governance practices. WTW reported directly to the Committee.

Effective August 2025, the Committee engaged Pearl Meyer & Partners, LLC ("Pearl Meyer") as its independent

compensation consultant. Pearl Meyer reports directly to the Committee and provides independent advice and expertise in

connection with executive and director compensation matters, including market assessments, program design, and

governance best practices.

In accordance with SEC rules and NYSE listing standards, the Committee assessed the independence of both WTW and Pearl

Meyer, taking into consideration the applicable independence factors, and determined that each consultant's work did not

raise any conflicts of interest. Neither WTW nor Pearl Meyer provided any other services to the Company during their

respective engagements with the Committee.

***Use of Compensation Data and Peer Groups***

In determining 2025 compensation for our executives, including our NEOs, the Committee considered multiple sources of

market data. These sources included published compensation survey data covering the broader healthcare industry,

companies operating hospitals, health systems and integrated health networks, as well as general industry companies of

comparable size and complexity.

The Committee also considered public company peer group compensation information as a reference point in evaluating

base salary levels, short- and long-term incentive targets, and total target direct compensation opportunities. With the

assistance of WTW, the Committee previously established a public company peer group and, after reviewing the

composition of the peer group in connection with the determination of 2025 compensation, determined that no changes to

the peer group were needed from 2024 to 2025. The peer group consists of the following:

---

| | |
|:---|:---|
| Acadia Healthcare Company, Inc. | Ensign Group, Inc. |
| Brookdale Senior Living Inc. | Quest Diagnostics Incorporated |
| Community Health Systems, Inc. | Select Medical Holdings Corp. |
| DaVita Inc. | Surgery Partners, Inc. |
| Encompass Health Corp.  | Universal Health Services, Inc. |

---

The Committee believes that these companies represent relevant comparators based on industry focus, operating profile,

size, and executive talent market considerations. The Committee intends to review the peer group composition at least

annually to ensure ongoing relevance.

**Elements of Executive Compensation**

The primary elements of our executive compensation program include base salaries, short-term incentives in the form of

annual cash bonuses, and long-term incentives in the form of equity-based compensation. The table below provides an

summary of the primary elements of the Company's executive compensation.

---

| | | |
|:---|:---|:---|
| **Element** | **How It's Paid** | **Overview** |
| **Base Salary** | Cash<br>(Fixed)<br>| •Provides a competitive fixed rate of pay relative to similar <br>positions in the market, and enable the Company to attract and <br>retain critical executive talent<br>•Based on job scope, level of responsibilities, individual <br>performance, experience, and market levels <br>|
| **Short-Term (Annual)** <br>**Incentives**<br>| Cash<br>(Variable)<br>| •Rewards the achievement of rigorous annual financial and <br>strategic objectives aligned with our Critical Indicators and long-<br>term stockholder value<br>•Determined based on measurable financial, operational, quality, <br>and individual performance outcomes<br>|
| **Long-Term Incentives** | Equity<br>(Variable)<br>| •Incentivizes executives to deliver sustained long-term financial <br>and strategic performance that drives stockholder value creation <br>while reinforcing retention and executive stock ownership<br>•Awards combine performance-based and time-vested equity, <br>with a majority of the opportunity tied to the achievement of <br>performance objectives<br>•Realized value varies based on Company performance and stock <br>price<br>|

---

***Base Salaries***

Annual base salaries for our NEOs are designed to provide a fixed level of cash compensation intended to attract and retain

highly qualified executives. The Committee reviews base salary levels at least annually. In determining whether

adjustments are appropriate, the Committee considers a range of factors, including the executive's individual performance,

experience in the role, internal equity considerations, and competitive market data, including peer group and survey

benchmarking information.

In March 2025, the Committee reviewed base salary levels for our NEOs. Mr. Bonick, our CEO, did not receive a base salary

increase for 2025. The Committee approved increases for certain other NEOs based on the factors described above. The

Committee determined that the resulting base salary levels are competitive and appropriate relative to relevant market

benchmarks. The table below sets forth the base salary rates in effect for our NEOs as of December 31, 2024 and as of April

15, 2025:

---

| | | | |
|:---|:---|:---|:---|
| **Name** | **Annual Salary** <br>**Rate as of** <br>**December 31, 2024**<br>| **Annual Salary** <br>**Rate as of** <br>**April 15, 2025**<br>| **% Increase** |
| Marty Bonick | $1076000 | $1076000 | —% |
| Alfred Lumsdaine | $628000 | $660000 | 5.1% |
| David Caspers<sup>(1)</sup> | N/A  | $700000 | N/A |
| Stephen C. Petrovich | $536000 | $552000 | 3.0% |
| David Schultz<sup>(2)</sup> | $685000 | $695000 | 1.5% |
| Ethan Chernin<sup>(3)</sup> | $600000 | $618000 | 3.0% |
| (1)Mr. Caspers was appointed as the Company's Chief Operating Officer, effective March 31, 2025.<br>(2)Mr. Schultz departed from the Company effective June 16, 2025.<br>(3)Mr. Chernin departed from the Company effective March 24, 2026. | (1)Mr. Caspers was appointed as the Company's Chief Operating Officer, effective March 31, 2025.<br>(2)Mr. Schultz departed from the Company effective June 16, 2025.<br>(3)Mr. Chernin departed from the Company effective March 24, 2026. | (1)Mr. Caspers was appointed as the Company's Chief Operating Officer, effective March 31, 2025.<br>(2)Mr. Schultz departed from the Company effective June 16, 2025.<br>(3)Mr. Chernin departed from the Company effective March 24, 2026. | (1)Mr. Caspers was appointed as the Company's Chief Operating Officer, effective March 31, 2025.<br>(2)Mr. Schultz departed from the Company effective June 16, 2025.<br>(3)Mr. Chernin departed from the Company effective March 24, 2026. |

---

In recognition of their individual performance and a review of the factors described above, effective April 15, 2026, the

salaries of Messrs. Bonick, Lumsdaine, Caspers and Petrovich were increased by 3.0% to $1,108,542, $679,805, $721,003

and $568,572, respectively.

***Short-Term (Annual) Incentive Compensation***

Each of our NEOs is eligible to earn short-term incentive compensation based on Corporate Performance goals and

Individual Performance goals. Short-term incentive awards are earned based on pre-established performance objectives,

including those tied to our Critical Indicators, reinforcing the link between pay and performance.

The table below presents the 2025 Critical Indicators and the goals and metrics for measuring performance against these

objectives:

---

| | | |
|:---|:---|:---|
| **Critical Indicators** | **Description / Goal** | **Associated Plan Metrics** |
| **Financial** | •Deliver strong financial <br>performance<br>| • Adjusted EBITDAR as a percentage of budget\*<br>•Adjusted EBITDAR margin improvement<br>|
| **Quality and Experience** | •Ensure we deliver high <br>levels of quality care<br>| •Measured based on performance objectives relating to <br>six individual quality and patient satisfaction metrics <br>as reflected in our quality/experience index<br>|
| \*Adjusted EBITDAR is defined as net income plus (i) provision for income taxes, (ii) interest expense and (iii) depreciation and amortization expense <br>(or EBITDA), as adjusted to deduct noncontrolling interest earnings, and excludes the effects of losses on the extinguishment and modification of <br>debt; other non-operating losses; Cybersecurity Incident recoveries, net of incremental information technology and litigation costs; certain legal <br>matters and related costs; restructuring, exit and acquisition-related costs; change in accounting estimate; New Mexico professional liability <br>accrual; expenses incurred in connection with the implementation of our integrated health information technology system provided by Epic <br>Systems; equity-based compensation expense; loss from disposed operations; and rent expense payable to real estate investment trusts ("REITs"), <br>as reported in the Consolidated Financial Statements in the Company's Annual Report on Form 10-K for the year ended December 31, 2025 filed <br>with the SEC. For a reconciliation of Adjusted EBITDAR to net income, the most directly comparable GAAP financial measure, please see <br>"Reconciliation of Non-GAAP Measures" included on page [58](#i86b9ce36f36244588cbb1deefbc6ec50_70) of this Proxy Statement. | \*Adjusted EBITDAR is defined as net income plus (i) provision for income taxes, (ii) interest expense and (iii) depreciation and amortization expense <br>(or EBITDA), as adjusted to deduct noncontrolling interest earnings, and excludes the effects of losses on the extinguishment and modification of <br>debt; other non-operating losses; Cybersecurity Incident recoveries, net of incremental information technology and litigation costs; certain legal <br>matters and related costs; restructuring, exit and acquisition-related costs; change in accounting estimate; New Mexico professional liability <br>accrual; expenses incurred in connection with the implementation of our integrated health information technology system provided by Epic <br>Systems; equity-based compensation expense; loss from disposed operations; and rent expense payable to real estate investment trusts ("REITs"), <br>as reported in the Consolidated Financial Statements in the Company's Annual Report on Form 10-K for the year ended December 31, 2025 filed <br>with the SEC. For a reconciliation of Adjusted EBITDAR to net income, the most directly comparable GAAP financial measure, please see <br>"Reconciliation of Non-GAAP Measures" included on page [58](#i86b9ce36f36244588cbb1deefbc6ec50_70) of this Proxy Statement. | \*Adjusted EBITDAR is defined as net income plus (i) provision for income taxes, (ii) interest expense and (iii) depreciation and amortization expense <br>(or EBITDA), as adjusted to deduct noncontrolling interest earnings, and excludes the effects of losses on the extinguishment and modification of <br>debt; other non-operating losses; Cybersecurity Incident recoveries, net of incremental information technology and litigation costs; certain legal <br>matters and related costs; restructuring, exit and acquisition-related costs; change in accounting estimate; New Mexico professional liability <br>accrual; expenses incurred in connection with the implementation of our integrated health information technology system provided by Epic <br>Systems; equity-based compensation expense; loss from disposed operations; and rent expense payable to real estate investment trusts ("REITs"), <br>as reported in the Consolidated Financial Statements in the Company's Annual Report on Form 10-K for the year ended December 31, 2025 filed <br>with the SEC. For a reconciliation of Adjusted EBITDAR to net income, the most directly comparable GAAP financial measure, please see <br>"Reconciliation of Non-GAAP Measures" included on page [58](#i86b9ce36f36244588cbb1deefbc6ec50_70) of this Proxy Statement. |

---

The 2025 performance targets were established based on the Company's operating budget and reflect the Committee's

expectation of meaningful year-over-year financial growth, margin expansion, and continued high-quality patient care. The

2025 Adjusted EBITDAR target of $774.3 million represented approximately 17% growth over the 2024 baseline of $661.8

million, which is equal to 2024 actual Adjusted EBITDAR of $658.9 million plus noncontrolling interest earnings of $2.9

million attributable to Ventas. The 2025 Adjusted EBITDAR margin target of 13.5% reflected a 240 basis point improvement

over 2024 actual performance of 11.1%.

The quality and experience component is measured through a Quality / Experience Index comprised of six individual quality

and patient satisfaction metrics: (i) AHS HAI Roll Up, (ii) AHS Sepsis 1a, (iii) AHS Diabetic Control – A1C, (iv) AHS HCAHPS, (v)

AHS Physician Net Promoter Score, and (vi) AHS Medicare Annual Wellness Visits. The Committee established minimum,

goal and maximum performance targets for each metric. Each metric is measured individually, and the results are combined

to determine the overall Quality / Experience Index score.

If Adjusted EBITDAR performance did not reach the minimum threshold of $740.0 million for 2025, no payout would be

made under the 90% Corporate Performance component of the STIP.

The table below presents the 2025 performance goals and weighting for the Corporate Performance component of the

2025 short-term incentive, which the Committee believes appropriately balances the expectation of sustained high-quality

performance with continued financial and operational discipline.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Indicator** | **Metric** | **Metric** <br>**Weight**<br>| **Performance Range** | **Performance** <br>**Target**<br>| **Payout Range** |
| **Financial** | **Adjusted** <br>**EBITDAR** <br>($M) | **50.0%** | **Minimum** | $740.0 | 50% |
| **Financial** | **Adjusted** <br>**EBITDAR** <br>($M) | **50.0%** |  |  |  |
| **Financial** | **Adjusted** <br>**EBITDAR** <br>($M) | **50.0%** | **Goal** | $774.3 | 100% |
| **Financial** | **Adjusted** <br>**EBITDAR** <br>($M) | **50.0%** |  |  |  |
| **Financial** | **Adjusted** <br>**EBITDAR** <br>($M) | **50.0%** | **Maximum** | $832.0 | 200% |
| **Financial** |  |  |  |  |  |
| **Financial** |  |  |  |  |  |
| **Financial** | **Adjusted EBITDAR margin** <br>**improvement** | **25.0%** | **Minimum** | 12.9% | 50% |
| **Financial** | **Adjusted EBITDAR margin** <br>**improvement** | **25.0%** |  |  |  |
| **Financial** | **Adjusted EBITDAR margin** <br>**improvement** | **25.0%** | **Goal** | 13.5% | 100% |
| **Financial** | **Adjusted EBITDAR margin** <br>**improvement** | **25.0%** |  |  |  |
| **Financial** | **Adjusted EBITDAR margin** <br>**improvement** | **25.0%** | **Maximum** | 14.5% | 150% |
| **Quality and** <br>**Experience** | **Comprised of six individual** <br>**quality and patient** <br>**satisfaction metrics** | **25.0%** | **Minimum** | 0.85 | 50% |
| **Quality and** <br>**Experience** | **Comprised of six individual** <br>**quality and patient** <br>**satisfaction metrics** | **25.0%** |  |  |  |
| **Quality and** <br>**Experience** | **Comprised of six individual** <br>**quality and patient** <br>**satisfaction metrics** | **25.0%** | **Goal** | 1.00 | 100% |
| **Quality and** <br>**Experience** | **Comprised of six individual** <br>**quality and patient** <br>**satisfaction metrics** | **25.0%** |  |  |  |
| **Quality and** <br>**Experience** | **Comprised of six individual** <br>**quality and patient** <br>**satisfaction metrics** | **25.0%** | **Maximum** | 1.15 | 125% |

---

The Individual Performance component of the 2025 short-term incentive is weighted at 10% and is based on the

achievement of specific individual objectives, including goals related to strategic growth initiatives, financial performance,

operational priorities and talent recruitment, retention and development. Target payout for this component is 100%, with a

payout range of 0% to 125% based on minimum and maximum levels of achievement, respectively.

Payouts between performance levels are determined using straight-line interpolation.

In March 2026, the Committee reviewed Company performance for fiscal year 2025 and determined the level of

achievement against the pre-established performance goals, as reflected in the table below. Based on this review, the

Committee determined that the minimum Adjusted EBITDAR performance threshold was not achieved and, as a result, no

payout was earned under the Corporate Performance component of the STIP. Consistent with this outcome, no amounts

were earned under the Individual Performance component on a formulaic basis.

---

| | | | |
|:---|:---|:---|:---|
| <br>**Weight** | **Adjusted** <br>**EBITDAR ($M)**<br>**50%** | **Adjusted EBITDAR** <br>**Margin** <br>**Improvement**<br>**25%** | **Quality /** <br>**Experience Index**<br>**25%** |
| Minimum  | $740.0 | 12.9% | 0.85 |
| Goal | $774.3 | 13.5% | 1.00 |
| Maximum | $832.0 | 14.5% | 1.15 |
| **2025 Actual Result** | **$709.3** | **12.7%** | **1.14** |
| % Achievement | —% | —% | 114% |
| Actual Payout % | —% | —% | —% |
| Weighted Actual Payout % | —% | —% | —% |

---

The Company's Adjusted EBITDAR performance was below expectations primarily as a result of sustained professional fee

inflation and increased payor denials in the second half of the year, which pressured margins despite solid volume and

revenue growth. While the Company outperformed in five of the six quality and patient satisfaction metrics during 2025 —

which, absent the financial threshold requirement would have resulted in above-target performance for the quality

component — the failure to meet the minimum Adjusted EBITDAR threshold precluded any payout under the Corporate

Performance component. The Committee believes this outcome reinforces the Company's pay-for-performance philosophy

and underscores the importance of achieving overall financial performance objectives.

The remaining 10% of the short-term incentive opportunity is based on Individual Performance objectives relating to

operational execution, strategic initiatives, talent management and leadership effectiveness. Based on overall Company

performance and the failure to meet the minimum Adjusted EBITDAR threshold required to fund the Corporate

Performance component, no amounts were earned under the Individual Performance component on a formulaic basis.

The Committee evaluated individual performance and exercised discretion to approve limited cash bonus awards outside of

the STIP to certain NEOs in recognition of their contributions to operational execution and strategic priorities during a

challenging year, while maintaining a conservative overall compensation outcome.

Mr. Bonick did not receive any payout with respect to the Individual Performance component or any discretionary bonus for

2025. During 2025, we appointed Mr. Caspers as Chief Operating Officer to scale operations, enhance patient and provider

experiences, and integrate digital, marketing, and contact center strategies to improve engagement. At the time of Mr.

Casper's recruitment, internal forecasts indicated that the Company's performance was trending toward target levels.

However, year-end results were ultimately impacted by performance trends that were largely established prior to his

arrival. The Board determined that holding a new leader accountable for financial outcomes determined before his tenure

would be counterproductive to our recruitment and engagement goals. Accordingly, the Board awarded Mr. Caspers a

discretionary bonus equal to his target opportunity for 2025, pro-rated for his time of service during the year. This pro-rated

bonus recognizes Mr. Caspers' immediate contributions and ensures his full focus on growing stockholder value in the years

ahead.

Target short-term incentive levels are reviewed annually by the Committee, and each NEO's 2025 target opportunity,

expressed as a percentage of base salary, is provided in the table below. Based on the performance outcomes and decisions

described above, no short-term incentives were earned under the STIP but the Committee approved the discretionary

award payments shown below for 2025, which were paid in March 2026:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Name** | **Salary as of** <br>**December 31, 2025**<br>| **Short-Term** <br>**Incentive Target** <br>**Opportunity**<sup>(1)</sup><br>| **Total Achieved**<sup>(1)</sup> | **Bonus Payment** |
| Marty Bonick | $1076000 | 125% | —% | $— |
| Alfred Lumsdaine | $660000 | 90% | —% | $50000<br><sup>(2)</sup> |
| David Caspers | $700000 | 90% | —% | $476386<br><sup>(3)</sup> |
| Stephen C. Petrovich | $552000 | 75% | —% | $35190<br><sup>(4)</sup> |
| David Schultz <sup>(5)</sup> | $695000 | 90% | —% | $— |
| Ethan Chernin | $618000 | 75% | —% | $23175<br><sup>(6)</sup> |
| (1)Shown as a percentage of base salary<br>(2)This was a discretionary bonus awarded to Mr. Lumsdaine for his oversight and management of the Company's initial audit over the effectiveness of <br>internal control over financial reporting under the Sarbanes-Oxley Act of 2002.<br>(3)As discussed above, this was a discretionary bonus awarded to recognize Mr. Caspers for his immediate contributions in 2025.<br>(4)This was a discretionary bonus awarded to Mr. Petrovich for his contributions to operational performance in a challenging environment, advancing <br>strategic initiatives, and managing cost pressures.<br>(5)Mr. Schultz served as President, Hospital Operations during fiscal 2025 and departed the Company effective June 16, 2025.<br>(6)This was a discretionary bonus awarded to Mr. Chernin for his contributions to operational performance in a challenging environment, advancing <br>strategic initiatives, and managing cost pressures. | (1)Shown as a percentage of base salary<br>(2)This was a discretionary bonus awarded to Mr. Lumsdaine for his oversight and management of the Company's initial audit over the effectiveness of <br>internal control over financial reporting under the Sarbanes-Oxley Act of 2002.<br>(3)As discussed above, this was a discretionary bonus awarded to recognize Mr. Caspers for his immediate contributions in 2025.<br>(4)This was a discretionary bonus awarded to Mr. Petrovich for his contributions to operational performance in a challenging environment, advancing <br>strategic initiatives, and managing cost pressures.<br>(5)Mr. Schultz served as President, Hospital Operations during fiscal 2025 and departed the Company effective June 16, 2025.<br>(6)This was a discretionary bonus awarded to Mr. Chernin for his contributions to operational performance in a challenging environment, advancing <br>strategic initiatives, and managing cost pressures. | (1)Shown as a percentage of base salary<br>(2)This was a discretionary bonus awarded to Mr. Lumsdaine for his oversight and management of the Company's initial audit over the effectiveness of <br>internal control over financial reporting under the Sarbanes-Oxley Act of 2002.<br>(3)As discussed above, this was a discretionary bonus awarded to recognize Mr. Caspers for his immediate contributions in 2025.<br>(4)This was a discretionary bonus awarded to Mr. Petrovich for his contributions to operational performance in a challenging environment, advancing <br>strategic initiatives, and managing cost pressures.<br>(5)Mr. Schultz served as President, Hospital Operations during fiscal 2025 and departed the Company effective June 16, 2025.<br>(6)This was a discretionary bonus awarded to Mr. Chernin for his contributions to operational performance in a challenging environment, advancing <br>strategic initiatives, and managing cost pressures. | (1)Shown as a percentage of base salary<br>(2)This was a discretionary bonus awarded to Mr. Lumsdaine for his oversight and management of the Company's initial audit over the effectiveness of <br>internal control over financial reporting under the Sarbanes-Oxley Act of 2002.<br>(3)As discussed above, this was a discretionary bonus awarded to recognize Mr. Caspers for his immediate contributions in 2025.<br>(4)This was a discretionary bonus awarded to Mr. Petrovich for his contributions to operational performance in a challenging environment, advancing <br>strategic initiatives, and managing cost pressures.<br>(5)Mr. Schultz served as President, Hospital Operations during fiscal 2025 and departed the Company effective June 16, 2025.<br>(6)This was a discretionary bonus awarded to Mr. Chernin for his contributions to operational performance in a challenging environment, advancing <br>strategic initiatives, and managing cost pressures. | (1)Shown as a percentage of base salary<br>(2)This was a discretionary bonus awarded to Mr. Lumsdaine for his oversight and management of the Company's initial audit over the effectiveness of <br>internal control over financial reporting under the Sarbanes-Oxley Act of 2002.<br>(3)As discussed above, this was a discretionary bonus awarded to recognize Mr. Caspers for his immediate contributions in 2025.<br>(4)This was a discretionary bonus awarded to Mr. Petrovich for his contributions to operational performance in a challenging environment, advancing <br>strategic initiatives, and managing cost pressures.<br>(5)Mr. Schultz served as President, Hospital Operations during fiscal 2025 and departed the Company effective June 16, 2025.<br>(6)This was a discretionary bonus awarded to Mr. Chernin for his contributions to operational performance in a challenging environment, advancing <br>strategic initiatives, and managing cost pressures. |

---

***Long-Term Equity Compensation***

Long-term equity compensation is a core component of our executive compensation framework and is designed to align

executive interests with long-term stockholder value creation while promoting retention and sustained performance. Equity

awards provide executives with meaningful exposure to stock price performance and, in the case of performance-based

awards, link realized compensation directly to the achievement of pre-established financial objectives.

***2025 Long-Term Equity Compensation Awards***

On April 1, 2025, the Compensation Committee awarded long-term equity-based incentive awards consisting of (i) RSUs

(35%) and (ii) PRSUs (65%). The Committee determined the grant levels based on a number of factors, including Company

performance and individual performance, internal equity, our compensation philosophy and competitive market data and

related positioning. The long-term incentive award opportunity for each of our NEOs is shown in the table below.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **RSUs** | **RSUs** | **PRSUs (at Target)** | **PRSUs (at Target)** |
| <br>**NEO** | **Value ($)** | **RSUs (#)** | **Value ($)** | **PRSUs (#)** |
| Marty Bonick | 1750000 | 134927 | 3250000 | 239499 |
| Alfred Lumsdaine | 700000 | 53971 | 1300000 | 95800 |
| David Caspers | 428750 | 33057 | 796250 | 58678 |
| Stephen C. Petrovich | 288750 | 22263 | 536250 | 39518 |
| David Schultz | 350000 | 26985 | 650000 | 47901 |
| Ethan Chernin | 271250 | 20914 | 503750 | 37122 |

---

For additional information regarding the 2025 annual equity awards, see "Grants of Plan-Based Awards in Fiscal 2025

Table."

***Time-Based Restricted Stock Units***

RSUs provide executives with time-based equity that supports retention and reinforces alignment with stockholders. Each

RSU represents the right to receive one share of Company Common Stock, subject to continued service through the

applicable vesting date. For the 2025 annual grants, RSUs vest in three substantially equal installments over a three-year

period, generally contingent on continued employment. The value ultimately realized depends on the Company's share

price at the time of vesting, directly aligning executives' interests with long-term stockholder outcomes.

***Performance-Based Restricted Stock Units***

PRSUs provide executives the opportunity to earn shares of Company Common Stock based on the achievement of pre-

established financial performance objectives, subject to continued service through the vesting date. For the 2025 annual

grants, performance is measured from January 1, 2025 through December 31, 2025. Any earned PRSUs are subject to a

three-year service-based vesting schedule, with final vesting on April 1, 2028, generally contingent on continued

employment. Performance is based on two core financial metrics:

• Adjusted EBITDAR (60%), which the Committee believes is a key indicator of operating performance, earnings

growth and cash flow generation; and

• Net revenue (40%), which reflects topline growth and the Company's ability to expand services and patient

volumes.

The Committee selected these metrics because they align directly with the Company's strategic priorities of driving

sustainable earnings growth, expanding margins, and scaling operations responsibly.

Threshold, target and maximum performance levels were established at the beginning of the performance period. For each

metric:

• 50% of target shares are earned for threshold performance;

• 100% are earned for target performance; and

• 200% are earned for maximum performance.

Performance between levels is determined using straight-line interpolation. No shares are earned for performance below

threshold.

In light of regulatory uncertainty within the healthcare sector and the resulting volatility affecting longer-term forecasting,

the Committee determined that a one-year performance period for the 2025 PRSUs was appropriate to ensure rigorous and

responsible goal-setting. Importantly, the Committee maintained a three-year service-based vesting requirement to

reinforce retention and long-term accountability. In addition, a three-year relative Total Stockholder Return ("TSR")

modifier was incorporated to further align realized compensation with stockholder outcomes over the full vesting period.

Relative TSR will be measured against a customized peer group of healthcare services companies, ensuring that realized

payouts reflect both absolute financial performance and relative stock price performance.

***2025 PRSU Results***

Based on 2025 results, performance for the 2025 PRSU grant resulted in 90.1% of shares at target being earned, subject to

the relative TSR modifier, which will be measured from January 1, 2025 through December 31, 2027, and continued

employment through April 1, 2028.

***2024 PRSU Results***

With respect to the 2024 annual grants of PRSUs, performance was measured over the two-year period ended December

31, 2025, based on the achievement of Adjusted EBITDAR and net revenue. The service-based vesting period for these

awards continues through December 31, 2026.

The performance metrics were weighted 60% for Adjusted EBITDAR and 40% for net revenue, with threshold, target and

maximum performance levels established for each metric at the beginning of the performance period. Based on results for

the 2024–2025 period, Adjusted EBITDAR achievement was 100.2% of target and net revenue achievement was 115.6% of

target, resulting in a weighted achievement of 106.4% of target.

**Employment Agreements and Executive Severance Program**

Messrs. Bonick, Lumsdaine and Petrovich are party to employment agreements that provide for compensation, severance

and other customary terms. Mr. Caspers is employed pursuant to an offer letter that sets forth the principal terms of his

compensation and severance protection.

The Company maintains an Executive Severance Plan that provides benefits in the event of a qualifying termination,

including enhanced protections in connection with a change in control. A detailed description of these arrangements is

provided under "Executive Compensation – Employment Agreements and Offer Letters" and "Executive Compensation –

Potential Payments upon Termination or Change in Control."

Mr. Schultz, former President, Hospital Operations, and Mr. Chernin, former President, Health Services, departed the

Company on June 16, 2025 and March 24, 2026, respectively. Their departures were treated as Qualifying Terminations

under the Executive Severance Plan, and they are entitled to severance benefits in accordance with its terms.

**Other Compensation Guidelines, Policies and Practices**

We have established certain policies and practices to ensure that our compensation programs appropriately align the

interests of our executives with the interests of our stockholders.

***Stock Ownership Guidelines***

The Committee established stock ownership guidelines in order to further align the long-term interests of our executives

and non-employee directors with those of our stockholders. Our stock ownership guidelines require that our NEOs and

other executive leadership team members (collectively, "Covered Executives") and applicable non-employee directors own

shares of our Common Stock (as determined under the guidelines) having an aggregate value equal to a multiple of the

Covered Executive's annual base salary or non-employee director's annual base cash retainer as follows:

---

| | |
|:---|:---|
| **Position** | **Multiple** |
| Chief Executive Officer (Mr. Bonick) | 5x Annual Base Salary |
| Other NEOs (Messrs. Lumsdaine, Caspers, Petrovich, Schultz and Chernin) | 3x Annual Base Salary |
| Other Covered Executives | 2x Annual Base Salary |
| Non-Employee Directors | 5x Annual Cash Retainer |

---

Our Covered Executives and applicable non-employee directors are required to hold 50% of shares acquired as a result of

exercise or settlement of compensatory awards until these ownership guidelines have been met. These retention

requirements will apply to NEOs and non-employee directors during periods in which, and to the extent that, the above

guidelines are not met. The ownership guidelines above do not apply to any non-employee director who does not

participate in our director compensation program.

Each Covered Executive and applicable non-employee director has until the later of five years after the completion of our

initial public offering (the "IPO") and the date such individual first becomes a Covered Executive or non-employee director,

as applicable, to comply with the stock ownership guidelines.

As of December 31, 2025, each NEO's equity holdings substantially exceeded the minimum ownership guidelines, except

Mr. Caspers, who has until the fifth anniversary of the date on which he joined the Company, or March 31, 2030, and Mr.

Lumsdaine, who has until the fifth anniversary of the IPO, or July 18, 2029, to attain the minimum ownership guideline.

Messrs. Schultz and Chernin departed from the Company effective June 16, 2025 and March 24, 2026, respectively, and are

no longer subject to the minimum ownership guidelines.

As of December 31, 2025, each of our non-employee directors, other than Messrs. DeMichiei, Sotir and Sen, Ms. Campion

and Dr. Robinson, have equity holdings that exceeded the non-employee director minimum ownership guideline. Messrs.

Sotir and Sen, Ms. Campion and Dr. Robinson each have until the fifth anniversary of the IPO, or July 18, 2029, while Mr.

DeMichiei has until the fifth anniversary of the date on which he was appointed to the Board, or April 2, 2030, to attain the

minimum ownership guideline.

***Clawback Policy***

The Committee established an incentive compensation recoupment, or "clawback" policy that is intended to comply with

the Dodd-Frank Act and applicable SEC and NYSE rules. Under the policy, if we are required to prepare an accounting

restatement due to material noncompliance with any financial reporting requirement under the securities laws, including

any required accounting restatement to correct an error in previously issued financial statements that is material to the

previously issued financial statements, or that would result in a material misstatement if the error were corrected in a

current period or left uncorrected, we will recoup from each executive officer, including NEOs, any erroneously awarded

incentive-based compensation as defined in the policy. For purposes of the policy, incentive-based compensation includes

compensation granted, earned or vested based upon our attainment of specified financial reporting metrics and recovery is

required regardless of fault. The policy does not limit any other rights or remedies the Company, the Board or the

Committee may have. These remedies would be in addition to, and not in lieu of, any penalties imposed by law

enforcement agencies, regulators or other authorities, such as Section 304 of the Sarbanes-Oxley Act.

***Insider Trading Policy***

We have adopted an Insider Trading Policy that governs the purchase, sale, and/or other transactions of our securities by

our directors, officers and employees. In addition, with regard to the Company's trading in its own securities, it is the

Company's policy to comply with the federal securities laws and the applicable exchange listing requirements.

***Equity Grant Practices***

The Committee's typical practice is to grant equity awards to our officers during the first or second quarter of each year. We

do not engage in the practice of timing grants with the release of material non-public information. In 2025, we did not grant

stock options or other stock-based compensation other than Common Stock, RSUs and PRSUs.

***Benefits and Perquisites***

The Company's executives, including the NEOs, are eligible to participate in the benefit plans that are available to

substantially all of the Company's employees, including defined contribution savings plans, medical, dental and life

insurance plans and long-term disability plans. Additionally, the Company provides relocation benefits when appropriate.

For additional information regarding the NEOs' participation in the Company's defined contribution savings plan, see

"Retirement Benefits."

***Retirement Benefits***

Our NEOs participate in our defined contribution savings plan, the Ardent Health Services Retirement Savings Plan (the

"Company Savings Plan"). Participants in the Company Savings Plan may contribute up to 99% of their salary, subject to

applicable IRS limits. The Company provides annual safe harbor matching contributions equal to 100% of the first 3% of a

participant's pay that is contributed as an elective deferral and 50% of the next 2% of a participant's pay that is contributed

as an elective deferral. Additionally, the Company may make non-elective contributions to the participant's Company

Savings Plan account at its election, subject to certain restrictions. The amount of any Company contributions for our NEOs

in 2023, 2024 and 2025 is reflected below as "All Other Compensation" in the "Executive Compensation – Summary

Compensation Table" following this section.

None of the NEOs participate in a defined benefit pension plan or nonqualified deferred compensation savings plan that

relates to the Company or any of its affiliates.

***Deductibility of Executive Compensation***

Section 162(m) of the Internal Revenue Code of 1986, as amended (the "Code"), places a limit of $1 million on the amount

of compensation per year that a public company may deduct for federal income tax purposes with respect to certain

executive officers. The Committee weighs the potential effect of non-deductibility, but also believes that it is important to

retain flexibility in designing compensation programs to incentivize conduct that achieves our goals. The Committee

acknowledges that some earnings that are achieved under these programs may result in payments to our NEOs that will not

be tax-deductible due to the limits of Section 162(m) of the Code.

***Accounting for Stock-Based Compensation***

We follow the Financial Accounting Standards Board Accounting Standards Codification Topic 718 ("ASC Topic 718") for our

stock-based compensation awards. ASC Topic 718 requires us to measure and record the compensation expense in our

income statement for all share-based payment awards made to our employees and the non-employee members of our

Board, including equity awards, based on the grant date "fair value" of the award and, in most cases, will be recognized

ratably over the award's requisite service period (which, generally, will correspond to the award's vesting schedule). This

calculation is performed for accounting purposes and reported in the executive compensation tables required by federal

securities laws, even though the recipient of the awards may never realize any value from their awards.

**Compensation Committee Report**

The Committee has reviewed and discussed with management the section entitled "Compensation Discussion and Analysis"

contained in this Proxy Statement. Based on this review and discussion, the Committee has recommended to our Board that

the section entitled "Compensation Discussion and Analysis" be included in this Proxy Statement and incorporated into our

Annual Report on Form 10-K for the year ended December 31, 2025.

Compensation Committee:

Ellen Havdala, Chair

Peter Bulgarelli

Peter Bynoe

Suzanne Campion

Rahul Sen

**Executive Compensation**

**Summary Compensation Table** 

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Name and** <br>**Principal Position**<br>| **Year** | **Salary** | **Bonus**<sup>(1)</sup> | **Stock** <br>**Awards**<sup>(3)</sup><br>| **Non-Equity** <br>**Incentive Plan** <br>**Compensation**<sup>(4)</sup><br>| **All Other** <br>**Compensation** <sup>(5)</sup><br>| **Total** |
| **Marty Bonick**<br>*President and Chief* <br>*Executive Officer* | 2025 | $1076000 | $— | $5000004 | $— | $14000 | $6090004 |
| **Marty Bonick**<br>*President and Chief* <br>*Executive Officer* | 2024 | $1060485 | $— | $4520272 | $1345300 | $13200 | $6939257 |
| **Marty Bonick**<br>*President and Chief* <br>*Executive Officer* | 2023 | $988623 | $— | $— | $1207454 | $13200 | $2209277 |
| **Alfred Lumsdaine**<br>*Chief Financial Officer* | 2025 | $650235 | $50000 | $2000010 | $— | $14000 | $2714245 |
| **Alfred Lumsdaine**<br>*Chief Financial Officer* | 2024 | $622632 | $— | $2220890 | $571192 | $13200 | $3427914 |
| **Alfred Lumsdaine**<br>*Chief Financial Officer* | 2023 | $594314 | $— | $278800 | $431120 | $13200 | $1317434 |
| **David Caspers**<br>*Chief Operating Officer* | 2025 | $511541 | $551386<br><sup>(2)</sup> | $1325021<br><sup>(6)</sup> | $— | $59622 | $2447570 |
| **David Caspers**<br>*Chief Operating Officer* | 2024 | $— | $— | $— | $— | $— | $— |
| **David Caspers**<br>*Chief Operating Officer* | 2023 | $— | $— | $— | $— | $— | $— |
| **Stephen C. Petrovich**<br>*Executive Vice President* <br>*and General Counsel* | 2025 | $547051 | $35190 | $825010 | $— | $14000 | $1421251 |
| **Stephen C. Petrovich**<br>*Executive Vice President* <br>*and General Counsel* | 2024 | $531091 | $— | $991419 | $501913 | $13200 | $2037623 |
| **Stephen C. Petrovich**<br>*Executive Vice President* <br>*and General Counsel* | 2023 | $508579 | $— | $64780 | $371644 | $13200 | $958203 |
| **David Schultz**<br>*Former President,* <br>*Hospital Operations* | 2025 | $389866 | $— | $1000012 | $— | $674241 | $2064119 |
| **David Schultz**<br>*Former President,* <br>*Hospital Operations* | 2024 | $652116 | $— | $1347291<br><sup>(7)</sup> | $554894 | $461557 | $3015858 |
| **David Schultz**<br>*Former President,* <br>*Hospital Operations* | 2023 | $342948 | $225000<br><sup>(2)</sup> | $98400 | $— | $59259 | $725607 |
| **Ethan Chernin**<br>*Former President,* <br>*Health Services* | 2025 | $612466 | $23175 | $775001 | $— | $73672 | $1484314 |
| **Ethan Chernin**<br>*Former President,* <br>*Health Services* | 2024 | $343856 | $50000<br><sup>(2)</sup> | $750016 | $268037 | $80610 | $1492519 |
| **Ethan Chernin**<br>*Former President,* <br>*Health Services* | 2023 | $— | $— | $— | $— | $— | $— |
| (1)The values in this column reflect discretionary bonuses paid to our NEOs, including certain one-time cash awards outside of the STIP that were <br>approved by the Committee.  | (1)The values in this column reflect discretionary bonuses paid to our NEOs, including certain one-time cash awards outside of the STIP that were <br>approved by the Committee.  | (1)The values in this column reflect discretionary bonuses paid to our NEOs, including certain one-time cash awards outside of the STIP that were <br>approved by the Committee.  | (1)The values in this column reflect discretionary bonuses paid to our NEOs, including certain one-time cash awards outside of the STIP that were <br>approved by the Committee.  | (1)The values in this column reflect discretionary bonuses paid to our NEOs, including certain one-time cash awards outside of the STIP that were <br>approved by the Committee.  | (1)The values in this column reflect discretionary bonuses paid to our NEOs, including certain one-time cash awards outside of the STIP that were <br>approved by the Committee.  | (1)The values in this column reflect discretionary bonuses paid to our NEOs, including certain one-time cash awards outside of the STIP that were <br>approved by the Committee.  | (1)The values in this column reflect discretionary bonuses paid to our NEOs, including certain one-time cash awards outside of the STIP that were <br>approved by the Committee.  |
| (2)Pursuant to Mr. Schultz's offer letter entered into in connection with his appointment as President, Hospital Operations, we agreed that Mr. <br>Schultz would receive his target bonus award in respect of his 2023 service prior to the above promotion irrespective of satisfaction of the <br>performance goals thereunder. Pursuant to Mr. Chernin's offer letter, he received a $50,000 sign-on bonus after his first month of employment. <br>Pursuant to Mr. Caspers' offer letter, he received a $75,000 cash sign-on bonus after his first month of employment, which is included in Mr. <br>Casper's bonus amount for 2025. | (2)Pursuant to Mr. Schultz's offer letter entered into in connection with his appointment as President, Hospital Operations, we agreed that Mr. <br>Schultz would receive his target bonus award in respect of his 2023 service prior to the above promotion irrespective of satisfaction of the <br>performance goals thereunder. Pursuant to Mr. Chernin's offer letter, he received a $50,000 sign-on bonus after his first month of employment. <br>Pursuant to Mr. Caspers' offer letter, he received a $75,000 cash sign-on bonus after his first month of employment, which is included in Mr. <br>Casper's bonus amount for 2025. | (2)Pursuant to Mr. Schultz's offer letter entered into in connection with his appointment as President, Hospital Operations, we agreed that Mr. <br>Schultz would receive his target bonus award in respect of his 2023 service prior to the above promotion irrespective of satisfaction of the <br>performance goals thereunder. Pursuant to Mr. Chernin's offer letter, he received a $50,000 sign-on bonus after his first month of employment. <br>Pursuant to Mr. Caspers' offer letter, he received a $75,000 cash sign-on bonus after his first month of employment, which is included in Mr. <br>Casper's bonus amount for 2025. | (2)Pursuant to Mr. Schultz's offer letter entered into in connection with his appointment as President, Hospital Operations, we agreed that Mr. <br>Schultz would receive his target bonus award in respect of his 2023 service prior to the above promotion irrespective of satisfaction of the <br>performance goals thereunder. Pursuant to Mr. Chernin's offer letter, he received a $50,000 sign-on bonus after his first month of employment. <br>Pursuant to Mr. Caspers' offer letter, he received a $75,000 cash sign-on bonus after his first month of employment, which is included in Mr. <br>Casper's bonus amount for 2025. | (2)Pursuant to Mr. Schultz's offer letter entered into in connection with his appointment as President, Hospital Operations, we agreed that Mr. <br>Schultz would receive his target bonus award in respect of his 2023 service prior to the above promotion irrespective of satisfaction of the <br>performance goals thereunder. Pursuant to Mr. Chernin's offer letter, he received a $50,000 sign-on bonus after his first month of employment. <br>Pursuant to Mr. Caspers' offer letter, he received a $75,000 cash sign-on bonus after his first month of employment, which is included in Mr. <br>Casper's bonus amount for 2025. | (2)Pursuant to Mr. Schultz's offer letter entered into in connection with his appointment as President, Hospital Operations, we agreed that Mr. <br>Schultz would receive his target bonus award in respect of his 2023 service prior to the above promotion irrespective of satisfaction of the <br>performance goals thereunder. Pursuant to Mr. Chernin's offer letter, he received a $50,000 sign-on bonus after his first month of employment. <br>Pursuant to Mr. Caspers' offer letter, he received a $75,000 cash sign-on bonus after his first month of employment, which is included in Mr. <br>Casper's bonus amount for 2025. | (2)Pursuant to Mr. Schultz's offer letter entered into in connection with his appointment as President, Hospital Operations, we agreed that Mr. <br>Schultz would receive his target bonus award in respect of his 2023 service prior to the above promotion irrespective of satisfaction of the <br>performance goals thereunder. Pursuant to Mr. Chernin's offer letter, he received a $50,000 sign-on bonus after his first month of employment. <br>Pursuant to Mr. Caspers' offer letter, he received a $75,000 cash sign-on bonus after his first month of employment, which is included in Mr. <br>Casper's bonus amount for 2025. | (2)Pursuant to Mr. Schultz's offer letter entered into in connection with his appointment as President, Hospital Operations, we agreed that Mr. <br>Schultz would receive his target bonus award in respect of his 2023 service prior to the above promotion irrespective of satisfaction of the <br>performance goals thereunder. Pursuant to Mr. Chernin's offer letter, he received a $50,000 sign-on bonus after his first month of employment. <br>Pursuant to Mr. Caspers' offer letter, he received a $75,000 cash sign-on bonus after his first month of employment, which is included in Mr. <br>Casper's bonus amount for 2025. |
| (3)The values in this column reflect the aggregate grant date fair values of our equity-based compensation awards in accordance with ASC Topic 718. <br>See "Long-Term Equity Compensation" in the Compensation Discussion and Analysis section of this Proxy Statement for additional information <br>regarding these equity-based compensation awards and their terms. With respect to our PRSU awards, we report grant date fair value at target-<br>level performance, which is the probable achievement level of the performance conditions. Assuming achievement of performance goals at the <br>maximum level, the aggregate grant date fair value of these PRSUs for 2025 and 2024, respectively, would be Mr. Bonick, $6,500,002 and <br>$5,876,352; Mr. Lumsdaine, $2,600,012 and $1,837,696; Mr. Caspers, $1,592,520 and $—; Mr. Petrovich, $1,072,518 and $1,044,992; Mr. Schultz <br>$1,300,034 and $1,335,744; and Mr. Chernin, $1,007,492 and $975,040. With respect to the 2023 time-based Class C unit awards (i.e., the Class <br>C-1 Units), the Company employed a Black-Scholes option pricing model to determine the grant date fair value of its equity-based awards, which <br>was used to allocate the estimated equity value of the Company to the various unit classes. Such equity value of the Company was estimated using <br>income and market valuation approaches, including then-recent sales of the Company's common units. Such estimates required the input of <br>highly subjective, complex assumptions. The Company's valuation assumptions are described in Note 9, "Equity," in the Notes to the Consolidated <br>Financial Statements in the Company's Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC. | (3)The values in this column reflect the aggregate grant date fair values of our equity-based compensation awards in accordance with ASC Topic 718. <br>See "Long-Term Equity Compensation" in the Compensation Discussion and Analysis section of this Proxy Statement for additional information <br>regarding these equity-based compensation awards and their terms. With respect to our PRSU awards, we report grant date fair value at target-<br>level performance, which is the probable achievement level of the performance conditions. Assuming achievement of performance goals at the <br>maximum level, the aggregate grant date fair value of these PRSUs for 2025 and 2024, respectively, would be Mr. Bonick, $6,500,002 and <br>$5,876,352; Mr. Lumsdaine, $2,600,012 and $1,837,696; Mr. Caspers, $1,592,520 and $—; Mr. Petrovich, $1,072,518 and $1,044,992; Mr. Schultz <br>$1,300,034 and $1,335,744; and Mr. Chernin, $1,007,492 and $975,040. With respect to the 2023 time-based Class C unit awards (i.e., the Class <br>C-1 Units), the Company employed a Black-Scholes option pricing model to determine the grant date fair value of its equity-based awards, which <br>was used to allocate the estimated equity value of the Company to the various unit classes. Such equity value of the Company was estimated using <br>income and market valuation approaches, including then-recent sales of the Company's common units. Such estimates required the input of <br>highly subjective, complex assumptions. The Company's valuation assumptions are described in Note 9, "Equity," in the Notes to the Consolidated <br>Financial Statements in the Company's Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC. | (3)The values in this column reflect the aggregate grant date fair values of our equity-based compensation awards in accordance with ASC Topic 718. <br>See "Long-Term Equity Compensation" in the Compensation Discussion and Analysis section of this Proxy Statement for additional information <br>regarding these equity-based compensation awards and their terms. With respect to our PRSU awards, we report grant date fair value at target-<br>level performance, which is the probable achievement level of the performance conditions. Assuming achievement of performance goals at the <br>maximum level, the aggregate grant date fair value of these PRSUs for 2025 and 2024, respectively, would be Mr. Bonick, $6,500,002 and <br>$5,876,352; Mr. Lumsdaine, $2,600,012 and $1,837,696; Mr. Caspers, $1,592,520 and $—; Mr. Petrovich, $1,072,518 and $1,044,992; Mr. Schultz <br>$1,300,034 and $1,335,744; and Mr. Chernin, $1,007,492 and $975,040. With respect to the 2023 time-based Class C unit awards (i.e., the Class <br>C-1 Units), the Company employed a Black-Scholes option pricing model to determine the grant date fair value of its equity-based awards, which <br>was used to allocate the estimated equity value of the Company to the various unit classes. Such equity value of the Company was estimated using <br>income and market valuation approaches, including then-recent sales of the Company's common units. Such estimates required the input of <br>highly subjective, complex assumptions. The Company's valuation assumptions are described in Note 9, "Equity," in the Notes to the Consolidated <br>Financial Statements in the Company's Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC. | (3)The values in this column reflect the aggregate grant date fair values of our equity-based compensation awards in accordance with ASC Topic 718. <br>See "Long-Term Equity Compensation" in the Compensation Discussion and Analysis section of this Proxy Statement for additional information <br>regarding these equity-based compensation awards and their terms. With respect to our PRSU awards, we report grant date fair value at target-<br>level performance, which is the probable achievement level of the performance conditions. Assuming achievement of performance goals at the <br>maximum level, the aggregate grant date fair value of these PRSUs for 2025 and 2024, respectively, would be Mr. Bonick, $6,500,002 and <br>$5,876,352; Mr. Lumsdaine, $2,600,012 and $1,837,696; Mr. Caspers, $1,592,520 and $—; Mr. Petrovich, $1,072,518 and $1,044,992; Mr. Schultz <br>$1,300,034 and $1,335,744; and Mr. Chernin, $1,007,492 and $975,040. With respect to the 2023 time-based Class C unit awards (i.e., the Class <br>C-1 Units), the Company employed a Black-Scholes option pricing model to determine the grant date fair value of its equity-based awards, which <br>was used to allocate the estimated equity value of the Company to the various unit classes. Such equity value of the Company was estimated using <br>income and market valuation approaches, including then-recent sales of the Company's common units. Such estimates required the input of <br>highly subjective, complex assumptions. The Company's valuation assumptions are described in Note 9, "Equity," in the Notes to the Consolidated <br>Financial Statements in the Company's Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC. | (3)The values in this column reflect the aggregate grant date fair values of our equity-based compensation awards in accordance with ASC Topic 718. <br>See "Long-Term Equity Compensation" in the Compensation Discussion and Analysis section of this Proxy Statement for additional information <br>regarding these equity-based compensation awards and their terms. With respect to our PRSU awards, we report grant date fair value at target-<br>level performance, which is the probable achievement level of the performance conditions. Assuming achievement of performance goals at the <br>maximum level, the aggregate grant date fair value of these PRSUs for 2025 and 2024, respectively, would be Mr. Bonick, $6,500,002 and <br>$5,876,352; Mr. Lumsdaine, $2,600,012 and $1,837,696; Mr. Caspers, $1,592,520 and $—; Mr. Petrovich, $1,072,518 and $1,044,992; Mr. Schultz <br>$1,300,034 and $1,335,744; and Mr. Chernin, $1,007,492 and $975,040. With respect to the 2023 time-based Class C unit awards (i.e., the Class <br>C-1 Units), the Company employed a Black-Scholes option pricing model to determine the grant date fair value of its equity-based awards, which <br>was used to allocate the estimated equity value of the Company to the various unit classes. Such equity value of the Company was estimated using <br>income and market valuation approaches, including then-recent sales of the Company's common units. Such estimates required the input of <br>highly subjective, complex assumptions. The Company's valuation assumptions are described in Note 9, "Equity," in the Notes to the Consolidated <br>Financial Statements in the Company's Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC. | (3)The values in this column reflect the aggregate grant date fair values of our equity-based compensation awards in accordance with ASC Topic 718. <br>See "Long-Term Equity Compensation" in the Compensation Discussion and Analysis section of this Proxy Statement for additional information <br>regarding these equity-based compensation awards and their terms. With respect to our PRSU awards, we report grant date fair value at target-<br>level performance, which is the probable achievement level of the performance conditions. Assuming achievement of performance goals at the <br>maximum level, the aggregate grant date fair value of these PRSUs for 2025 and 2024, respectively, would be Mr. Bonick, $6,500,002 and <br>$5,876,352; Mr. Lumsdaine, $2,600,012 and $1,837,696; Mr. Caspers, $1,592,520 and $—; Mr. Petrovich, $1,072,518 and $1,044,992; Mr. Schultz <br>$1,300,034 and $1,335,744; and Mr. Chernin, $1,007,492 and $975,040. With respect to the 2023 time-based Class C unit awards (i.e., the Class <br>C-1 Units), the Company employed a Black-Scholes option pricing model to determine the grant date fair value of its equity-based awards, which <br>was used to allocate the estimated equity value of the Company to the various unit classes. Such equity value of the Company was estimated using <br>income and market valuation approaches, including then-recent sales of the Company's common units. Such estimates required the input of <br>highly subjective, complex assumptions. The Company's valuation assumptions are described in Note 9, "Equity," in the Notes to the Consolidated <br>Financial Statements in the Company's Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC. | (3)The values in this column reflect the aggregate grant date fair values of our equity-based compensation awards in accordance with ASC Topic 718. <br>See "Long-Term Equity Compensation" in the Compensation Discussion and Analysis section of this Proxy Statement for additional information <br>regarding these equity-based compensation awards and their terms. With respect to our PRSU awards, we report grant date fair value at target-<br>level performance, which is the probable achievement level of the performance conditions. Assuming achievement of performance goals at the <br>maximum level, the aggregate grant date fair value of these PRSUs for 2025 and 2024, respectively, would be Mr. Bonick, $6,500,002 and <br>$5,876,352; Mr. Lumsdaine, $2,600,012 and $1,837,696; Mr. Caspers, $1,592,520 and $—; Mr. Petrovich, $1,072,518 and $1,044,992; Mr. Schultz <br>$1,300,034 and $1,335,744; and Mr. Chernin, $1,007,492 and $975,040. With respect to the 2023 time-based Class C unit awards (i.e., the Class <br>C-1 Units), the Company employed a Black-Scholes option pricing model to determine the grant date fair value of its equity-based awards, which <br>was used to allocate the estimated equity value of the Company to the various unit classes. Such equity value of the Company was estimated using <br>income and market valuation approaches, including then-recent sales of the Company's common units. Such estimates required the input of <br>highly subjective, complex assumptions. The Company's valuation assumptions are described in Note 9, "Equity," in the Notes to the Consolidated <br>Financial Statements in the Company's Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC. | (3)The values in this column reflect the aggregate grant date fair values of our equity-based compensation awards in accordance with ASC Topic 718. <br>See "Long-Term Equity Compensation" in the Compensation Discussion and Analysis section of this Proxy Statement for additional information <br>regarding these equity-based compensation awards and their terms. With respect to our PRSU awards, we report grant date fair value at target-<br>level performance, which is the probable achievement level of the performance conditions. Assuming achievement of performance goals at the <br>maximum level, the aggregate grant date fair value of these PRSUs for 2025 and 2024, respectively, would be Mr. Bonick, $6,500,002 and <br>$5,876,352; Mr. Lumsdaine, $2,600,012 and $1,837,696; Mr. Caspers, $1,592,520 and $—; Mr. Petrovich, $1,072,518 and $1,044,992; Mr. Schultz <br>$1,300,034 and $1,335,744; and Mr. Chernin, $1,007,492 and $975,040. With respect to the 2023 time-based Class C unit awards (i.e., the Class <br>C-1 Units), the Company employed a Black-Scholes option pricing model to determine the grant date fair value of its equity-based awards, which <br>was used to allocate the estimated equity value of the Company to the various unit classes. Such equity value of the Company was estimated using <br>income and market valuation approaches, including then-recent sales of the Company's common units. Such estimates required the input of <br>highly subjective, complex assumptions. The Company's valuation assumptions are described in Note 9, "Equity," in the Notes to the Consolidated <br>Financial Statements in the Company's Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC. |
| (4)The values in this column represent the payment of 2023 and 2024 annual short-term cash incentive awards, paid in 2024 and 2025, respectively, <br>under the STIP.  | (4)The values in this column represent the payment of 2023 and 2024 annual short-term cash incentive awards, paid in 2024 and 2025, respectively, <br>under the STIP.  | (4)The values in this column represent the payment of 2023 and 2024 annual short-term cash incentive awards, paid in 2024 and 2025, respectively, <br>under the STIP.  | (4)The values in this column represent the payment of 2023 and 2024 annual short-term cash incentive awards, paid in 2024 and 2025, respectively, <br>under the STIP.  | (4)The values in this column represent the payment of 2023 and 2024 annual short-term cash incentive awards, paid in 2024 and 2025, respectively, <br>under the STIP.  | (4)The values in this column represent the payment of 2023 and 2024 annual short-term cash incentive awards, paid in 2024 and 2025, respectively, <br>under the STIP.  | (4)The values in this column represent the payment of 2023 and 2024 annual short-term cash incentive awards, paid in 2024 and 2025, respectively, <br>under the STIP.  | (4)The values in this column represent the payment of 2023 and 2024 annual short-term cash incentive awards, paid in 2024 and 2025, respectively, <br>under the STIP.  |
| (5)Details with respect to the 2025 amounts in this column are set forth in the table below.  | (5)Details with respect to the 2025 amounts in this column are set forth in the table below.  | (5)Details with respect to the 2025 amounts in this column are set forth in the table below.  | (5)Details with respect to the 2025 amounts in this column are set forth in the table below.  | (5)Details with respect to the 2025 amounts in this column are set forth in the table below.  | (5)Details with respect to the 2025 amounts in this column are set forth in the table below.  | (5)Details with respect to the 2025 amounts in this column are set forth in the table below.  | (5)Details with respect to the 2025 amounts in this column are set forth in the table below.  |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Name** | **Relocation** <br>**Allowance**<br>**Temporary** <br>**Housing and** <br>**Moving Costs**<br>| **Company**<br>**Savings Plan**<br>**Contributions**<br>| **Severance** <br>**Payments**<br>| **Total** |
| Marty Bonick | $— | $14000 | $— | $14000 |
| Alfred Lumsdaine | $— | $14000 | $— | $14000 |
| David Caspers | $45622 | $14000 | $— | $59622 |
| Stephen C. Petrovich | $— | $14000 | $— | $14000 |
| David Schultz | $— | $14000 | $660241 | $674241 |
| Ethan Chernin | $59672 | $14000 | $— | $73672 |

---

---

| |
|:---|
| (6)Included in this amount is a $100,000 sign-on bonus in the form of Common Stock issued to Mr. Caspers pursuant to his offer letter. |
| (7)On January 2, 2024, Mr. Schultz was issued a grant of 14,676 Class C-1 Units. None of these pre-IPO Class C-1 Units converted to restricted stock <br>awards ("RSAs") in connection with the Corporate Conversion defined on page [51](#i86b9ce36f36244588cbb1deefbc6ec50_64) of this Proxy Statement. Instead, Class C-1 Units were cancelled <br>for no value pursuant to the terms set forth in the plan of conversion (including the conversion formula set forth therein). Therefore, the grant <br>date value with respect to such Class C units is assumed to be $0 and is not otherwise reported in this table. |

---

**Grants of Plan-Based Awards in Fiscal 2025 Table**

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | | | **Estimated Future Payouts Under Non-**<br>**Equity Incentive Plan Awards**<sup>(1)</sup> | **Estimated Future Payouts Under Non-**<br>**Equity Incentive Plan Awards**<sup>(1)</sup> | **Estimated Future Payouts Under Non-**<br>**Equity Incentive Plan Awards**<sup>(1)</sup> | **Estimated Future Payouts Under** <br>**Equity Incentive Plan Awards**<sup>(2)</sup> | **Estimated Future Payouts Under** <br>**Equity Incentive Plan Awards**<sup>(2)</sup> | **Estimated Future Payouts Under** <br>**Equity Incentive Plan Awards**<sup>(2)</sup> | **All Other Stock** <br>**Awards:** <br>**Number of** <br>**Shares of Stock** <br>**or Units**<sup>(3)</sup> | **Grant Date** <br>**Fair Value of** <br>**Stock** <br>**Awards**<sup>(4)</sup> |
| | | | | | | | | | **All Other Stock** <br>**Awards:** <br>**Number of** <br>**Shares of Stock** <br>**or Units**<sup>(3)</sup> | **Grant Date** <br>**Fair Value of** <br>**Stock** <br>**Awards**<sup>(4)</sup> |
| <br>**Name** | <br>**Grant Date** | <br>**Award** <br>**Type**<br>| <br>**Threshold**<sup>(5)</sup> | <br>**Target** | <br>**Maximum** | <br>**Threshold**  | <br>**Target** | <br>**Maximum** | **All Other Stock** <br>**Awards:** <br>**Number of** <br>**Shares of Stock** <br>**or Units**<sup>(3)</sup> | **Grant Date** <br>**Fair Value of** <br>**Stock** <br>**Awards**<sup>(4)</sup> |
| Marty Bonick | 01/01/2025 | STIP | $605250 | $1345000 | $2210844 |  |  |  |  | $— |
| Marty Bonick | 04/01/2025 | RSU | $— | $— | $— |  |  |  | 134927 | $1750003 |
| Marty Bonick | 04/01/2025 | PRSU | $— | $— | $— | 119750 | 239499 | 478998 |  | $3250001 |
| Alfred <br>Lumsdaine | 01/01/2025 | STIP | $267300 | $594000 | $976388 |  |  |  |  | $— |
| Alfred <br>Lumsdaine | 04/01/2025 | RSU | $— | $— | $— |  |  |  | 53971 | $700004 |
| Alfred <br>Lumsdaine | 04/01/2025 | PRSU | $— | $— | $— | 47900 | 95800 | 191600 |  | $1300006 |
| David <br>Caspers <sup>(6)</sup> | 03/31/2025 | STIP | $214374 | $476386 | $783059 |  |  |  |  | $— |
| David <br>Caspers <sup>(6)</sup> | 04/01/2025 | CS | $— | $— | $— |  |  |  | 7711 | $100012 |
| David <br>Caspers <sup>(6)</sup> | 04/01/2025 | RSU | $— | $— | $— |  |  |  | 33057 | $428749 |
| David <br>Caspers <sup>(6)</sup> | 04/01/2025 | PRSU | $— | $— | $— | 29339 | 58678 | 117356 |  | $796260 |
| Stephen C. <br>Petrovich | 01/01/2025 | STIP | $186300 | $414000 | $680513 |  |  |  |  | $— |
| Stephen C. <br>Petrovich | 04/01/2025 | RSU | $— | $— | $— |  |  |  | 22263 | $288751 |
| Stephen C. <br>Petrovich | 04/01/2025 | PRSU | $— | $— | $— | 19759 | 39518 | 79036 |  | $536259 |
| David <br>Schultz | 01/01/2025 | STIP | $157896 | $350879 | $576757 |  |  |  |  | $— |
| David <br>Schultz | 04/01/2025 | RSU | $— | $— | $— |  |  |  | 26985 | $349995 |
| David <br>Schultz | 04/01/2025 | PRSU | $— | $— | $— | 23951 | 47901 | 95802 |  | $650017 |
| Ethan <br>Chernin | 01/01/2025 | STIP | $208575 | $463500 | $761878 |  |  |  |  | $— |
| Ethan <br>Chernin | 04/01/2025 | RSU | $— | $— | $— |  |  |  | 20914 | $271255 |
| Ethan <br>Chernin | 04/01/2025 | PRSU | $— | $— | $— | 18561 | 37122 | 74244 |  | $503746 |
| (1)The values in these columns represent the Threshold, Target and Maximum annual bonus opportunities for 2025 under our Short-Term Incentive Plan <br>(abbreviated above as "STIP"). Under the plan terms, if our minimum performance criteria are not met, no bonus is payable. The Threshold amounts <br>disclosed assume a minimum level of achievement for each metric under the STIP.  | (1)The values in these columns represent the Threshold, Target and Maximum annual bonus opportunities for 2025 under our Short-Term Incentive Plan <br>(abbreviated above as "STIP"). Under the plan terms, if our minimum performance criteria are not met, no bonus is payable. The Threshold amounts <br>disclosed assume a minimum level of achievement for each metric under the STIP.  | (1)The values in these columns represent the Threshold, Target and Maximum annual bonus opportunities for 2025 under our Short-Term Incentive Plan <br>(abbreviated above as "STIP"). Under the plan terms, if our minimum performance criteria are not met, no bonus is payable. The Threshold amounts <br>disclosed assume a minimum level of achievement for each metric under the STIP.  | (1)The values in these columns represent the Threshold, Target and Maximum annual bonus opportunities for 2025 under our Short-Term Incentive Plan <br>(abbreviated above as "STIP"). Under the plan terms, if our minimum performance criteria are not met, no bonus is payable. The Threshold amounts <br>disclosed assume a minimum level of achievement for each metric under the STIP.  | (1)The values in these columns represent the Threshold, Target and Maximum annual bonus opportunities for 2025 under our Short-Term Incentive Plan <br>(abbreviated above as "STIP"). Under the plan terms, if our minimum performance criteria are not met, no bonus is payable. The Threshold amounts <br>disclosed assume a minimum level of achievement for each metric under the STIP.  | (1)The values in these columns represent the Threshold, Target and Maximum annual bonus opportunities for 2025 under our Short-Term Incentive Plan <br>(abbreviated above as "STIP"). Under the plan terms, if our minimum performance criteria are not met, no bonus is payable. The Threshold amounts <br>disclosed assume a minimum level of achievement for each metric under the STIP.  | (1)The values in these columns represent the Threshold, Target and Maximum annual bonus opportunities for 2025 under our Short-Term Incentive Plan <br>(abbreviated above as "STIP"). Under the plan terms, if our minimum performance criteria are not met, no bonus is payable. The Threshold amounts <br>disclosed assume a minimum level of achievement for each metric under the STIP.  | (1)The values in these columns represent the Threshold, Target and Maximum annual bonus opportunities for 2025 under our Short-Term Incentive Plan <br>(abbreviated above as "STIP"). Under the plan terms, if our minimum performance criteria are not met, no bonus is payable. The Threshold amounts <br>disclosed assume a minimum level of achievement for each metric under the STIP.  | (1)The values in these columns represent the Threshold, Target and Maximum annual bonus opportunities for 2025 under our Short-Term Incentive Plan <br>(abbreviated above as "STIP"). Under the plan terms, if our minimum performance criteria are not met, no bonus is payable. The Threshold amounts <br>disclosed assume a minimum level of achievement for each metric under the STIP.  | (1)The values in these columns represent the Threshold, Target and Maximum annual bonus opportunities for 2025 under our Short-Term Incentive Plan <br>(abbreviated above as "STIP"). Under the plan terms, if our minimum performance criteria are not met, no bonus is payable. The Threshold amounts <br>disclosed assume a minimum level of achievement for each metric under the STIP.  | (1)The values in these columns represent the Threshold, Target and Maximum annual bonus opportunities for 2025 under our Short-Term Incentive Plan <br>(abbreviated above as "STIP"). Under the plan terms, if our minimum performance criteria are not met, no bonus is payable. The Threshold amounts <br>disclosed assume a minimum level of achievement for each metric under the STIP.  |
| (2)The values shown reflect the number of shares attributable to the 2025 PRSUs. The 2025 PRSUs vest on April 1, 2028, subject to the NEO's continued service <br>with the Company until such time, attainment of performance criteria set by the Committee, and results of the three-year relative TSR modifier. The <br>performance criteria under the 2025 PRSUs relate to achievement of Adjusted EBITDAR and net revenue metrics over the 2025 calendar year. These metrics <br>relate to separate portions of the target number of PRSUs under each PRSU award, such that 60% of the target PRSUs relate to the Adjusted EBITDAR metric <br>and 40% of the target PRSUs relate to the net revenue metric. | (2)The values shown reflect the number of shares attributable to the 2025 PRSUs. The 2025 PRSUs vest on April 1, 2028, subject to the NEO's continued service <br>with the Company until such time, attainment of performance criteria set by the Committee, and results of the three-year relative TSR modifier. The <br>performance criteria under the 2025 PRSUs relate to achievement of Adjusted EBITDAR and net revenue metrics over the 2025 calendar year. These metrics <br>relate to separate portions of the target number of PRSUs under each PRSU award, such that 60% of the target PRSUs relate to the Adjusted EBITDAR metric <br>and 40% of the target PRSUs relate to the net revenue metric. | (2)The values shown reflect the number of shares attributable to the 2025 PRSUs. The 2025 PRSUs vest on April 1, 2028, subject to the NEO's continued service <br>with the Company until such time, attainment of performance criteria set by the Committee, and results of the three-year relative TSR modifier. The <br>performance criteria under the 2025 PRSUs relate to achievement of Adjusted EBITDAR and net revenue metrics over the 2025 calendar year. These metrics <br>relate to separate portions of the target number of PRSUs under each PRSU award, such that 60% of the target PRSUs relate to the Adjusted EBITDAR metric <br>and 40% of the target PRSUs relate to the net revenue metric. | (2)The values shown reflect the number of shares attributable to the 2025 PRSUs. The 2025 PRSUs vest on April 1, 2028, subject to the NEO's continued service <br>with the Company until such time, attainment of performance criteria set by the Committee, and results of the three-year relative TSR modifier. The <br>performance criteria under the 2025 PRSUs relate to achievement of Adjusted EBITDAR and net revenue metrics over the 2025 calendar year. These metrics <br>relate to separate portions of the target number of PRSUs under each PRSU award, such that 60% of the target PRSUs relate to the Adjusted EBITDAR metric <br>and 40% of the target PRSUs relate to the net revenue metric. | (2)The values shown reflect the number of shares attributable to the 2025 PRSUs. The 2025 PRSUs vest on April 1, 2028, subject to the NEO's continued service <br>with the Company until such time, attainment of performance criteria set by the Committee, and results of the three-year relative TSR modifier. The <br>performance criteria under the 2025 PRSUs relate to achievement of Adjusted EBITDAR and net revenue metrics over the 2025 calendar year. These metrics <br>relate to separate portions of the target number of PRSUs under each PRSU award, such that 60% of the target PRSUs relate to the Adjusted EBITDAR metric <br>and 40% of the target PRSUs relate to the net revenue metric. | (2)The values shown reflect the number of shares attributable to the 2025 PRSUs. The 2025 PRSUs vest on April 1, 2028, subject to the NEO's continued service <br>with the Company until such time, attainment of performance criteria set by the Committee, and results of the three-year relative TSR modifier. The <br>performance criteria under the 2025 PRSUs relate to achievement of Adjusted EBITDAR and net revenue metrics over the 2025 calendar year. These metrics <br>relate to separate portions of the target number of PRSUs under each PRSU award, such that 60% of the target PRSUs relate to the Adjusted EBITDAR metric <br>and 40% of the target PRSUs relate to the net revenue metric. | (2)The values shown reflect the number of shares attributable to the 2025 PRSUs. The 2025 PRSUs vest on April 1, 2028, subject to the NEO's continued service <br>with the Company until such time, attainment of performance criteria set by the Committee, and results of the three-year relative TSR modifier. The <br>performance criteria under the 2025 PRSUs relate to achievement of Adjusted EBITDAR and net revenue metrics over the 2025 calendar year. These metrics <br>relate to separate portions of the target number of PRSUs under each PRSU award, such that 60% of the target PRSUs relate to the Adjusted EBITDAR metric <br>and 40% of the target PRSUs relate to the net revenue metric. | (2)The values shown reflect the number of shares attributable to the 2025 PRSUs. The 2025 PRSUs vest on April 1, 2028, subject to the NEO's continued service <br>with the Company until such time, attainment of performance criteria set by the Committee, and results of the three-year relative TSR modifier. The <br>performance criteria under the 2025 PRSUs relate to achievement of Adjusted EBITDAR and net revenue metrics over the 2025 calendar year. These metrics <br>relate to separate portions of the target number of PRSUs under each PRSU award, such that 60% of the target PRSUs relate to the Adjusted EBITDAR metric <br>and 40% of the target PRSUs relate to the net revenue metric. | (2)The values shown reflect the number of shares attributable to the 2025 PRSUs. The 2025 PRSUs vest on April 1, 2028, subject to the NEO's continued service <br>with the Company until such time, attainment of performance criteria set by the Committee, and results of the three-year relative TSR modifier. The <br>performance criteria under the 2025 PRSUs relate to achievement of Adjusted EBITDAR and net revenue metrics over the 2025 calendar year. These metrics <br>relate to separate portions of the target number of PRSUs under each PRSU award, such that 60% of the target PRSUs relate to the Adjusted EBITDAR metric <br>and 40% of the target PRSUs relate to the net revenue metric. | (2)The values shown reflect the number of shares attributable to the 2025 PRSUs. The 2025 PRSUs vest on April 1, 2028, subject to the NEO's continued service <br>with the Company until such time, attainment of performance criteria set by the Committee, and results of the three-year relative TSR modifier. The <br>performance criteria under the 2025 PRSUs relate to achievement of Adjusted EBITDAR and net revenue metrics over the 2025 calendar year. These metrics <br>relate to separate portions of the target number of PRSUs under each PRSU award, such that 60% of the target PRSUs relate to the Adjusted EBITDAR metric <br>and 40% of the target PRSUs relate to the net revenue metric. | (2)The values shown reflect the number of shares attributable to the 2025 PRSUs. The 2025 PRSUs vest on April 1, 2028, subject to the NEO's continued service <br>with the Company until such time, attainment of performance criteria set by the Committee, and results of the three-year relative TSR modifier. The <br>performance criteria under the 2025 PRSUs relate to achievement of Adjusted EBITDAR and net revenue metrics over the 2025 calendar year. These metrics <br>relate to separate portions of the target number of PRSUs under each PRSU award, such that 60% of the target PRSUs relate to the Adjusted EBITDAR metric <br>and 40% of the target PRSUs relate to the net revenue metric. |
| (3)The values in this column represent the number of RSUs and Common Stock awards (abbreviated above as "CS") granted in 2025. With respect to the 2025 <br>RSUs granted on April 1, 2025, the RSUs vest in three substantially equal installments, with approximately one-third of the RSUs vesting on each of April 1, <br>2026, April 1, 2027 and April 1, 2028, subject to the NEO's continued service with the Company through each applicable vesting date. | (3)The values in this column represent the number of RSUs and Common Stock awards (abbreviated above as "CS") granted in 2025. With respect to the 2025 <br>RSUs granted on April 1, 2025, the RSUs vest in three substantially equal installments, with approximately one-third of the RSUs vesting on each of April 1, <br>2026, April 1, 2027 and April 1, 2028, subject to the NEO's continued service with the Company through each applicable vesting date. | (3)The values in this column represent the number of RSUs and Common Stock awards (abbreviated above as "CS") granted in 2025. With respect to the 2025 <br>RSUs granted on April 1, 2025, the RSUs vest in three substantially equal installments, with approximately one-third of the RSUs vesting on each of April 1, <br>2026, April 1, 2027 and April 1, 2028, subject to the NEO's continued service with the Company through each applicable vesting date. | (3)The values in this column represent the number of RSUs and Common Stock awards (abbreviated above as "CS") granted in 2025. With respect to the 2025 <br>RSUs granted on April 1, 2025, the RSUs vest in three substantially equal installments, with approximately one-third of the RSUs vesting on each of April 1, <br>2026, April 1, 2027 and April 1, 2028, subject to the NEO's continued service with the Company through each applicable vesting date. | (3)The values in this column represent the number of RSUs and Common Stock awards (abbreviated above as "CS") granted in 2025. With respect to the 2025 <br>RSUs granted on April 1, 2025, the RSUs vest in three substantially equal installments, with approximately one-third of the RSUs vesting on each of April 1, <br>2026, April 1, 2027 and April 1, 2028, subject to the NEO's continued service with the Company through each applicable vesting date. | (3)The values in this column represent the number of RSUs and Common Stock awards (abbreviated above as "CS") granted in 2025. With respect to the 2025 <br>RSUs granted on April 1, 2025, the RSUs vest in three substantially equal installments, with approximately one-third of the RSUs vesting on each of April 1, <br>2026, April 1, 2027 and April 1, 2028, subject to the NEO's continued service with the Company through each applicable vesting date. | (3)The values in this column represent the number of RSUs and Common Stock awards (abbreviated above as "CS") granted in 2025. With respect to the 2025 <br>RSUs granted on April 1, 2025, the RSUs vest in three substantially equal installments, with approximately one-third of the RSUs vesting on each of April 1, <br>2026, April 1, 2027 and April 1, 2028, subject to the NEO's continued service with the Company through each applicable vesting date. | (3)The values in this column represent the number of RSUs and Common Stock awards (abbreviated above as "CS") granted in 2025. With respect to the 2025 <br>RSUs granted on April 1, 2025, the RSUs vest in three substantially equal installments, with approximately one-third of the RSUs vesting on each of April 1, <br>2026, April 1, 2027 and April 1, 2028, subject to the NEO's continued service with the Company through each applicable vesting date. | (3)The values in this column represent the number of RSUs and Common Stock awards (abbreviated above as "CS") granted in 2025. With respect to the 2025 <br>RSUs granted on April 1, 2025, the RSUs vest in three substantially equal installments, with approximately one-third of the RSUs vesting on each of April 1, <br>2026, April 1, 2027 and April 1, 2028, subject to the NEO's continued service with the Company through each applicable vesting date. | (3)The values in this column represent the number of RSUs and Common Stock awards (abbreviated above as "CS") granted in 2025. With respect to the 2025 <br>RSUs granted on April 1, 2025, the RSUs vest in three substantially equal installments, with approximately one-third of the RSUs vesting on each of April 1, <br>2026, April 1, 2027 and April 1, 2028, subject to the NEO's continued service with the Company through each applicable vesting date. | (3)The values in this column represent the number of RSUs and Common Stock awards (abbreviated above as "CS") granted in 2025. With respect to the 2025 <br>RSUs granted on April 1, 2025, the RSUs vest in three substantially equal installments, with approximately one-third of the RSUs vesting on each of April 1, <br>2026, April 1, 2027 and April 1, 2028, subject to the NEO's continued service with the Company through each applicable vesting date. |
| (4)Amounts reported in this column reflect the aggregate grant date fair value of the applicable RSUs, PRSUs and CS granted in 2025, computed in accordance <br>with ASC Topic 718. For a discussion of the assumptions and methodologies used to calculate the amounts reflected in the table above, please see footnote 3 <br>to the "Summary Compensation Table" above. | (4)Amounts reported in this column reflect the aggregate grant date fair value of the applicable RSUs, PRSUs and CS granted in 2025, computed in accordance <br>with ASC Topic 718. For a discussion of the assumptions and methodologies used to calculate the amounts reflected in the table above, please see footnote 3 <br>to the "Summary Compensation Table" above. | (4)Amounts reported in this column reflect the aggregate grant date fair value of the applicable RSUs, PRSUs and CS granted in 2025, computed in accordance <br>with ASC Topic 718. For a discussion of the assumptions and methodologies used to calculate the amounts reflected in the table above, please see footnote 3 <br>to the "Summary Compensation Table" above. | (4)Amounts reported in this column reflect the aggregate grant date fair value of the applicable RSUs, PRSUs and CS granted in 2025, computed in accordance <br>with ASC Topic 718. For a discussion of the assumptions and methodologies used to calculate the amounts reflected in the table above, please see footnote 3 <br>to the "Summary Compensation Table" above. | (4)Amounts reported in this column reflect the aggregate grant date fair value of the applicable RSUs, PRSUs and CS granted in 2025, computed in accordance <br>with ASC Topic 718. For a discussion of the assumptions and methodologies used to calculate the amounts reflected in the table above, please see footnote 3 <br>to the "Summary Compensation Table" above. | (4)Amounts reported in this column reflect the aggregate grant date fair value of the applicable RSUs, PRSUs and CS granted in 2025, computed in accordance <br>with ASC Topic 718. For a discussion of the assumptions and methodologies used to calculate the amounts reflected in the table above, please see footnote 3 <br>to the "Summary Compensation Table" above. | (4)Amounts reported in this column reflect the aggregate grant date fair value of the applicable RSUs, PRSUs and CS granted in 2025, computed in accordance <br>with ASC Topic 718. For a discussion of the assumptions and methodologies used to calculate the amounts reflected in the table above, please see footnote 3 <br>to the "Summary Compensation Table" above. | (4)Amounts reported in this column reflect the aggregate grant date fair value of the applicable RSUs, PRSUs and CS granted in 2025, computed in accordance <br>with ASC Topic 718. For a discussion of the assumptions and methodologies used to calculate the amounts reflected in the table above, please see footnote 3 <br>to the "Summary Compensation Table" above. | (4)Amounts reported in this column reflect the aggregate grant date fair value of the applicable RSUs, PRSUs and CS granted in 2025, computed in accordance <br>with ASC Topic 718. For a discussion of the assumptions and methodologies used to calculate the amounts reflected in the table above, please see footnote 3 <br>to the "Summary Compensation Table" above. | (4)Amounts reported in this column reflect the aggregate grant date fair value of the applicable RSUs, PRSUs and CS granted in 2025, computed in accordance <br>with ASC Topic 718. For a discussion of the assumptions and methodologies used to calculate the amounts reflected in the table above, please see footnote 3 <br>to the "Summary Compensation Table" above. | (4)Amounts reported in this column reflect the aggregate grant date fair value of the applicable RSUs, PRSUs and CS granted in 2025, computed in accordance <br>with ASC Topic 718. For a discussion of the assumptions and methodologies used to calculate the amounts reflected in the table above, please see footnote 3 <br>to the "Summary Compensation Table" above. |
| (5)The Threshold amounts reported in this table do not include any value for the Individual Performance metrics as there is no specific minimum threshold that <br>NEOs can earn as the payouts for such Individual Performance metrics range from 0% to 125%. | (5)The Threshold amounts reported in this table do not include any value for the Individual Performance metrics as there is no specific minimum threshold that <br>NEOs can earn as the payouts for such Individual Performance metrics range from 0% to 125%. | (5)The Threshold amounts reported in this table do not include any value for the Individual Performance metrics as there is no specific minimum threshold that <br>NEOs can earn as the payouts for such Individual Performance metrics range from 0% to 125%. | (5)The Threshold amounts reported in this table do not include any value for the Individual Performance metrics as there is no specific minimum threshold that <br>NEOs can earn as the payouts for such Individual Performance metrics range from 0% to 125%. | (5)The Threshold amounts reported in this table do not include any value for the Individual Performance metrics as there is no specific minimum threshold that <br>NEOs can earn as the payouts for such Individual Performance metrics range from 0% to 125%. | (5)The Threshold amounts reported in this table do not include any value for the Individual Performance metrics as there is no specific minimum threshold that <br>NEOs can earn as the payouts for such Individual Performance metrics range from 0% to 125%. | (5)The Threshold amounts reported in this table do not include any value for the Individual Performance metrics as there is no specific minimum threshold that <br>NEOs can earn as the payouts for such Individual Performance metrics range from 0% to 125%. | (5)The Threshold amounts reported in this table do not include any value for the Individual Performance metrics as there is no specific minimum threshold that <br>NEOs can earn as the payouts for such Individual Performance metrics range from 0% to 125%. | (5)The Threshold amounts reported in this table do not include any value for the Individual Performance metrics as there is no specific minimum threshold that <br>NEOs can earn as the payouts for such Individual Performance metrics range from 0% to 125%. | (5)The Threshold amounts reported in this table do not include any value for the Individual Performance metrics as there is no specific minimum threshold that <br>NEOs can earn as the payouts for such Individual Performance metrics range from 0% to 125%. | (5)The Threshold amounts reported in this table do not include any value for the Individual Performance metrics as there is no specific minimum threshold that <br>NEOs can earn as the payouts for such Individual Performance metrics range from 0% to 125%. |
| (6)Mr. Caspers was appointed as Chief Operating Officer effective March 31, 2025. Thus, the STIP amounts above are prorated to reflect the partial year spent <br>in the position. | (6)Mr. Caspers was appointed as Chief Operating Officer effective March 31, 2025. Thus, the STIP amounts above are prorated to reflect the partial year spent <br>in the position. | (6)Mr. Caspers was appointed as Chief Operating Officer effective March 31, 2025. Thus, the STIP amounts above are prorated to reflect the partial year spent <br>in the position. | (6)Mr. Caspers was appointed as Chief Operating Officer effective March 31, 2025. Thus, the STIP amounts above are prorated to reflect the partial year spent <br>in the position. | (6)Mr. Caspers was appointed as Chief Operating Officer effective March 31, 2025. Thus, the STIP amounts above are prorated to reflect the partial year spent <br>in the position. | (6)Mr. Caspers was appointed as Chief Operating Officer effective March 31, 2025. Thus, the STIP amounts above are prorated to reflect the partial year spent <br>in the position. | (6)Mr. Caspers was appointed as Chief Operating Officer effective March 31, 2025. Thus, the STIP amounts above are prorated to reflect the partial year spent <br>in the position. | (6)Mr. Caspers was appointed as Chief Operating Officer effective March 31, 2025. Thus, the STIP amounts above are prorated to reflect the partial year spent <br>in the position. | (6)Mr. Caspers was appointed as Chief Operating Officer effective March 31, 2025. Thus, the STIP amounts above are prorated to reflect the partial year spent <br>in the position. | (6)Mr. Caspers was appointed as Chief Operating Officer effective March 31, 2025. Thus, the STIP amounts above are prorated to reflect the partial year spent <br>in the position. | (6)Mr. Caspers was appointed as Chief Operating Officer effective March 31, 2025. Thus, the STIP amounts above are prorated to reflect the partial year spent <br>in the position. |

---

**Employment Agreements and Offer Letters**

***Marty Bonick***

Mr. Bonick is a party to an amended and restated employment agreement with AHS Management Company, Inc. ("AHS"),

pursuant to which he is employed as the Company's President and Chief Executive Officer. Pursuant to the agreement,

which is dated as of January 10, 2025, Mr. Bonick's initial term of employment ends on December 31, 2027, with automatic

one-year term renewals unless either party gives timely written notice of non-renewal. Under the terms of the agreement,

Mr. Bonick's base salary is set at $1,076,000, which base salary may be increased to such other amount as approved by the

Board from time to time. In addition, the terms of the agreement provide that Mr. Bonick is eligible to (i) receive grants

under the Ardent Health Partners, Inc. 2024 Omnibus Incentive Award Plan (the "2024 Plan") and (ii) participate in the

Company's annual bonus program (i.e., the STIP) with a target annual bonus opportunity established by the Board each year

during the term of the agreement.

***Alfred Lumsdaine***

Mr. Lumsdaine is a party to an amended and restated employment agreement with AHS, pursuant to which he is employed

as the Company's Chief Financial Officer. Pursuant to the agreement, which is dated as of January 10, 2025, Mr.

Lumsdaine's initial term of employment ends on December 31, 2027, with automatic one-year term renewals unless either

party gives timely written notice of non-renewal. Under the terms of the agreement, Mr. Lumsdaine's base salary is set at

$628,000, which base salary may be increased to such other amount as approved by the Board from time to time (as noted

above, Mr. Lumsdaine's base salary as of December 31, 2025 was $660,000). In addition, the terms of the agreement

provide that Mr. Lumsdaine is eligible to (i) receive grants under the 2024 Plan and (ii) participate in the Company's annual

bonus program (i.e., the STIP) with a target annual bonus opportunity established by the Board each year during the term of

the agreement.

***David Caspers***

Mr. Caspers is not party to an employment agreement with AHS or the Company itself. However, Mr. Caspers accepted an

offer letter, dated February 17, 2025, which outlines the basic terms of his employment with AHS. The offer letter with Mr.

Caspers provides for an annual base salary of $700,000, a sign-on bonus of $175,000, which is comprised of $75,000 of cash

and $100,000 in the form of our Common Stock, the opportunity to participate in the STIP for a prorated portion of the

2025 fiscal year with a target bonus of 90% of his base salary, and a yearly equity grant with a target value equal to 1.75

times his annual base salary. In addition, Mr. Caspers is entitled to receive certain relocation reimbursement and interim

travel benefits as well as participate in the same employee benefit and perquisite programs as other senior officers of the

Company.

***Stephen C. Petrovich***

Mr. Petrovich is a party to an employment agreement with AHS, pursuant to which he is employed as the Company's

Executive Vice President and General Counsel. The agreement became effective on August 4, 2015 and extends until his

termination of employment. Under the terms of the agreement, Mr. Petrovich's base salary was initially set at $375,000,

which base salary may be changed to such higher amount as approved by the Committee from time to time (as noted

above, Mr. Petrovich's base salary as of December 31, 2025 was $552,000). Under the terms of the agreement, Mr.

Petrovich is eligible to participate in the Company's annual bonus program on such terms as determined by the Board. In

addition, pursuant to the terms of the agreement, Mr. Petrovich is eligible to participate in any fringe benefit and employee

benefit programs available to other similarly situated senior officers of AHS.

***David Schultz***

On June 16, 2025, the Company and Mr. Schultz determined that Mr. Schultz would no longer serve as President, Hospital

Operations and would depart the Company effective immediately. The Company treated Mr. Schultz's departure from the

Company as a "Qualifying Termination" pursuant to the Company's Executive Severance Plan (the "Severance Plan"). Mr.

Schultz's severance benefits are described under "Executive Compensation – Potential Payments upon Termination or

Change in Control."

Mr. Schultz was not party to an employment agreement with AHS or the Company itself. However, in connection with his

promotion to President, Hospital Operations, Mr. Schultz accepted an offer letter, dated November 28, 2023, which

outlined the basic terms of his employment with AHS. As a general matter, the compensation-related terms set forth in the

offer letter with Mr. Schultz ceased to be applicable to him over the course of the first half of 2024 (i.e., in 2024, (i) Mr.

Schultz became subject to the STIP for the entirety of the 2024 fiscal year with a target bonus of 90% of his base salary, and

(ii) the Committee established (A) Mr. Schultz's 2024 base salary rate of $685,000, and (B) 2024 target equity award equal

to 150% of his base salary). However, Mr. Schultz received a grant of Class C-1 Units pursuant to the offer letter on January

2, 2024. In addition, pursuant to the offer letter, Mr. Schultz remained entitled during 2024 to receive (x) relocation

reimbursement benefits, (y) a related miscellaneous expense allowance up to $10,000, and (z) temporary housing benefits

in connection with his relocation from Washington state to Nashville, Tennessee.

***Ethan Chernin***

Mr. Chernin was not party to an employment agreement with AHS or the Company itself. However, Mr. Chernin accepted

an offer letter, dated March 28, 2024, which outlined the basic terms of his employment with AHS. The offer letter with Mr.

Chernin provides for an annual base salary of $600,000, a sign-on bonus of $50,000, the opportunity to participate in the

STIP for a prorated portion of the 2024 fiscal year with a target bonus of 75% of his base salary, and a yearly equity grant

with a target value equal to 1.25 times his annual base salary. In addition, Mr. Chernin was entitled to receive certain

relocation reimbursement benefits and participate in the same employee benefit and perquisite programs as other senior

officers of the Company.

**Outstanding Equity Awards at Fiscal 2025 Year-End**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Name** | **Grant Date** | **Award** <br>**Type**<br>| **Number of Shares** <br>**or Units of Stock** <br>**that have not** <br>**Vested**<sup>(1)</sup><br>| **Market Value of** <br>**Shares or Units of** <br>**Stock that have** <br>**not Vested**<sup>(2)</sup><br>| **Equity Incentive** <br>**Plan Awards:** <br>**Number of** <br>**Unearned Shares,** <br>**Units or Other** <br>**Rights that have** <br>**not Vested**<sup>(3)</sup><br>| **Equity Incentive Plan** <br>**Awards: Market or** <br>**Payout Value of** <br>**Unearned Shares, Units** <br>**or Other Rights that** <br>**have not Vested**<sup>(2)</sup> <br>|
| Marty Bonick | 09/01/2020 | RSA<sup>(5)</sup> | 439434 | $3880202 |  | $— |
|  | 07/18/2024 | RSU | 65921 | $582082 |  | $— |
|  | 07/18/2024 | PRSU |  | $— | 183636 | $1621506 |
|  | 04/01/2025 | RSU | 134927 | $1191405 |  | $— |
|  | 04/01/2025 | PRSU |  | $— | 239499 | $2114776 |
| Alfred Lumsdaine | 09/08/2021 | RSA<sup>(4)</sup> | 4649 | $41051 |  | $— |
|  | 09/08/2021 | RSA<sup>(5)</sup> | 29295 | $258675 |  | $— |
|  | 07/18/2024 | RSU | 20615 | $182030 |  | $— |
|  | 07/18/2024 | PRSU |  | $— | 57428 | $507089 |
|  | 09/25/2024 | RSU | 27828 | $245721 |  | $— |
|  | 04/01/2025 | RSU | 53971 | $476564 |  | $— |
|  | 04/01/2025 | PRSU |  | $— | 95800 | $845914 |
| David Caspers | 04/01/2025 | RSU | 33057 | $291893 |  | $— |
|  | 04/01/2025 | PRSU |  | $— | 58678 | $518127 |
| Stephen C. Petrovich | 10/01/2015 | RSA<sup>(5)</sup> | 259266 | $2289319 |  | $— |
|  | 07/13/2018 | RSA<sup>(5)</sup> | 22195 | $195982 |  | $— |
|  | 07/18/2024 | RSU | 11723 | $103514 |  | $— |
|  | 07/18/2024 | PRSU |  | $— | 32656 | $288352 |
|  | 09/25/2024 | RSU | 6466 | $57095 |  | $— |
|  | 04/01/2025 | RSU | 22263 | $196582 |  | $— |
|  | 04/01/2025 | PRSU |  | $— | 39518 | $348944 |
| David Schultz | 07/18/2024 | PRSU |  | $— | 15545 | $137262 |
|  | 04/01/2025 | PRSU |  | $— | 3363 | $29695 |
| Ethan Chernin | 07/18/2024 | RSU | 10937 | $95574 |  | $— |
|  | 07/18/2024 | PRSU |  | $— | 30470 | $269050 |
|  | 04/01/2025 | RSU | 20914 | $184671 |  | $— |
|  | 04/01/2025 | PRSU |  | $— | 37122 | $327787 |

---

---

| |
|:---|
| (1)Represents (i) unvested RSAs issued in 2024 in connection with conversion of the Class C-1 Units and Class C-2 Units pursuant to the Corporate <br>Conversion (the vesting terms of such RSAs are described in footnotes 4 and 5 below), and (ii) remaining portion of unvested RSUs granted in 2024 <br>and 2025. With respect to the RSUs granted on July 18, 2024, the remaining RSUs vest in two substantially equal installments, with approximately <br>one-half of the RSUs vesting on each of March 31, 2026 and March 31, 2027, subject to the NEO's continued service with the Company through <br>each applicable vesting date. With respect to the RSUs granted on September 25, 2024, the remaining RSUs vest in two substantially equal <br>installments with approximately one-half of the RSUs vesting on each of September 25, 2026 and September 25, 2027, subject to the NEO's <br>continued service with the Company through each applicable vesting date. With respect to the RSUs granted on April 1, 2025, the RSUs vest in <br>three substantially equal installments with approximately one-third of the RSUs vesting on each of April 1, 2026, April 1, 2027 and April 1, 2028, <br>subject to the NEO's continued service with the Company through each applicable vesting date. |
| (2)Based on the per share closing price of our Common Stock of $8.83 on December 31, 2025.  |
| (3)Represents unvested 2024 PRSUs granted on July 18, 2024, which vest on December 31, 2026, subject to the NEO's continued service with the <br>Company until such time and attainment of performance criteria set by the Committee. The performance criteria under the 2024 PRSUs relate to <br>achievement of Adjusted EBITDAR and net revenue metrics over the cumulative 2024-2025 period. These metrics relate to separate portions of <br>the target number of PRSUs under each PRSU award, such that 60% of the target PRSUs relate to the Adjusted EBITDAR metric and 40% of the <br>target PRSUs relate to the net revenue metric. Also represents unvested 2025 PRSUs granted on April 1, 2025, which vest on April 1, 2028, subject <br>to the NEO's continued service with the Company until such time, attainment of performance criteria set by the Committee, and results of the <br>three-year relative TSR modifier. The performance criteria under the 2025 PRSUs relate to achievement of Adjusted EBITDAR and net revenue <br>metrics over the 2025 calendar year. These metrics relate to separate portions of the target number of PRSUs under each PRSU award, such that <br>60% of the target PRSUs relate to the Adjusted EBITDAR metric and 40% of the target PRSUs relate to the net revenue metric. |
| (4)Represents unvested RSAs that were issued with respect to awards of pre-IPO Class C-1 Units that were converted into RSAs on July 17, 2024 in <br>connection with the Corporate Conversion and in accordance with a formula set forth in the plan of conversion. These RSAs vest ratably in <br>substantially equal installments each calendar quarter over the remainder of the 5-year vesting period that applied to the related pre-IPO Class <br>C-1 Units, subject to the NEO's continued service with the Company through each applicable vesting date. |
| (5)Represents remaining portion of unvested RSAs that were issued with respect to awards of pre-IPO Class C-2 Units that were converted into RSAs <br>on July 17, 2024 in connection with the Corporate Conversion and in accordance with a formula set forth in the plan of conversion. These RSAs <br>vest in two substantially equal installments on each of March 31, 2026 and March 31, 2027, subject to the NEO's continued service with the <br>Company through each applicable vesting date. |

---

**Stock Vested in Fiscal 2025**

---

| | | |
|:---|:---|:---|
| **Name** | **Number of** <br>**Shares Acquired** <br>**on Vesting**<br>| **Stock Awards** <br>**Value Realized** <br>**on Vesting**<br>|
| Marty Bonick<sup>(1)</sup> | 252677 | $2997523 |
| Alfred Lumsdaine<sup>(2)</sup> | 48161 | $609836 |
| David Caspers |  | $— |
| Stephen C. Petrovich<sup>(3)</sup> | 149825 | $1752897 |
| David Schultz<sup>(4)</sup> | 48007 | $626469 |
| Ethan Chernin <sup>(5)</sup> | 5469 | $75199 |

---

(1) Represents shares of our Common Stock issued to Mr. Bonick in connection with the vesting of RSUs on March 31, 2025 (32,960 shares) and the vesting of RSAs on July 17, 2025 (219,717 shares). The value realized on such vesting is based on our closing stock price on the respective vesting dates.

(2) Represents shares of our Common Stock issued to Mr. Lumsdaine in connection with the vesting of RSUs on March 31, 2025 (10,307 shares) and September 25, 2025 (13,914 shares) and the vesting of RSAs on March 31, 2025 (2,323 shares), June 30, 2025 (2,323 shares), July 17, 2025 (14,648 shares), September 30, 2025 (2,323 shares) and December 31, 2025 (2,323 shares). The value realized on such vesting is based on our closing stock price on the respective vesting dates.

(3) Represents shares of our Common Stock issued to Mr. Petrovich in connection with the vesting of RSUs on March 31, 2025 (5,861 shares) and September 25, 2025 (3,233 shares) and the vesting of RSAs July 17, 2025 (140,731 shares). The value realized on such vesting is based on our closing stock price on the respective vesting dates.

(4) Represents shares of our Common Stock issued to Mr. Schultz in connection with the vesting of RSUs on March 31, 2025 (7,492 shares) and in connection with the accelerated vesting of certain of Mr. Schultz's RSUs upon his termination on June 16, 2025 (40,515 shares). The value realized on such vesting is based on our closing stock price on the respective vesting dates.

(5) Represents shares of our Common Stock issued to Mr. Chernin in connection with the vesting of RSUs on March 31, 2025. The value realized on such vesting is based on our closing stock price on the vesting date.

**Potential Payments upon Termination or Change in Control** 

Each of Messrs. Bonick, Lumsdaine and Petrovich is party to an employment agreement which provides for severance

payments in connection with a termination of employment under certain circumstances. Mr. Caspers is, and Messrs. Schultz

and Chernin prior to their departure from the Company were, eligible for certain severance payments pursuant to the

Severance Plan.

• In the case of Mr. Bonick, the applicable severance benefits are outlined in his employment agreement. The

terms of his such severance benefits are consistent with the severance guidelines approved by the Committee

prior to our IPO. Thus, although the employment agreement was entered into on January 10, 2025, such

severance benefits are described below.

In the event of a termination of the executive's employment by the executive for Good Reason or by the

Company without Cause (as such terms are defined in the executive's amended and restated employment

agreement), the executive is entitled to severance benefits equal to (i) the sum of his base salary and target

bonus (A) multiplied by two and payable in substantially equal installments in accordance with our normal

payroll practices for 24 months, or (B) if such termination occurs in connection with a Change in Control (as

defined in the executive's amended and restated employment agreement), multiplied by three and payable in

a lump sum, and (ii) monthly COBRA coverage reimbursements for up to 18 months. A termination without

Cause for these purposes includes non-renewal of the stated term of employment by the Company. In

addition, in the event of the executive's disability, he is entitled to continued base salary payments during the

six-month period following his termination of employment.

• In the case of Mr. Lumsdaine, the applicable severance benefits are outlined in his employment agreement.

The terms of such severance benefits are consistent with the severance guidelines approved by the

Committee prior to our IPO. Thus, although the employment agreement was entered into on January 10, 2025,

such severance benefits are described below.

In the event of a termination of the executive's employment by the executive for Good Reason or by the

Company without Cause (as such terms are defined in the executive's amended and restated employment

agreement), the executive is entitled to severance benefits equal to (i) the sum of his base salary and target

bonus (A) multiplied by 1.5 and payable in substantially equal installments in accordance with our normal

payroll practices for 18 months, or (B) if the qualifying termination occurs in connection with a Change in

Control (as defined in the executive's amended and restated employment agreement), multiplied by two and

payable in a lump sum and (ii) reimbursement of the monthly cost for COBRA coverage for up to 18 months. A

termination without Cause for these purposes includes non-renewal of the stated term of employment by the

Company. In addition, in the event of the executive's disability, he is entitled to continued base salary

payments during the six-month period following his termination of employment.

• In the case of Mr. Petrovich, in the event of a termination of the executive's employment by the executive for

Good Reason or by the Company without Cause (as such terms are defined in the executive's employment

agreement), the executive is entitled to a severance payment equal to a multiple of two times (i) the highest

base salary rate in effect during the term of the agreement, (ii) the highest bonus level that would be paid to

the executive if the bonus plan targets were achieved (regardless of actual achievement), and (iii) an

additional amount equal to 15% of his base salary at the time of termination. These severance payments are

to be made in equal installments over the 24-month period following termination, subject to acceleration in

the event the executive dies post-termination. In addition, in the event of the executive's disability, he is

entitled to continued base salary payments during the six-month period following his termination of

employment. The severance provisions in Mr. Petrovich's employment agreement also provide that he will be

entitled to reimbursement of his reasonable attorney's fees and costs (and related arbitration, mediation and

litigation costs) in the event he successfully resolves certain compensation and benefits claims in his favor.

• In the case of Mr. Caspers, and Messrs. Schultz and Chernin prior to their departure, the Severance Plan

applies in the event of a termination of the executive's employment by the executive for Good Reason or by

the Company without Cause (as defined in the Severance Plan). In such case, the executive is entitled to a

severance payment equal to (i) the sum of the executive's base salary and target bonus (A) multiplied by 1.5

and payable in substantially equal installments in accordance with our normal payroll practices for 18 months,

or (B) if the qualifying termination occurs in connection with a change in control of the Company, multiplied by

two and payable in a lump sum, and (ii) reimbursement of the monthly cost for COBRA coverage for up to 18

months.

For purposes of the foregoing employment agreements and the Severance Plan:

• "Cause" generally means the executive's (i) willful refusal to perform, or gross negligence in performing, the

reasonable duties of his office, (ii) conviction of or guilty plea to any crime punishable as a felony, or involving

fraud or embezzlement, any crime involving moral turpitude or any crime in connection with the delivery of

healthcare services, (iii) inability to participate in applicable federal healthcare programs, (iv) any act involving

moral turpitude that materially affects the performance of his duties, (v) use of alcohol in violation of company

policies or illegal use of drugs, (vi) engagement in fraud, theft, misappropriation or embezzlement with respect

to the Company or any of its affiliates, (vii) exclusion from participation in any applicable federal healthcare

program, or (viii) sanctioning by any federal or state governmental agency or department and/or being listed

on the Health and Human Services cumulative sanctions report, or excluded by the General Services

Administration, as set forth on the list of excluded providers.

• "Change in Control" generally means (i) any person becomes the direct or indirect beneficial owner of more

than 50% of the Company's then-outstanding voting securities, (ii) directors serving on the Board during a

specified period cease to constitute at least a majority of the Board unless such directors are approved by a

vote of at least a majority of the incumbent directors, and (iii) consummation of any merger, reorganization or

consolidation involving the Company, a complete liquidation of the Company or sale of substantially all of the

Company's assets involving, as applicable, one or more parties that are unrelated to the Company unless the

holders of the voting securities of the Company immediately prior to the transaction own more than 50% of

the then combined voting power of the voting securities of the company resulting from such transaction in

substantially the same proportions of their ownership of such voting securities of the Company prior to the

transaction.

Each employment agreement contains restrictive covenants where the executive is subject to during such executive's

employment and each executive will in all cases be subject to such restrictive covenants following such executive's

termination of employment. The executives who are party to employment agreements are bound by a perpetual

confidentiality restriction, as well as post-employment non-competition and employee non-solicitation restrictions. For

Messrs. Bonick and Lumsdaine, the post-employment non-competition and non-solicitation restricted period is the 12-

month period following each individual's respective termination of employment. For Mr. Petrovich, the restricted period is

the 24-month period following his termination of employment (or, in the case of a termination without cause, the 12-

month period following termination of employment). The Company may implement similar restrictive covenants for Mr.

Caspers pursuant to the Severance Plan.

**Treatment of Equity Awards** 

As discussed above in the CD&A under "Long-Term Equity Compensation," our NEOs have received awards of RSAs, RSUs

and/or PRSUs.

• With respect to RSAs that were issued with respect to the related pre-IPO Class C-1 Unit awards, (i) the next

quarterly vesting tranche of those awards will vest in the event the NEO's service is terminated without Cause and

any remaining unvested portion of those awards will forfeit, and (ii) the entire unvested portion of those awards

will accelerate in the event of a Change in Control (as such terms are defined in the RSA award agreement).

• With respect to the RSAs that were issued with respect to the related pre-IPO Class C-2 Unit awards, the unvested

portion of those awards will forfeit in the event the NEO's service is terminated for any reason.

• With respect to RSUs granted in connection with the 2024 RSUs and the special RSU grants, (i) the unvested

portion of those awards will vest in the event the NEO's service is terminated without Cause or the NEO resigns

with Good Reason (as such terms are defined in the RSU award agreement), and (ii) the entire unvested portion of

those awards will vest in the event the NEO's service is terminated due to disability.

• With respect to PRSUs granted in connection with the 2024 and 2025 PRSUs, (i) a pro-rated portion of those

awards will remain eligible to vest in the event the NEO's service is terminated without Cause or the NEO resigns

with Good Reason (as such terms are defined in the RSU award agreement), based on the period in which the NEO

remained in service prior to December 31, 2026, and (ii) the entirety of those awards will remain eligible to vest in

the event the NEO's service is terminated due to disability, in each case, subject to attainment of the relevant

performance conditions thereunder.

• With respect to RSUs granted in connection with the 2025 RSUs, (i) in the event the NEO's service is terminated

without Cause or the NEO resigns with Good Reason (as such terms are defined in the RSU award agreement), the

number of RSUs that were otherwise scheduled to vest on the anniversary date that immediately follows such

termination will vest, and (ii) in the event the NEO's service is terminated due to disability, the entire unvested

portion of those awards will vest.

The following table summarizes the payments that would have been made to our NEOs (other than Mr. Schultz who was

not employed as of December 31, 2025) upon the occurrence of a termination of employment or a change in control,

assuming that each NEO's termination of employment with the Company or a change in control occurred on December 31,

2025. Amounts shown do not include (i) accrued but unpaid salary, and (ii) other benefits earned or accrued by the

continuing NEO during his employment that are available to all salaried employees and that do not discriminate in scope,

terms or operations in favor of executive officers.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Name / Type of Payment** | **Change in** <br>**Control**<br>| **Termination by** <br>**the Company** <br>**Without Cause** <br>**or Employee's** <br>**Resignation for** <br>**Good Reason** <br>**Following a** <br>**Change in** <br>**Control**<br>| **Termination by** <br>**the Company** <br>**Without Cause** <br>**or Employee's** <br>**Resignation for** <br>**Good Reason**<br>| **Termination by** <br>**the Company** <br>**For Cause or** <br>**Employee's** <br>**Resignation** <br>**Without Good** <br>**Reason**<br>| **Disability** | **Termination**<br>**due to**<br>**Death**<br>|
| **Marty Bonick** |  |  |  |  |  |  |
| Severance | $— | $7263000 | $4842000 | $— | $538000 | $— |
| Health and Welfare | $— | $42427 | $42427 | $— | $— | $— |
| Accelerated Vesting of RSAs <br>(Converted Class C-2 Units)<br>| $— | $— | $— | $— | $— | $— |
| Accelerated Vesting of RSU <br>Awards<sup>(1)</sup><br>| $— | $980012 | $980012 | $— | $1773488 | $1773488 |
| Accelerated Vesting of PRSU <br>Awards<sup>(2)</sup><br>| $— | $1491836 | $1491836 | $— | $3736282 | $3736282 |
| **Total** | **$—** | **$9777275** | **$7356275** | **$—** | **$6047770** | **$5509770** |
| **Alfred Lumsdaine** |  |  |  |  |  |  |
| Severance | $— | $2508000 | $1881000 | $— | $330000 | $— |
| Health and Welfare | $— | $52852 | $52852 | $— | $— | $— |
| Accelerated Vesting of RSAs <br>(Converted Class C-1 Units)<sup>(3)</sup><br>| $41051 | $— | $20512 | $— | $— | $— |
| Accelerated Vesting of RSAs <br>(Converted Class C-2 Units)<br>| $— | $— | $— | $— | $— | $— |
| Accelerated Vesting of RSU <br>Awards<sup>(1)</sup><br>| $— | $586924 | $586924 | $— | $904316 | $904316 |
| Accelerated Vesting of PRSU <br>Awards<sup>(2)</sup><br>| $— | $512805 | $512805 | $— | $1353003 | $1353003 |
| **Total** | **$41051** | **$3660581** | **$3054093** | **$—** | **$2587319** | **$2257319** |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Name / Type of Payment** | **Change in** <br>**Control**<br>| **Termination by** <br>**the Company** <br>**Without Cause** <br>**or Employee's** <br>**Resignation for** <br>**Good Reason** <br>**Following a** <br>**Change in** <br>**Control**<br>| **Termination by** <br>**the Company** <br>**Without Cause** <br>**or Employee's** <br>**Resignation for** <br>**Good Reason**<br>| **Termination by** <br>**the Company** <br>**For Cause or** <br>**Employee's** <br>**Resignation** <br>**Without Good** <br>**Reason**<br>| **Disability** | **Termination**<br>**due to**<br>**Death**<br>|
| **David Caspers** |  |  |  |  |  |  |
| Severance | $— | $2352772 | $1764579 | $— | $— | $— |
| Health and Welfare | $— | $39736 | $39736 | $— | $— | $— |
| Accelerated Vesting of RSU <br>Awards<sup>(1)</sup><br>| $— | $97492 | $97492 | $— | $291893 | $291893 |
| Accelerated Vesting of PRSU <br>Awards<sup>(2)</sup><br>| $— | $129886 | $129886 | $— | $518127 | $518127 |
| **Total** | **$—** | **$2619886** | **$2031693** | **$—** | **$810020** | **$810020** |
| **Stephen C. Petrovich** |  |  |  |  |  |  |
| Severance | $— | $2014800 | $2014800 | $— | $276000 | $— |
| Accelerated Vesting of RSAs <br>(Converted Class C-2 Units)<br>| $— | $— | $— | $— | $— | $— |
| Accelerated Vesting of RSU <br>Awards<sup>(1)</sup><br>| $— | $226267 | $226267 | $— | $357191 | $357191 |
| Accelerated Vesting of PRSU <br>Awards<sup>(2)</sup><br>| $— | $258493 | $258493 | $— | $637296 | $637296 |
| **Total** | **$—** | **$2499560** | **$2499560** | **$—** | **$1270487** | **$994487** |
| **Ethan Chernin** |  |  |  |  |  |  |
| Severance | $— | $2163000 | $1622250 | $— | $— | $— |
| Health and Welfare | $— | $41995 | $41995 | $— | $— | $— |
| Accelerated Vesting of RSU <br>Awards<sup>(1)</sup><br>| $— | $158254 | $158254 | $— | $281244 | $281244 |
| Accelerated Vesting of PRSU <br>Awards<sup>(2)</sup><br>| $— | $241741 | $241741 | $— | $596837 | $596837 |
| **Total** | **$—** | **$2604990** | **$2064240** | **$—** | **$878081** | **$878081** |

---

(1)The 2024 RSU award agreements provide that, upon the termination of any of the NEO's employment due to disability or death, by the Company

without "cause" or by the NEO for "good reason," all outstanding unvested RSUs will vest. The 2025 RSU award agreements provide that upon the

termination of any of the NEO's employment due to disability or death, all outstanding unvested RSUs will vest, or provide that upon termination of

any NEO's employment by the Company without "cause" or by the NEO for "good reason," the number of RSUs that were otherwise scheduled to

vest on the anniversary date that immediately follows such termination will vest. The amounts set forth above with respect to the 2024 and 2025

RSUs are based on their value using our closing stock price of $8.83 as of December 31, 2025.

(2)The 2024 and 2025 PRSU award agreements provide that, upon the termination of any of the NEO's employment due to disability or death, the

PRSUs will remain eligible to vest in full, based upon actual performance at the later of the conclusion of the performance period or the date of such

termination. Upon a termination of employment by the Company without "cause" or by the NEO for "good reason," the PRSUs will remain eligible

to vest on a pro-rata basis, based upon actual performance at the later of the conclusion of the performance period or the date of such termination

(with pro-rata vesting based on the number of days the NEO remained in employment from the grant date relative to the full vesting period that

applies to the PRSUs, which ends on December 31, 2026 for the 2024 PRSUs and on April 1, 2028 for the 2025 PRSUs). The amounts set forth above

with respect to the 2024 and 2025 PRSUs are based on their value using our closing stock price of $8.83 as of December 31, 2025 assuming target-

level performance.

(3)Pursuant to Mr. Lumsdaine's RSA award agreement that relates to his converted Class C-1 Units, such RSAs become fully vested upon the

occurrence of a "change in control." The amounts set forth above with respect to the unvested RSAs is based on their value using our closing stock

price of $8.83 as of December 31, 2025.

. <br>

**CEO Pay Ratio**

As required by Section 953(b) of the Dodd-Frank Act and Item 402(u) of Regulation S-K, we are providing the following

information regarding the relationship between the annual total compensation of our employees and the annual total

compensation of Marty Bonick, our President and Chief Executive Officer.

The 2025 annual total compensation of the median compensated employee as of December 31, 2025, excluding Mr. Bonick,

was $56,682. The 2025 annual total compensation of Mr. Bonick was $6,090,004. Based on these amounts, the ratio of our

President and Chief Executive Officer's 2025 annual total compensation to that of our median compensated employee was

approximately 107:1.

The pay ratio disclosed above represents a reasonable estimate calculated in a manner consistent with SEC rules. We

identified our median employee using total annual W-2 wages of employees who were employed for the entirety of 2025

and the annualized value of total gross wages earned during 2025 for employees who commenced employment during

2025 and were employed as of December 31, 2025. Our employee population consisted of full-time, part-time, and

temporary employees. The inclusion of part-time and temporary employees reduces the median annual total compensation

of our employee population. Due to the nature of the healthcare industry, including workforce turnover and job status

changes, we identified the employee population and median employee as of December 31, 2025 based on our payroll and

employment records. After identifying the median employee, we calculated that employee's annual total compensation for

2025 using the same methodology used to determine the annual total compensation of our NEOs, as reflected in the

"Summary Compensation Table" included elsewhere in this Proxy Statement.

The SEC's rules for identifying the median compensated employee and calculating the CEO pay ratio based on that

employee's annual total compensation allow companies to adopt a variety of methodologies and make reasonable

estimates and assumptions that reflect their employee populations and compensation practices. As a result, the pay ratios

reported by other companies may not be comparable to the pay ratio reported above, as other companies may have

different workforce compositions and compensation practices or utilize different methodologies, estimates, and

assumptions in their calculations.

**Pay Versus Performance**

The following table and supporting narrative contain information regarding compensation actually paid ("CAP") to our NEOs

and the relationship to Company performance in accordance with SEC rules. Neither CAP nor the amount reported in the

Summary Compensation Table reflect the amount of compensation actually paid, earned or received during the applicable

year. Per SEC rules, CAP was calculated by adjusting Summary Compensation Table total compensation values for the

applicable year as described in the footnotes to the table.

**Pay Versus Performance Table**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Year** | **Summary** <br>**Compensation** <br>**Table Total for** <br>**PEO** <sup>(1)</sup> | **Compensation** <br>**Actually Paid** <br>**to PEO** <sup>(1)</sup> | **Average** <br>**Summary** <br>**Compensation** <br>**Table Total** <br>**for Non-PEO** <br>**NEOs** <sup>(2)</sup> | **Average** <br>**Compensation** <br>**Actually Paid** <br>**to Non-PEO** <br>**NEOs** <sup>(2)</sup> | **Value of Initial Fixed $100** <br>**Investment Based On**: | **Value of Initial Fixed $100** <br>**Investment Based On**: | **Net** <br>**Income**<br>**($M)** | **Adjusted** <br>**EBITDAR** <br>**($M)** <sup>(4)</sup> |
| **Year** | **Summary** <br>**Compensation** <br>**Table Total for** <br>**PEO** <sup>(1)</sup> | **Compensation** <br>**Actually Paid** <br>**to PEO** <sup>(1)</sup> | **Average** <br>**Summary** <br>**Compensation** <br>**Table Total** <br>**for Non-PEO** <br>**NEOs** <sup>(2)</sup> | **Average** <br>**Compensation** <br>**Actually Paid** <br>**to Non-PEO** <br>**NEOs** <sup>(2)</sup> | | | **Net** <br>**Income**<br>**($M)** | **Adjusted** <br>**EBITDAR** <br>**($M)** <sup>(4)</sup> |
| **Year** | **Summary** <br>**Compensation** <br>**Table Total for** <br>**PEO** <sup>(1)</sup> | **Compensation** <br>**Actually Paid** <br>**to PEO** <sup>(1)</sup> | **Average** <br>**Summary** <br>**Compensation** <br>**Table Total** <br>**for Non-PEO** <br>**NEOs** <sup>(2)</sup> | **Average** <br>**Compensation** <br>**Actually Paid** <br>**to Non-PEO** <br>**NEOs** <sup>(2)</sup> | **Total** <br>**Shareholder** <br>**Return**<br>| **Peer Group** <br>**Total** <br>**Shareholder** <br>**Return** <sup>(3)</sup><br>| **Net** <br>**Income**<br>**($M)** | **Adjusted** <br>**EBITDAR** <br>**($M)** <sup>(4)</sup> |
| 2025 | $6090004 | $(3171355) | $2026300 | $216369 | $55 | $105 | $230 | $709 |
| 2024 | $6939257 | $18696908 | $2493471 | $4440157 | $106 | $94 | $300 | $659 |

---

(1)Reflects compensation for our CEO, Marty Bonick, who served as our Principal Executive Officer ("PEO") in 2024 and 2025.

(2)For both years presented, reflects compensation for Alfred Lumsdaine, Stephen C. Petrovich, David Schultz and Ethan Chernin, and, with respect to

2025, additionally reflects compensation for David Caspers, as shown in the Summary Compensation Table above.

(3)Peer Group used for TSR comparisons reflects the S&P Health Care Index. TSR calculation assumes an initial investment of $100 at the market close of

July 18, 2024, the date our stock commenced trading on the NYSE. Data for the S&P Health Care Index assumes reinvestment of dividends.

(4)The Company-selected measure is Adjusted EBITDAR, as defined in the "Supplemental Non-GAAP Valuation Measure" section in the Company's

Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC.

To calculate CAP for our PEO and other NEOs, the following adjustments were made to Summary Compensation Table total

compensation for the year ended December 31, 2025.

---

| | | |
|:---|:---|:---|
| **Adjustments** | **PEO**  | **Other NEOs** |
| **Summary Compensation Table Total** | **$6090004** | **$2026300** |
| Deduction for amount reported in "Stock Awards" column of the Summary Compensation Table | (5000004) | (1185011) |
| Addition of fair value at fiscal year (FY) end of equity awards granted during the FY that remained <br>outstanding <br>| 2905859 | 566773 |
| Addition of fair value at vesting date of equity awards granted during the FY that vested during the FY |  | 43245 |
| Addition of change in fair value at FY end versus prior FY end for awards granted in prior FY that <br>remained outstanding<br>| (5849014) | (996308) |
| Addition of change in fair value at vesting date versus prior FY end for awards granted in prior FY that <br>vested during the FY<br>| (1318200) | (238630) |
| **Compensation Actually Paid** | **$(3171355)** | **$216369** |

---

***Equity Valuation Assumptions***

Measurement date equity fair values are calculated with assumptions derived on a basis consistent with those used for

grant date fair value purposes. Restricted stock units are valued based on the closing stock price on the relevant

measurement date. Performance stock units subject to non-market-based conditions are valued based on revised

assumptions of the probable payout on the applicable measurement dates and the closing stock price on that date.

**Tabular List of Company Performance Measures**

The following table alphabetically lists the measures we believe are most important in linking compensation actually paid to

Company performance during 2025.

1. Adjusted EBITDAR

2. Adjusted EBITDAR margin

3. Net revenue

Further details on these measures and how they feature in our compensation plans can be found in the section entitled

"Compensation Discussion and Analysis."

**Pay Versus Performance: Graphical Description**

The illustrations below depict CAP (as calculated in accordance with the SEC rules) and its relationship to the following

measures:

1. the Company's cumulative TSR and the Peer Group's cumulative TSR;

2. the Company's net income; and

3. the Company-selected measure, which is Adjusted EBITDAR.

***CAP and Cumulative TSR / Cumulative TSR of the Peer Group***

![CAP vs ARDT and Peer TSR.jpg](ardt-20260408_g3.jpg)

***CAP and Net Income***

![CAP vs ARDT Net Income.jpg](ardt-20260408_g4.jpg)

***CAP and Adjusted EBITDAR***

![CAP vs Adj EBITDAR.jpg](ardt-20260408_g5.jpg)

**Director Compensation**

In connection with our IPO, the Committee established a compensation program for our non-employee directors for their

service on the Board (the "Director Program"). The Director Program consists of annual cash retainers and grants of time-

based RSUs under the 2024 Plan ("Annual Director RSUs"). Under the Director Program, each participating non-employee

director receives an annual cash retainer of $100,000 and a grant of Annual Director RSUs with a vesting period of 12

months and a grant date value of $185,000 for their service on the Board. In addition, depending on their position with the

Board, participating non-employee directors will receive the following additional annual cash retainers for their service on

the Board:

---

| | |
|:---|:---|
| **Position** | **Additional Retainer** |
| Chairperson of the Board | $125000 |
| Audit and Compliance Committee |  |
| Chairperson | $30000 |
| Committee Member | $15000 |
| Compensation Committee |  |
| Chairperson | $20000 |
| Committee Member | $10000 |
| Nominating and Corporate Governance Committee |  |
| Chairperson | $15000 |
| Committee Member | $7500 |
| Patient Safety and Quality of Care Committee |  |
| Chairperson | $20000 |
| Committee Member | $10000 |

---

The annual cash retainers are paid in four equal quarterly installments and pro-rated for any partial year of service on the

Board. Similarly, grants of Annual Director RSUs will be prorated for any partial year of service, such that for any new or

replacement non-affiliated non-employee directors appointed during a fiscal year, they would receive a pro-rata portion of

Annual Director RSUs based on the time remaining in the fiscal year of their appointment.

Any unvested portion of the annual equity award generally is forfeited upon a such director's termination of Board service,

other than due to (i) death, (ii) disability or (iii) such director's continued service until the first annual meeting of

stockholders following the date of grant that applies to such Annual Director RSUs where such director (A) fails to be re-

elected as a member of the Board (other than for reasons related to such director's misconduct or similar circumstances),

or (B) does not stand for re-election.

In addition, the Board will review, from time to time, our director compensation program to ensure we can continue to

attract and retain highly qualified Board members.

Mr. Bulgarelli, at the direction of Ventas, historically has been designated as ineligible to participate in the Director

Program, but will be eligible to participate for 2026 as a result of his retirement from Ventas.

**2025 Director Compensation**

The following table summarizes, for 2025, certain information regarding the compensation of our non-employee directors.

Mr. Bonick, our CEO, does not receive any separate compensation for his service on our Board. Please see "Executive

Compensation – Summary Compensation Table" for a summary of the compensation received by Mr. Bonick in 2025 in his

capacity as an executive officer. Mr. Bulgarelli, at the direction of Ventas, did not receive compensation for his service as a

director during 2025.

---

| | | | |
|:---|:---|:---|:---|
| **Name** | **Fees Earned or** <br>**Paid in Cash**<sup>(1)</sup><br>| **Stock** <br>**Awards**<sup>(2)(3)</sup><br>| **Total** |
| Peter Bynoe | $125000 | $169716 | $294716 |
| Suzanne Campion | $117500 | $169716 | $287216 |
| Robert DeMichiei <sup>(4)</sup> | $91875 | $129136 | $221011 |
| William Goodyear | $137500 | $169716 | $307216 |
| Ellen Havdala | $130000 | $169716 | $299716 |
| Edmondo Robinson | $135000 | $169716 | $304716 |
| Rahul Sen | $117500 | $169716 | $287216 |
| Mark Sotir | $225000 | $169716 | $394716 |
| Rob Webb | $125000 | $169716 | $294716 |

---

(1) Amounts reported in this column represent cash fees paid to each non-employee director during 2025 for his or her Board and committee service. Cash fees are paid quarterly in arrears.

(2) Amounts reported in this column reflect the aggregate grant date fair value for the Annual Director RSUs granted in 2025, computed in accordance with ASC Topic 718. The Company's valuation assumptions are described in Note 9, "Equity," in the Notes to the Consolidated Financial Statements in the Company's Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC.

(3) The aggregate number of shares subject to stock awards outstanding as of December 31, 2025 for each of the non-employee directors was as follows: Mr. Bynoe, 12,916 RSUs; Ms. Campion, 12,916 RSUs; Mr. DeMichiei, 10,073 RSUs; Mr. Goodyear, 12,916 RSUs; Ms. Havdala, 12,916 RSUs; Dr. Robinson, 12,916 RSUs; Mr. Sen, 12,916 RSUs; Mr. Sotir, 12,916 RSUs; and Mr. Webb, 12,916 RSUs. 

(4) Mr. DeMichiei joined the Board on April 2, 2025, and thus his fees earned and stock awards granted were pro-rated for his partial service during the year.

**Equity Compensation Plans**

The following table provides information as of December 31, 2025 about equity securities that may be issued under the

Company's existing equity compensation plans and arrangements:

---

| | | | |
|:---|:---|:---|:---|
| **Plan Category** | **Number of** <br>**Securities to be** <br>**Issued Upon** <br>**Exercise of** <br>**Outstanding** <br>**Options, Warrants** <br>**and Rights**<sup>(1)</sup><br>| **Weighted- Average** <br>**Exercise Price of** <br>**Outstanding** <br>**Options, Warrants** <br>**and Rights**<br>| **Number of** <br>**Securities** <br>**Remaining** <br>**Available for** <br>**Future Issuance** <br>**Under Equity** <br>**Compensation** <br>**Plans (Excluding** <br>**Securities** <br>**Reflected in the** <br>**First Column)**<br>|
| Equity compensation plans approved by security holders | 4049766 | $— | 8241657 |
| Equity compensation plans not approved by security holders |  |  |  |
| **Total** | **4049766** | **$—** | **8241657** |

---

(1)Includes 1,828,133 RSUs that vest solely upon the holder's continued employment through a certain date and 2,221,633 PRSUs that vest upon the

holder's continued employment and achievement of Company-wide financial targets over time. The PRSUs included in the table above represent

the number of shares that would be earned by the holders based upon achievement of target performance. The earned number of shares for PRSUs

can range from 0% to 200% depending upon the actual performance relative to target performance and the results of the relative TSR modifier.

For additional information regarding the Company's equity compensation plans, see Note 9, "Equity," in the Notes to the

Consolidated Financial Statements in the Company's Annual Report on Form 10-K for the year ended December 31, 2025

filed with the SEC.

**Proposal 3: Ratification of Appointment of Independent Registered Public Accounting** 

**Firm**

The Audit and Compliance Committee of the Board has appointed Ernst & Young LLP ("EY") as our independent registered

public accounting firm for the fiscal year ending December 31, 2026. Representatives of EY are expected to be present at

the Annual Meeting and will have an opportunity to make a statement if they desire and will be available to respond to

appropriate questions. Although ratification is not required by our Bylaws, or otherwise, our Board is submitting the

selection of EY to our stockholders for ratification as a matter of good corporate practice.

**Fees**

The following table presents fees for professional services rendered by EY for the audit of our annual financial statements

for the years ended December 31, 2025 and 2024, and fees incurred for other services rendered by EY for such years:

---

| | | |
|:---|:---|:---|
| | **2025** | **2024** |
| Audit fees <sup>(1)</sup> | $5854000 | $3909730 |
| Audit-related fees <sup>(2)</sup> | 98000 | 95382 |
| Tax fees <sup>(3)</sup> | 429561 | 454057 |
| All other fees |  |  |
| **Total fees** | **$6381561** | **$4459169** |

---

(1)Audit fees are primarily for the audit of our annual financial statements and the review of our quarterly financial statements. For 2025, these fees

include the audit of the effectiveness of our internal control over financial reporting under the Sarbanes-Oxley Act of 2002. For 2024, these fees

include services in connection with our IPO.

(2)Audit-related fees were for incremental audit and review services performed for certain subsidiaries of the Company.

(3)Tax fees were for tax planning, employment-related tax credits and tax advisory services.

**Pre-Approval of Auditor Services**

The charter of the Audit and Compliance Committee provides that the Audit and Compliance Committee must pre-approve

all auditing and non-auditing services to be provided by our auditor. In addition, the Audit and Compliance Committee shall

have the sole authority to approve any compensation to our auditor for any approved audit or non-audit services. For 2025,

all services provided by EY were pre-approved by the Audit and Compliance Committee. All non-audit services were

reviewed by the Audit and Compliance Committee, and the Audit and Compliance Committee concluded that the provision

of such services by EY was compatible with the maintenance of that firm's independence in the conduct of its auditing

functions.

**Required Vote**

The affirmative vote of the holders of a majority of the shares of Common Stock present in person or represented by proxy

at the Annual Meeting and entitled to vote on the matter is needed to ratify the appointment of EY as our independent

registered public accounting firm for the fiscal year ending December 31, 2026. Under Delaware law, an abstention will

have the same legal effect as a vote against the ratification of EY, and broker non-votes will have no effect on the outcome

of the ratification of the independent registered public accounting firm. If the appointment is not ratified, the matter will be

referred to the Audit and Compliance Committee for further review.

**The Audit and Compliance Committee and the Board recommend that the stockholders vote FOR** <br>**ratification of the appointment of EY as our independent registered public accounting** <br>**firm for the fiscal year ending December 31, 2026.**<br>

**Audit and Compliance Committee Report**

Our management has primary responsibility for preparing our financial statements and implementing internal controls over

financial reporting. Our independent registered public accounting firm, EY, is responsible for expressing an opinion on the

conformity of our audited financial statements with accounting principles generally accepted in the United States and the

effectiveness of our internal control over financial reporting.

The role and responsibilities of the Audit and Compliance Committee are set forth in a written charter adopted by our

Board of Directors. The charter is available on our website, *www.ardenthealth.com*, under the webpage "Investor Relations

– Governance – Governance Documents." The Audit and Compliance Committee reviews and reassesses the adequacy of

the charter annually or more often as necessary and recommends any proposed changes to the Board. The Audit and

Compliance Committee acted in accordance with its charter in 2025. In fulfilling its responsibilities for fiscal year 2025, the

Audit and Compliance Committee:

• Reviewed and discussed with management our unaudited quarterly financial statements during 2024 and our

audited financial statements for the fiscal year ended December 31, 2025, including a discussion of critical

accounting policies used in such financial statements;

• Discussed with EY the matters required to be discussed by the applicable requirements of the Public Company

Accounting Oversight Board and the SEC; and

• Received the written disclosures and the letter from EY as required by the applicable requirements of the

Public Company Accounting Oversight Board regarding EY's communications with the Audit and Compliance

Committee concerning independence and discussed with EY their independence from us and management.

Based on the Audit and Compliance Committee's review of the audited financial statements and discussions with

management and EY as described above, and in reliance thereon, the Audit and Compliance Committee recommended to

our Board that the audited financial statements for the fiscal year ended December 31, 2025 be included in our Annual

Report on Form 10-K for filing with the SEC.

Audit and Compliance Committee:

William Goodyear, Chair

Robert DeMichiei

Edmondo Robinson, M.D.

Rob Webb

**Certain Relationships and Related Party Transactions**

**Related Person Transaction Policy** 

We have established a written related party transaction policy that provides procedures for the review of transactions in

excess of $120,000 in any year between us and any covered person having a direct or indirect material interest with certain

exceptions. Covered persons include any director, executive officer, director nominee or stockholders known to us to

beneficially own 5% or more of our voting securities or any affiliates and immediate family members of the foregoing. Any

such related party transactions shall require advance approval by a majority of our independent directors or by our Audit

and Compliance Committee.

**Corporate Conversion**

In July 2024, the Company converted into a Delaware corporation and changed its name to Ardent Health Partners, Inc. (the

"Corporate Conversion"). As a result of the Corporate Conversion, the unitholders of Ardent Health Partners, LLC became

holders of shares of Common Stock of Ardent Health Partners, Inc. On June 3, 2025, Ardent Health Partners, Inc. changed its

name to Ardent Health, Inc. Ownership of beneficial owners can be found under "Security Ownership of Certain Beneficial

Owners and Management."

**Pure Health Equity Investment**

On May 1, 2023, Pure Health purchased a 26.1% interest in the Company from the unitholders for approximately $500

million. In connection with Pure Health's investment, unitholders were eligible to exercise tag-along rights to sell a

proportionate share of their individual equity ownership interest in the Company and AHP Health Partners, Inc., our direct

majority-owned subsidiary. Ventas exercised its tag-along right to sell its proportionate share of interest in both the

Company and AHP Health Partners, Inc. To fulfill Ventas' right to sell its proportionate share of noncontrolling ownership

interest in AHP Health Partners, Inc., we exercised our right to repurchase those shares from Ventas for $26.0 million

concurrent with Pure Health's purchase of a minority interest in our Company.

**Sale-Leaseback of Medical Office Buildings with Ventas**

On February 9, 2022, we completed the sale of 18 medical office buildings to Ventas in exchange for $204.0 million and

concurrently entered into agreements to lease the real estate back from Ventas over a 12-year initial term with eight

options to renew for additional five-year terms.

The initial terms of the lease agreements did not qualify for accounting treatment as sale-leaseback arrangements. Thus,

the held-for-sale assets were classified as held for sale and continued to depreciate over their respective useful lives.

Additionally, the net proceeds received from the transaction of $202.1 million were accounted for as a related party

deferred financing obligation.

On December 28, 2022, we amended certain renewal terms of the original lease agreements with Ventas such that the

amended terms qualified for accounting treatment as sale-leaseback arrangements. Upon amendment, we recognized a

gain of $157.8 million in other non-operating gains, related party for the year ended December 31, 2022. The aggregate

amount of all periodic payments pursuant to such lease agreements due on or after January 1, 2025 through the current

expiration date is approximately $111.6 million.

**Ventas Master Lease and the Relative Rights Agreement**

Prior to August 4, 2015, AHS Medical Holdings, LLC (the "Predecessor") was the limited liability company that owned the

assets and operations now owned by the Company. Effective August 4, 2015, Ventas purchased a majority of the

Predecessor's real estate assets. In a series of related transactions, the Predecessor's operations and real estate were

separated. Thereafter, Ventas retained ownership of the Predecessor's real estate while a combination of EGI-AM, Ventas

and the Predecessor's senior management team formed the Company, which acquired the Predecessor's operations on

August 4, 2015 for $519.5 million. The Company divested the majority of its real estate to Ventas as part of the transaction,

effective August 4, 2015, whereby Ventas purchased a majority of the Predecessor's real estate assets. The Company issued

$14.0 million of equity attributable to noncontrolling interests as part of such transaction on August 4, 2015. Prior to the

closing of the series of related transactions whereby EGI-AM, Ventas and the Predecessor's senior management team

formed the Company, which acquired the Predecessor's operations, effective August 4, 2015, the Company held certain

subordinated notes due to affiliates, which were repaid and terminated at such closing. The Company had $84.2 million of

subordinated notes due to an affiliate of the Company's former controlling unitholder at December 31, 2014 (Predecessor),

which were repaid on August 4, 2015. Interest expense associated with this debt totaled $5.1 million for the period January

1, 2015 to August 3, 2015 (Predecessor). The Company also had $6.7 million of subordinated notes due to affiliates of FFC

Partners (which owned common units and redeemable preferred units of the Company), which subordinated notes were

repaid on August 4, 2015. Interest expense associated with this debt totaled $408,000 for the period January 1, 2015 to

August 3, 2015 (Predecessor).

On August 4, 2015, we also entered into a 20-year master lease agreement (with a renewal option for an additional ten

years) with subsidiaries of Ventas, pursuant to which we lease ten of our hospitals. The ten wholly owned subsidiaries of

the Company that operate the hospitals subject to the Ventas Master Lease are "tenant" parties to the Ventas Master Lease

("Tenants"), and the Company, AHP Health Partners, Inc. and Ardent Legacy Holdings, LLC, a wholly owned direct subsidiary

of AHP Health Partners, Inc., are "guarantor" parties to the Ventas Master Lease ("Lease Guarantors"). The Lease

Guarantors provide an unsecured guarantee of the Tenants' obligations under the Ventas Master Lease in favor of the

Ventas "landlord" subsidiaries party thereto. The Ventas Master Lease includes an annual rent escalator equal to the lesser

of four times the Consumer Price Index (or 4x CPI) or 2.5%. The Company recorded rent expense of $137.3 million for the

year ended December 31, 2024 related to this agreement. In addition, Ventas also provided us with growth capital related

to the expansion and enhancement of our physical facilities of up to $30.0 million annually during the first five years of the

Ventas Master Lease. The aggregate amount of all periodic payments pursuant to the Ventas Master Lease due on or after

January 1, 2025 through the current expiration date is approximately $2.5 billion.

The Ventas Master Lease includes a number of significant operating and financial restrictions on us, including requirements

that we maintain certain minimum portfolio coverage ratio (defined as consolidated EBITDAR of Tenants, plus management

fees, as further adjusted for certain additional permitted add-backs (including estimated acquisition synergies), over

"minimum rent" (as defined)) of at least 2.2x and guarantor fixed charge coverage ratio (defined as consolidated EBITDAR,

as further adjusted for certain additional permitted add-backs (including estimated acquisition synergies), over fixed

charges) of at least 1.2x and do not exceed a certain guarantor net leverage ratio of 6.75x (defined as funded indebtedness

plus annual rent payments under operating leases, multiplied by 8.0, over consolidated EBITDAR, as further adjusted for

certain additional permitted add-backs (including estimated acquisition synergies)). If we breached our covenants under the

terms of the Ventas Master Lease, we would be in default thereunder, and Ventas would have the right in certain

circumstances to terminate the Ventas Master Lease and/or exercise a purchase option with respect to certain personal

property located at the leased facilities. The Ventas Master Lease contains a cross-acceleration provision that could result in

a default under the Ventas Master Lease in the event we default under the terms of certain of our debt instruments,

including our $325.0 million senior secured asset based revolving credit facility ("ABL Facility") and the senior secured term

loan facility (the "2021 Term Loan B Facility" and, together with the ABL Facility, the "Senior Secured Credit Facilities") and

the indenture governing the issuance of $300.0 million aggregate principal amount 5.750% Senior Notes due 2029 (the

"5.75% Senior Notes"), and the holders of such indebtedness elect to accelerate the obligations thereunder, together with

accrued but unpaid interest thereon. In such event, it is unlikely that we would be able to satisfy our obligations under all of

such accelerated indebtedness simultaneously. Moreover, pursuant to the terms of the Ventas Master Lease, Ventas has

the option upon the (i) expiration of the term of the Ventas Master Lease, (ii) earlier termination of the Ventas Master

Lease or (iii) occurrence of certain events of default under the Ventas Master Lease, to dispossess the Tenants under the

Ventas Master Lease from all or any portion of their leased premises. In connection with such dispossession, Ventas has the

right to purchase all of such Tenants' personal property (at fair market value) relating to such dispossessed premises other

than such Tenants' proprietary software, trademarks, accounts receivable, contracts with its affiliates and any other of such

Tenants' contracts or leases determined by Ventas or its designee.

Ventas, the trustee of the 5.75% Senior Notes and the administrative agents under our Senior Secured Credit Facilities are

parties to a Relative Rights Agreement that (among other things):

• sets forth the relative rights of Ventas and the administrative agents with respect to the properties and

collateral related to the Ventas Master Lease and securing our Senior Secured Credit Facilities;

• contains a cross-acceleration provision that allows Ventas to declare an event of default under the Ventas

Master Lease upon the acceleration of our obligations under our Senior Secured Credit Facilities, and allows

the administrative agents to declare an event of default under our Senior Secured Credit Facilities in the event

Ventas declares a termination of the Ventas Master Lease prior to the expiration of the term of the Ventas

Master Lease;

• provides Ventas with an option to purchase the debt obligations owed or guaranteed by the Tenants for no

more than $375.0 million (subject to reduction in certain circumstances, including for mandatory and

voluntary prepayments under our Senior Secured Credit Facilities) (the "Ventas Purchase Option Amount"),

together with the assignment of all security interests held by each lender under our Senior Secured Credit

Facilities and all other indebtedness incurred or guaranteed by the Tenants in all right, title and interest in the

Tenants, their assets, and the equity interests that we own in the Tenants. Upon exercise and consummation

of this purchase option, (i) all indebtedness of and guarantees by the Tenants under our Senior Secured Credit

Facilities is automatically assigned to Ventas by means of a separate tranche; (ii) the Company, AHP Health

Partners, Inc., as issuer of the 5.75% Senior Notes, and certain of its existing and future wholly owned

domestic subsidiaries that are guarantors under the 2021 Term Loan B Facility and the 5.75% Senior Notes will

provide unsecured, fully subordinated guarantees of the Tenants' indebtedness to Ventas under such tranche,

subordinated to the obligations of the Company and its direct and indirect subsidiaries under the Senior

Secured Credit Facilities and the 5.75% Senior Notes and to all other holders of debt that join the Relative

Rights Agreement; (iii) the Tenants' guarantees of the 5.75% Senior Notes will be automatically released; (iv)

the Tenants will become unrestricted subsidiaries for purposes of the Senior Secured Credit Facilities and the

indenture governing the 5.75% Senior Notes; and (v) the Ventas Purchase Option Amount will be applied to

reduce amounts outstanding under the Senior Secured Credit Facilities and all other indebtedness incurred or

guaranteed by the Tenants (with holders of the 5.75% Senior Notes not being entitled to any of the proceeds

received by the lenders upon the exercise of Ventas' purchase option);

• provides that, regardless of whether or not Ventas exercises its purchase option, the maximum amount of the

guarantee of the 5.75% Senior Notes by the guarantors that are Tenants, together with the amount of the

indebtedness of and guarantees by such guarantors under the Senior Secured Credit Facilities and all other

indebtedness incurred or guaranteed by the Tenants, cannot exceed $375.0 million; and

• provides that, in certain circumstances, the Tenants and our entities that are guarantors under the Ventas

Master Lease and their respective affiliates may enter into, guaranty and incur other or additional secured or

unsecured indebtedness under new credit facilities, indentures, instruments or other debt documentation so

long as, in each case, (i) to the extent required under the Ventas Master Lease, the agent, lender or trustee in

respect of such indebtedness enters into a joinder agreement to the Relative Rights Agreement; (ii) the

principal amount of the obligations thereunder, together with the amount of indebtedness of and the

guarantees by such guarantors under the Senior Secured Credit Facilities and all other indebtedness incurred

or guaranteed (whether secured or unsecured) by the Tenants, cannot exceed $375.0 million; (iii) the interest

rate or yield applicable thereto shall not increase by more than 5.0% per annum in the aggregate above such

applicable rate as in effect on June 28, 2018; and (iv) at the time of incurrence of such indebtedness and the

guarantees thereunder, the consolidated net leverage ratio (as defined in the Ventas Master Lease, and on a

pro forma basis) shall not exceed 6.25x, subject to certain exceptions.

**Registration Rights Agreement**

On July 3, 2015, certain of our executive officers and management team, EGI-AM and Ventas (the "Investors") entered into

a Registration Rights Agreement (the "Registration Rights Agreement") with the Company. In connection with Pure Health's

investment in the Company, on May 1, 2023, the Company and EGI-AM amended the Registration Rights Agreement to add

Pure Health as an Investor under the Registration Rights Agreement. Pursuant to the Registration Rights Agreement, at any

time after 180 days following the effective date of a registration statement for an initial public offering of the Company's

equity, the Investors may request that the Company register a portion of the Investors' registrable equity securities under

the Securities Act of 1933, as amended (the "Securities Act"). The Registration Rights Agreement also provides for

customary piggyback registration rights.

***Demand Registration Rights***

The holders of at least a majority of the Registerable Securities (as defined therein) outstanding can request that we

register all or a portion of their shares on Form S-1 or any similar long-form registration, and the holders of at least 4% of

the Registerable Securities outstanding can request that we register all or a portion of their shares on Form S-3, if available.

Such holders are entitled to request four registrations on Form S-1 and an unlimited number of registrations on Form S-3 or

any similar short-form registration. The Company is not obligated to effect, or to take any action to effect, a demand

registration (A) within 180 days after the effective date of a previous demand registration, (B) that would cause there to be

more than two registration statements on any form other than Form S-3 to be concurrently effective or (C) if the Company

delivers a delay notice, in which case the demand registration may be deferred for up to 120 calendar days after the

Company's receipt of the registration request from the holder.

In addition, the Company is not obligated to effect, or take action to effect, a registration on Form S-3 (A) within 30 calendar

days before the anticipated filing date of a Company-initiated registration (as determined by the Board in good faith), (B) if

the Company has effected two short-form demand registrations within the preceding twelve months or (C) the anticipated

aggregate offering price, net of selling expenses, for any such registration is less than $5.0 million.

***Piggyback Registration Rights***

The Registration Rights Agreement provides for "piggyback" registration rights allowing the holders to include their shares

in any registration of our equity securities under the Securities Act in connection with the public offering of such securities

solely for cash, subject to certain marketing and other limitations. As a result, whenever we propose to file a registration

statement under the Securities Act, other than with respect to a registration related to employee benefit plans, on any form

that does not include substantially the same information as would be required to be included in a registration statement

covering the sale of Common Stock held by such holders, in which the only Common Stock being registered is Common

Stock issuable upon conversion of debt securities that are also being registered, or related to a transaction under Rule

145 under the Securities Act, the holder of these shares are entitled to notice of the registration and have the right, subject

to limitations that the underwriters may impose on the number of shares included in the registration, to include their

shares in the registration. In an underwritten offering, the managing underwriter, if any, has the right, subject to specified

conditions, to limit the number of shares such holders may include.

***Expenses of Registration***

We will pay the registration expenses of the holders of the shares registered pursuant to the demand and piggyback

registration rights described above.

***Expiration of Registration Rights***

The demand and piggyback registration rights described above will terminate upon any transaction or series of related

transactions, other than a public offering, pursuant to which any person or group of related persons (other than the parties

to the Registration Rights Agreement) acquires, in the aggregate, (i) equity securities of the Company or its subsidiaries

possessing the right to receive a majority of the distributions of the Company or the Company's equityholders or (ii) all or

substantially all of the assets of the Company and its subsidiaries.

**Services Agreement**

We entered into a letter agreement (the "Services Agreement") with EGI-AM, pursuant to which EGI-AM representatives

provides us with ongoing strategic, advisory and consulting services, including (i) advice on financing structures and our

relationship with lenders and bankers, (ii) advice regarding public and private offerings of debt and equity securities, (iii)

advice regarding asset dispositions, acquisitions or other asset management strategies, (iv) advice regarding potential

business acquisitions, dispositions or combinations involving us or our affiliates or (v) such other related advice as may be

reasonably requested by us. EGI-AM does not receive a fee for the provision of the strategic, advisory or consulting services

set forth in the Services Agreement, but may be periodically reimbursed by us, upon request, for (i) travel and out-of-

pocket expenses (not to exceed $50,000 in the aggregate with respect to any single proposed matter unless EGI-AM obtains

our prior consent), and (ii) all reasonable fees and disbursements of counsel, accountants and other professionals incurred

in connection with EGI-AM's services on any proposed matter thereunder (provided that we have given prior consent

to EGI-AM's engagement with respect to such proposed matter). In consideration of the services to be provided by EGI-

AM and its representatives under the Services Agreement, we agreed to indemnify EGI-AM for certain losses incurred

by EGI-AM relating to or arising out of the Services Agreement or the services provided thereunder. The Services Agreement

has a term of one year and will be automatically extended for successive one-year periods unless terminated by either party

at least 60 days prior to any extension date or otherwise terminated at any time for any reason upon at least 60 days' prior

written notice to the other party.

In addition, the Services Agreement provides that EGI-AM is entitled to certain information and access rights in its capacity

as stockholder. During the term of the Services Agreement and for so long as EGI-AM owns in the aggregate shares

representing at least 5% of the total number of our Common Stock issued and outstanding, we agree to provide EGI-

AM and its designated representatives with (i) any business plan and budget of the Company and such other financial and

operating data, reports and other information with respect to our business, assets, properties, prospects or corporate

affairs as EGI-AM may reasonably request and (ii) reasonable access to our premises, books, computer software application

systems, files and records and to our officers and key employees for consultation with respect to matters relating to our

business and affairs, subject to confidentiality and other customary limitations.

**Nomination Agreement**

We entered into the Nomination Agreement with EGI-AM and ALH Holdings, LLC (a subsidiary of Ventas). Pursuant to the

terms of the Nomination Agreement, EGI-AM has the right, but not the obligation, to nominate, and the Company must use

reasonable best efforts to cause the Board to include in its membership, (a) a majority of our directors, and to designate the

Chairman of the Board, as long as EGI-AM beneficially owns 50% or more of the total voting power of our outstanding

Common Stock with respect to the election of directors, (b) 40% of our directors (rounded up to the nearest whole

number), as long as EGI-AM beneficially owns 40% or more, but less than 50% of the total voting power of our outstanding

Common Stock, (c) 30% of our directors (rounded up to the nearest whole number), as long as EGI-AM beneficially owns

30% or more, but less than 40% of the total voting power of our outstanding Common Stock, (d) 20% of our directors

(rounded up to the nearest whole number), as long as EGI-AM beneficially owns 20% or more, but less than 30% of the total

voting power of our outstanding Common Stock, (e) 10% of our directors (rounded up to the nearest whole number), as

long as EGI-AM beneficially owns 10% or more, but less than 20% of the total voting power of our outstanding Common

Stock, and (f) one (1) director, as long as EGI-AM beneficially owns 4% or more, but less than 10% of the total voting power

of our outstanding Common Stock. In addition, ALH Holdings, LLC (a subsidiary of Ventas) has the right, but not the

obligation, to nominate, and the Company must use reasonable best efforts to cause the Board to include in its

membership, one (1) director, as long as ALH Holdings, LLC and any of its affiliates (including Ventas) together beneficially

own 4% or more of the total voting power of our outstanding Common Stock. In the event that a vacancy is created at any

time by the death, disqualification, resignation or removal of a director nominated by EGI-AM or ALH Holdings, LLC, EGI-AM

or ALH Holdings, LLC (as applicable) has the right to designate a replacement to fill such vacancy.

The Nomination Agreement also provides that, for so long as EGI-AM has such nomination rights, the Board must use

reasonable best efforts to cause any committee of the Board to include in its membership at least one (1) director

nominated by EGI-AM, provided that, in each case, such individual satisfies all applicable SEC and stock exchange

requirements (after taking into account all available exemptions under the rules of the applicable stock exchange). For so

long as EGI-AM beneficially owns more than 50% of the total voting power of our outstanding Common Stock, EGI-AM's

designees comprise a majority of each of the compensation and nominating and corporate governance committees of the

Board, so long as the EGI-AM designees satisfy all applicable SEC and stock exchange requirements (after taking into

account all available exemptions under the rules of the applicable stock exchange).

**REIT Savings Letter Agreement**

We entered into an agreement with Ventas that provides Ventas with certain rights as long as it remains a stockholder.

These rights include: (i) if we redeem or repurchase any shares of capital stock from another stockholder (or enters into

another transaction that has a similar effect), then the shares held by Ventas shall automatically be repurchased at a price

per share equal to the fair market value per share, effective immediately prior to such other repurchase, redemption, or

purchase, only to the extent necessary so that Ventas does not own, directly, indirectly, or constructively, more than 9.9%

of the total combined voting power of all classes of our capital stock or of the total value of shares of all classes of our

capital stock (the "Ventas Ownership Condition"); (ii) if Ventas determines at any time in good faith that the Ventas

Ownership Condition is not met and Ventas delivers written notice thereof, we shall repurchase from Ventas, at a price per

share equal to the fair market value per share, such number of shares as specified in the notice so that the Ventas

Ownership Condition thereafter is met; (iii) if there is a purported transfer of shares, or other event that causes the Ventas

Ownership Condition to not be met, the number of shares that would cause the Ventas Ownership Condition to not be met

shall be automatically transferred to a trust for the benefit of a charitable beneficiary and Ventas shall have no rights in any

future income or appreciation in such shares; and (iv) from time to time, we must reasonably cooperate with and provide

any information to Ventas as may reasonably be required to determine whether the Ventas Ownership Condition is

satisfied. Under the REIT Savings Letter Agreement, fair market value is determined as of the end of the business day

immediately preceding the date of repurchase and means the volume weighted average of the closing sales prices of the

shares for the such day on all domestic securities exchanges on which the shares may at the time be listed but not less than

the per share price paid to any other person in the transaction giving rise to the repurchase.

**General Information**

**Stockholder Proposals and Nominations for 2027 Annual Meeting**

Pursuant to Rule 14a-8 under the Exchange Act, proper stockholder proposals intended to be presented at our 2027 annual

meeting of stockholders must be received by us at our principal executive offices at 340 Seven Springs Way, Suite 100,

Brentwood, Tennessee 37027 no later than December 9, 2026 for the proposals to be included in the Proxy Statement and

form of proxy card for that meeting.

If a stockholder desires to bring a matter before our annual meeting of stockholders and the matter is submitted outside

the process of Rule 14a-8, including with respect to nominations for election as directors, the stockholder must follow the

procedures set forth in our Bylaws. Our Bylaws provide generally that stockholder proposals and director nominations to be

considered at an annual meeting of stockholders may be made by a stockholder only if (1) the stockholder is entitled to

vote at the meeting, (2) the stockholder has complied with the notice and other requirements set forth in our Bylaws, and

(3) the stockholder gives timely written notice of the matter to our Corporate Secretary. To be timely, a stockholder's notice

must be received at our principal executive offices no later than the close of business on the 90th day nor earlier than the

close of business on the 120th day prior to the first anniversary of the date on which the Company first mailed its proxy

materials or a notice of availability of proxy materials (whichever is easier) for the immediately preceding year's annual

meeting of stockholders. However, in the event that our annual meeting is not within than 30 days from the first

anniversary of the preceding year's annual meeting of stockholders, written notice by the stockholder must be so delivered

not earlier than the close of business on the 120th day prior to such annual meeting and not later than the close of business

on the later of the 90th day prior to such annual meeting or the tenth day following the day on which public disclosure of

the date of such annual meeting, as originally convened, is first made by the Company. Under our Bylaws, notice with

respect to the 2027 annual meeting of stockholders must be received at our principal executive offices between the close of

business on December 9, 2026 and the close of business on January 8, 2027. The notice must set forth the information

required by the provisions of our Bylaws dealing with stockholder proposals and nominations of directors.

In addition to satisfying the foregoing requirements under our Bylaws, to comply with the universal proxy rules,

stockholders who intend to solicit proxies in support of director nominees other than our director nominees must provide

notice that sets forth the information required by Rule 14a-19 under the Exchange Act.

**Annual Report on Form 10-K**

As indicated in the Notice of Internet Availability of Proxy Materials, a copy of this Proxy Statement and our 2025 Annual

Report to Stockholders has been posted on the website *www.proxyvote.com*. Upon the written request of any stockholder

entitled to vote at the Annual Meeting, we will furnish, without charge, a copy of our Annual Report on Form 10-K for the

year ended December 31, 2025, as filed with the SEC. Requests should be directed to Ardent Health, Inc., 340 Seven Springs

Way, Suite 100, Brentwood, Tennessee 37027, Attention: Investor Relations, 615-296-3000. Our Annual Report to

Stockholders and Annual Report on Form 10-K are not proxy soliciting materials.

**Delivery of Documents to Stockholders Sharing an Address** 

Householding is a program adopted by the SEC that permits companies and intermediaries (e.g., brokers) to satisfy the

delivery requirements for annual reports, proxy statements and the Notices of Internet Availability of proxy materials sent

to multiple stockholders of record who have the same address by delivering a single annual report, proxy statement or

Notice of Internet Availability of Proxy Materials to that address. Householding is designed to reduce a company's printing

costs and postage fees. Brokers with account holders who are stockholders of the Company may be householding the

Company's proxy materials. If your household participates in the householding program, you will receive one Notice of

Internet Availability of Proxy Materials. If you are a beneficial holder, you can request information about householding from

your broker, bank or other nominee. If at any time you no longer wish to participate in householding and would prefer to

receive a separate proxy statement, annual report or Notice of Internet Availability of Proxy Materials, please notify your

broker if your shares are held in a brokerage account or us if you are a stockholder of record. You can notify us by sending a

written request to our Corporate Secretary at 340 Seven Springs Way, Suite 100, Brentwood, Tennessee 37027, or by calling

615-296-3000. In addition, we will promptly deliver, upon written or oral request to the address or telephone number

above, a separate copy of the annual report, proxy statement and Notice of Internet Availability of Proxy Materials to a

stockholder at a shared address to which a single copy of the documents was delivered.

If you receive more than one Notice of Internet Availability of Proxy Materials, this means that you have multiple accounts

holding Common Stock with brokers and/or the Company's transfer agent. Please vote all of your shares by following the

instructions included on each Notice of Internet Availability of Proxy Materials. Additionally, to avoid receiving multiple sets

of proxy materials in the future, the Company recommends that you contact Broadridge Financial Services, Inc. at

*www.proxyvote.com* or (800) 579-1639 to consolidate as many accounts as possible under the same name and address. If

you are a beneficial holder, please call your broker for instructions.

**Electronic Access to Proxy Statement and Annual Report to Stockholders** 

We have elected to provide this Proxy Statement and our 2025 Annual Report to Stockholders over the Internet through a

"notice and access" model. The Notice of Internet Availability of Proxy Materials provides instructions on how you may

access this Proxy Statement and our 2025 Annual Report to Stockholders on the Internet at *www.proxyvote.com* or request

a printed copy at no charge. In addition, the Notice of Internet Availability of Proxy Materials provides instructions on how

you may request to receive, at no charge, all future proxy materials in printed form by mail or electronically by email. Your

election to receive proxy materials by mail or email will remain in effect until you revoke it. Choosing to receive future proxy

materials by email will save us the cost of printing and mailing documents to stockholders and will reduce the impact of our

annual meetings on the environment.

Brentwood, TN

April 8, 2026

**Reconciliation of Non-GAAP Measures**

The following table presents a reconciliation of Adjusted EBITDAR, a valuation measure, to net income, determined in

accordance with U.S. generally accepted accounting principles:

---

| | |
|:---|:---|
| **(in thousands)** | **Year Ended** <br>**December 31, 2025**<br>|
| Net income | $230135 |
| <u>Adjusted EBITDAR Addbacks:</u> |  |
| Income tax expense | 56223 |
| Interest expense | 55202 |
| Depreciation and amortization | 155703 |
| Noncontrolling interest earnings | (94324) |
| Loss on extinguishment and modification of debt | 7344 |
| Other non-operating losses | 1130 |
| Cybersecurity Incident recoveries, net | (22655) |
| Certain legal matters and related costs | 900 |
| Restructuring, exit and acquisition-related costs | 13276 |
| Change in accounting estimate | 43298 |
| New Mexico professional liability accrual | 54468 |
| Epic expenses | 4837 |
| Equity-based compensation | 39293 |
| Loss from disposed operations | 207 |
| Rent expense payable to REITs | 164308 |
| Adjusted EBITDAR | $709345 |

---

![PROXY CARD - FINAL (from Broadridge)_Page_1.jpg](ardt-20260408_g6.jpg)

![PROXY CARD - FINAL (from Broadridge)_Page_2.jpg](ardt-20260408_g7.jpg)